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QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects observed 
following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone: 1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail: atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 




























Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, 
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 
The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700,
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS: 
1. 	 Health Effects Review.  The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying 
end points. 
2.	 Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to 
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each 
profile, and makes recommendations for derivation of MRLs. 
3. 	 Data Needs Review.  The Research Implementation Branch reviews data needs sections to assure 
consistency across profiles and adherence to instructions in the Guidance. 
































A peer review panel was assembled for tungsten.  The panel consisted of the following members:  
1.	 Finis Cavender, Ph.D., DABT, CEI, Consultant in Toxicology, 310 Lightwood Knot Road, Greer, 
South Carolina 29651; 
2.	 Richard Leggett, Ph.D., Life Sciences Division, Oak Ridge National Laboratory, 11401 Glen Iris 
Lane, Knoxville, Tennessee 37922-1744; 
3. 	 Robert Michaels, Ph.D., President, RAM TRAC Corporation, Toxicology & Risk Assessment 
Consulting, 3100 Rosendale Road, Schenectady, New York 12309; and 
4.	 Raghubir Sharma, Ph.D., Fred C. Davison Distinguished Chair in Toxicology, Department of 
Physiology and Pharmacology, The University of Georgia, Athens, Georgia 30602. 
These experts collectively have knowledge of tungsten's physical and chemical properties, toxicokinetics, 
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to 
humans.  All reviewers were selected in conformity with the conditions for peer review specified in 
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as 
amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.   
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
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1 TUNGSTEN  
1. PUBLIC HEALTH STATEMENT 

This public health statement tells you about tungsten and the effects of exposure to it.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites are then placed on the National Priorities List (NPL) and are targeted for 
long-term federal clean-up activities.  Tungsten has been found in at least 6 of the 1,662 current 
or former NPL sites.  Although the total number of NPL sites evaluated for this substance is not 
known, the possibility exists that the number of sites at which tungsten is found may increase in 
the future as more sites are evaluated.  This information is important because these sites may be 
sources of exposure and exposure to this substance may harm you. 
When a substance is released either from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment. Such a release does not always 
lead to exposure. You can be exposed to a substance only when you come in contact with it.  
You may be exposed by breathing, eating, or drinking the substance, or by skin contact. 
If you are exposed to tungsten, many factors will determine whether you will be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
it. You must also consider any other chemicals you are exposed to and your age, sex, diet, 
family traits, lifestyle, and state of health. 
1.1 WHAT IS TUNGSTEN? 
Tungsten is a naturally occurring element that, in most environments, is a solid.  In nature, it 
occurs in rocks and soil as minerals, but never as the pure metal.  Two kinds of tungsten-bearing 
mineral rocks, called wolframite and scheelite, are mined commercially.  The mineral ore is 
processed to recover the tungsten and turn it into either chemical compounds or metal.  
Elemental tungsten, like elemental copper or gold, is a metal.  Its color can range from tin white 














2 TUNGSTEN  
1. PUBLIC HEALTH STATEMENT 
pure metal or mixed with other metals to make alloys.  Tungsten alloys tend to be strong and 
flexible, resist wear, and conduct electricity well.  Tungsten and its alloys are used as light bulb 
filaments, as the part of x-ray tubes where x-rays are formed, as a catalyst to speed up chemical 
reactions, as a component of steel in high-speed tools, in turbine blades, in phonographic 
needles, as welding electrodes, as gyroscope wheels, as counterbalance and fishing weights, in 
darts, and in golf club components.  They can be used in bullets (as a replacement for lead) and 
in armor penetrators (as a substitute for depleted uranium).  Chemical compounds of tungsten are 
used for many purposes.  Cemented tungsten carbide, a hard substance used to make grinding 
wheels and cutting or forming tools, is the most common tungsten compound.  Other tungsten 
compounds are used in ceramic pigments, as fire retardant coatings for fabrics, and as fade-
resistant dyes for fabrics. More information on the chemical, physical properties, production, 
and uses of tungsten and its compounds are presented in Chapters 4, 5, and 6. 
1.2 WHAT HAPPENS TO TUNGSTEN WHEN IT ENTERS THE ENVIRONMENT?
Tungsten occurs naturally in the environment, in minerals, but not as the pure metal.  As an 
element, tungsten can be neither created nor destroyed chemically, although tungsten can change 
forms in the environment. 
Tungsten is released into air as fine dust-like particles by weathering.  Emissions from hard 
metal industries also increase tungsten levels in air.  The amount of tungsten that has been 
measured in the ambient air is, in general, less than 10 billionths of a gram per cubic meter (or 
parts per billion [ppb]). Very small dust particles of tungsten in the air fall out onto surface 
water, plant surfaces, and soil either by themselves or when rain or snow falls.  These tungsten 
particles eventually recycle back in the soil or in the bottoms of lakes, rivers, and ponds, where 
they stay and mix with tungsten that is already there. 
Tungsten in water originates mainly from dissolution of tungsten from rocks and soil that water 
runs over and through. Tungsten has not been detected in the vast majority of surface water and 
groundwaters of the United States. Some exceptions include areas near mines and natural 














3 TUNGSTEN  
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detected in municipal water and groundwater.  Only a very small fraction of tungsten in water 
originates from the settling of dust out of the air.  Most tungsten products of human-origin that 
enter waterways originate from industry discharges of waste water.  Tungsten in water may be in 
either soluble or insoluble forms.  Insoluble tungsten in water can settle to the bottom where it 
enters sediment.  Some insoluble tungsten compounds, however, can remain suspended in ocean 
water for many years, requiring as long as 1,000 years to settle to the bottom. 
Tungsten occurs naturally in soil as a mineral, or component of soil.  It occurs in amounts that 
vary over a wide range from less than 1 to as high as 83 thousandths of a gram per kilogram of 
soil. Another way to say this is that the tungsten concentration ranges from 1 to 83 parts per 
million (ppm) in soil by weight.  Disposal of coal ash, incinerator ash, and industrial wastes may 
increase the amount of tungsten in soil.  A portion of tungsten in soil does not dissolve in water, 
but remains bound and is not likely to move deeper into the ground and enter groundwater.  The 
remaining soluble portion may move deeper into the ground and enter groundwater if the pH is 
greater than 7.  In the environment, chemical reactions can change the water-soluble tungsten 
compounds into insoluble forms.  In some cases, water-insoluble tungsten compounds can 
change to soluble forms.  In general, exposure to water-soluble tungsten compounds in the 
environment will pose a greater threat to human health than water-insoluble forms.  More 
information about the fate and movement of tungsten in the environment is presented in 
Chapter 6. 
1.3 HOW MIGHT I BE EXPOSED TO TUNGSTEN? 
You can be exposed to low levels of tungsten by breathing air, drinking water, or eating food that 
contains tungsten.  The average ambient concentration of tungsten in air has been reported to be 
less than 10 nanograms in a cubic meter of air (1 nanogram is 1 billionth of a gram).  Cities have 
higher levels of tungsten in the air because tungsten is released from industry.  Tungsten has 
been detected in municipal water from Fallon, Nevada.  However, the amounts of tungsten in 
drinking water are generally not known.  This is probably because the tungsten levels are lower 
than the laboratory methods are able to detect without concentrating samples, or the laboratory 
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same reasons.  Tungsten in plants was either taken up by the plant or was attached to the plant as 
a component of the soil.  The concentration of tungsten in onions collected from Denmark is 
17 micrograms in a kilogram of fresh vegetables.  Although very limited data are available, 
exposure to tungsten from air, drinking water, and food is expected to be insignificant. 
In certain workplaces, you can be exposed to levels of tungsten in air that are higher than 
background levels, which are very small or none.  Exposures are mostly in the form of tungsten 
metal or tungsten carbide.  Occupational exposure to tungsten occurs primarily at places where 
individuals use hard metals containing tungsten or are engaged in the machining of these metals.  
This includes the grinding (pointing) of tungsten metal welding electrodes prior to use.  
Occupational exposure to tungsten carbide occurs during the machining of tungsten carbide tools 
in the manufacturing process.  The total number of individuals occupationally exposed to 
tungsten or its compounds has been estimated to be about 47,000. 
Tungsten metal and metal alloys occur in consumer products such as electronics, light bulb 
filaments, cemented tungsten carbide grinding wheels, carbide tipped tools, and “green” bullets.  
No other consumer products or products used in crafts, hobbies, or cottage industries were 
identified that contain significant amounts of tungsten.  It is unlikely that tungsten present in 
consumer products poses a hazard.  However, appropriate dust masks are recommended for 
amateur craftsmen engaging in activities that may potentially produce tungsten carbide dust (e.g., 
metal grinding).  More information about tungsten exposure is discussed in Chapter 6. 
1.4 HOW CAN TUNGSTEN ENTER AND LEAVE MY BODY? 
Tungsten can enter your body from the food you eat or the water you drink, from the air you 
breathe, or from contact with the skin.  When you eat, drink, breathe, or touch things containing 
tungsten compounds that can easily be dissolved in water, tungsten enters your blood and is 
carried to all parts of your body. Most of the tungsten that enters your blood is rapidly released 
from your body in the urine.  When you eat or drink things containing tungsten, much of the 
tungsten passes through your digestive system and is released from your body in the feces.  
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bloodstream from the lungs, and some of the tungsten is cleared from your lungs in mucus that is 
either swallowed or spit out. When you swallow tungsten that was first in your lungs, it passes 
through your digestive system as if you had eaten it.  Some enters your blood from your 
digestive system and some passes out with the feces.  A small portion of the tungsten that enters 
your blood may spend some time in bone, fingernails, or hair.  Some of this tungsten is slowly 
eliminated from your body through the urine and feces. 
1.5 HOW CAN TUNGSTEN AFFECT MY HEALTH? 
Scientists use many tests to protect the public from harmful effects of toxic chemicals and to find 
ways for treating persons who have been harmed. 
One way to learn whether a chemical will harm people is to determine how the body absorbs, 
uses, and releases the chemical.  For some chemicals, animal testing may be necessary.  Animal 
testing may also help identify health effects such as cancer or birth defects.  Without laboratory 
animals, scientists would lose a basic method for getting information needed to make wise 
decisions that protect public health.  Scientists have the responsibility to treat research animals 
with care and compassion.  Scientists must comply with strict animal care guidelines because 
laws today protect the welfare of research animals. 
You are not likely to experience any health effects that would be related to exposure to tungsten 
or tungsten compounds.  Tungsten compounds have caused breathing problems and changed 
behavior in some animals given very large amounts of tungsten compounds, but you are not 
likely to be exposed to amounts of tungsten in the air you breathe or the food or water you take 
into your body that would be large enough to cause similar effects.  If you are a worker who has 
inhaled tungsten heavy metal dust, your exposure would help determine if health effects similar 
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1.6 HOW CAN TUNGSTEN AFFECT CHILDREN? 
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age.  
Children could be affected in the same ways as adults.  In adult animals, very large amounts of 
tungsten compounds have been shown to cause breathing problems and changes in behavior.  
However, it is not likely that children would be exposed to amounts of tungsten in the air they 
breathe or the food or water they consume that would be large enough to cause effects similar to 
those that were seen in the animals.  Animal studies have shown that tungsten in the blood of a 
pregnant mother can enter the blood of a fetus in the womb.  Studies in dairy cows have shown 
that tungsten may also enter the milk.  There is no information to suggest that the effects seen in 
animals could not occur in humans.  We do not know whether unborn babies, babies, and 
children might differ from adults in their susceptibility to health effects from exposure to 
tungsten or tungsten compounds. 
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO TUNGSTEN? 
If your doctor finds that you have been exposed to substantial amounts of tungsten, ask whether 
your children might also have been exposed.  Your doctor might need to ask your state health 
department to investigate. 
Children living near waste sites containing tungsten are likely to be exposed to higher 
environmental levels of tungsten through breathing contaminated air, drinking contaminated 
water, touching soil, and eating contaminated soil.  Children sometimes eat dirt, which should be 
discouraged. Parents should supervise to see that children wash their hands frequently and 
before eating. Parents should consult their family physicians about whether (and how) hand-to­
mouth behaviors in their children might be discouraged.  If your community’s drinking water has 
been reported to contain elevated levels of tungsten, you should take advantage of alternative 
water sources such as bottled water for drinking.  Some children may be exposed to tungsten by 
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carbide grinding wheels. If you work at a facility that uses tungsten or have tungsten dust on 
your clothes, change your clothes and clean your hair and skin before leaving your job or work 
site and returning home.  Do not bring objects home such as work tools that may be 
contaminated with tungsten. 
1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
EXPOSED TO TUNGSTEN? 
Medical tests exist that can determine whether your body fluids contain high levels of tungsten.  
Samples of blood or feces can be collected in a doctor's office and sent to a laboratory that can 
measure tungsten levels.  It is easier for most laboratories to measure tungsten in blood than in 
feces. The presence of high levels of tungsten in the feces can mean recent high tungsten 
exposure. High levels of tungsten in the blood can mean high tungsten consumption and/or high 
exposure. High tungsten levels in blood or feces reflect the level of exposure to tungsten.  
Measuring tungsten levels in urine and saliva also may provide information about tungsten 
exposure. Tests to measure tungsten in hair may provide information on long-term tungsten 
exposure. More information on tests to measure tungsten in the body is located in Chapter 7. 
1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH? 
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. The EPA, the Occupational Safety and Health 
Administration (OSHA), and the Food and Drug Administration (FDA) are some federal 
agencies that develop regulations for toxic substances.  Recommendations provide valuable 
guidelines to protect public health, but cannot be enforced by law.  The Agency for Toxic 
Substances and Disease Registry (ATSDR) and the National Institute for Occupational Safety 
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Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a 
toxic substance in air, water, soil, or food that do not exceed a critical value that is usually based 
on levels that affect animals; they are then adjusted to levels that will help protect humans.  
Sometimes these not-to-exceed levels differ among federal organizations because they used 
different exposure times (an 8-hour workday or a 24-hour day), different animal studies, or other 
factors. 
Recommendations and regulations are also updated periodically as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for tungsten include the following: 
There are few guidelines for tungsten and tungsten compounds.  For tungsten and insoluble 
tungsten compounds, NIOSH has established a recommended exposure limit (REL; 10-hour time
weighted average) of 5 mg/m3 and a short-term exposure limit (STEL; 15-minute time weighted 
average) of 10 mg/m3. OSHA has established permissible exposure limits (PELs; 8-hour time 
weighted average) for tungsten of 5 mg/m3 (insoluble compounds) and 1 mg/m3 (soluble 
compounds) for construction and shipyard industries. 
More information on regulations and guidelines is available in Chapter 8. 
1.10 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, or contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses that result from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 
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and technical assistance number at 1-888-42ATSDR (1-888-422-8737), by e-mail at 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 
  Division of Toxicology 
1600 Clifton Road NE 
  Mailstop F-32 
  Atlanta, GA 30333 
  Fax: 1-770-488-4178 
Organizations for-profit may request copies of final Toxicological Profiles from the following: 
National Technical Information Service (NTIS) 

5285 Port Royal Road 

  Springfield, VA 22161 

  Phone: 1-800-553-6847 or 1-703-605-6000 
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2.1 	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TUNGSTEN IN THE 
UNITED STATES 
Tungsten is a naturally occurring element found in some rocks and soils.  In nature, tungsten exists in 
mineral forms, but not as the pure metal.  Tungsten is recovered from mineral ores to produce pure 
tungsten metal or tungsten alloys or compounds.  Alloys that contain tungsten and other metals are strong 
and flexible, resist wear, and conduct electricity well. Tungsten and its alloys are used in products such 
as light bulb filaments, x-ray tubes, phonographic needles, welding electrodes, gyroscope wheels, 
counterbalance and fishing weights, darts, and golf clubs.  Tungsten is also used in armor-piercing 
munitions.  Tungsten alloy “green” bullets are beginning to replace lead bullets in the United States and 
other countries.  Cemented tungsten carbide, a hard substance used to make grinding wheels and cutting 
or forming tools, is the most common tungsten compound.  Other products that contain tungsten 
compounds include ceramic pigments and fire retardant fabric coatings and dyes. 
Tungsten is released to the atmosphere by windblown dusts and during ore processing, tungsten alloy
(hard-metal) fabrication, tungsten carbide production and use, and municipal waste combustion.  
Tungsten enters waterways through the natural weathering of rocks and soils, by extraction and 
processing of tungsten, and via deposition of tungsten aerosols or dusts from both natural and 
anthropogenic sources.  The concentration of tungsten in ambient air is <10 ng/m3. Limited available 
information indicates that levels of tungsten in food are expected to be low.  For example, onions 
collected from 11 Danish sites contained tungsten at a mean level of 16.7 µg/kg fresh weight.  Levels of 
tungsten are expected to be low in most drinking water supplies in the United States.  However, elevated 
concentrations of tungsten have been observed in tap water samples taken from regions of Nevada where 
relatively high tungsten levels have been noted in surface water and groundwater.  For example, in 2002, 
a United States Geological Survey (USGS) study reported a mean tungsten concentration of 19.9 µg/L 
(range, 0.25–337 µg/L) in samples taken from private wells and public water supplies in Churchill 
County.  A CDC study of household water samples from the Churchill County community reported 
tungsten levels ranging from 0 to 217.3 µg/L.  In a follow up study, tungsten levels in the tap water of 
residents in the community of Yerington, which neighbors Churchill County, were measured at a mean 
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4.46 µg/L (range, 2.98–7.30 µg/L) for Churchill County residents, indicating that elevated tungsten levels 
in tap water are not unique to Churchill County.
The general population may be exposed to measurable amounts of tungsten by inhaling airborne tungsten.  
Tungsten blood and urine levels of 1–6 and 0.085 µg/L, respectively, have been measured in the general 
public.  However, elevated levels of tungsten in the drinking water of some areas indicate potential for 
significant oral exposure as well.  Based on the studies of residents in Churchill County (City of Fallon) 
and surrounding communities, the mean concentrations of tungsten in urine ranged from 0.48 to
1.19 µg/L and appeared to correlate with the concentrations of tungsten in tap water.  Individuals who 
work in manufacturing, fabricating, and reclaiming industries, especially individuals using hard metal 
materials or tungsten carbide machining tools, may be exposed to higher levels of tungsten or tungsten 
compounds than the general population.  Occupational exposure is primarily via inhalation of dust 
particles of elemental (metallic) tungsten and/or its compounds. 
2.2 SUMMARY OF HEALTH EFFECTS  
Pulmonary fibrosis, memory and sensory deficits, and increased mortality due to lung cancer have been 
attributed to occupational exposure to dusts generated in the hard metal industry.  Hard metal is an alloy
or encapsulated mixture that is composed of tungsten or tungsten carbide and cobalt (primarily, although 
the alloys may also contain yttrium, thorium, copper, nickel, iron, or molybdenum).  Based on the 
presence of tungsten oxide fibers in air samples taken at some hard metal facilities and demonstrations 
that tungsten oxide fibers are capable of generating hydroxyl radicals in human lung cells in vitro, it has 
been suggested that tungsten oxide fibers may contribute to the development of pulmonary fibrosis in 
hard metal workers.  Historically, the respiratory and neurological effects observed in hard metal workers 
have been attributed to cobalt, not tungsten.  Available epidemiological data do not implicate tungsten as 
a source of respiratory or neurological effects observed in hard metal workers.  Refer to the toxicological 
profile for cobalt for a discussion of health effects associated with exposure to dusts in the hard metal 
industry.
Limited reports associate tungsten exposure with reproductive and developmental effects such as 
decreased sperm motility, increased embryotoxicity, and delayed fetal skeletal ossification in animals.  
However, more detailed accounts of tungsten-induced reproductive and developmental toxicity were not 
located. Tungsten has been observed to cross the placental barrier and enter the fetus.  Dermal or ocular 
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carcinogenic potential of tungsten or tungsten compounds.  In one recent study, intramuscularly-
implanted tungsten alloy (91.1% tungsten, 6.0% nickel, and 2.9% cobalt) was shown to rapidly cause 
aggressive tumors in rats.  However, since both nickel and cobalt are known to cause tumors following 
intramuscular injection in rats, the carcinogenic role of tungsten itself was not determined.  Results of in 
vitro testing by one group of investigators indicate the potential for synergistic effects following exposure 
to tungsten alloys such as tungsten-cobalt-nickel and tungsten-nickel-iron.  Tungsten has recently been 
nominated to the National Toxicology Program (NTP) for toxicological characterization, which includes 
carcinogenicity testing. 
2.3 MINIMAL RISK LEVELS
Inhalation MRLs 
No inhalation MRLs were derived for tungsten or tungsten compounds since adequate data were not 
available for this route of exposure. 
Oral MRLs 
No oral MRLs were derived for tungsten or tungsten compounds due to a lack of availability of data for 
this route of exposure.  This finding will be evaluated based on a review of several recently translated 
foreign articles to determine if the data they contain and the scientific method under which they were 
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The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of tungsten.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal), since this factor influences the body’s response to some substances, and then by health 
effect (death, systemic, immunological, neurological, reproductive, developmental, genotoxic, and 
carcinogenic effects). These data are discussed in terms of three exposure periods:  acute (14 days or 
less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
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considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
3.2.1 Inhalation Exposure 
Pulmonary fibrosis, memory and sensory deficits, and increased mortality due to lung cancer have been 
attributed to occupational exposure to dusts generated during the manufacture or use of high tensile 
strength tungsten (hard metal) (see Bech 1974; Bech et al. 1962; Coates and Watson 1971; Jordan et al. 
1990; Kaplun and Mezentseva 1959; Lasfargues et al. 1994; Mezentseva 1967; Miller et al. 1953; Moulin 
et al. 1998; Vengerskaya and Salikhodzhaev 1962; Wild et al. 2000).  Hard metal is produced by sintering
a mixture of powders (typically tungsten carbide and cobalt) to form a tungsten alloy.  Variations can 
include the replacement of tungsten carbide with tungsten, the addition of other metals (yttrium, thorium,
copper, nickel, iron, or molybdenum) to achieve specific metallurgical properties, and the omission of 
cobalt. The term “hard-metal disease” has been coined to describe pulmonary effects resulting from
inhaled hard metal dust.  It is generally believed that the health effects observed in hard metal workers are 
the result of exposure to cobalt (see Davison et al. 1983; Harding 1950) or other metals (e.g., nickel), not 
tungsten. Refer to the ATSDR Toxicological Profile for Cobalt (Agency for Toxic Substances and 
Disease Registry 2004) and the ATSDR Toxicological Profile for Nickel (Agency for Toxic Substances 
and Disease Registry 2005) for health effects information on cobalt and nickel, respectively.  It has been 
suggested that tungsten carbide could increase the solubility of cobalt, effectively increasing cobalt-
induced toxicity (Lasfargues et al. 1995; Lison et al. 1995, 1996), although such a mechanism has not 























17 TUNGSTEN  
3. HEALTH EFFECTS 
3.2.1.1 Death 
No reports were located in which death in humans could be specifically associated with exposure to 
airborne tungsten or tungsten compounds.  Increased mortality has been attributed to occupational 
exposure to dusts containing tungsten carbide and cobalt among hard metal workers.  It is generally
believed that the health effects observed in hard metal workers are the result of exposure to cobalt (see 
Davison et al. 1983; Harding 1950) or other metals (e.g., nickel), not tungsten. Refer to the ATSDR 
Toxicological Profile for Cobalt (Agency for Toxic Substances and Disease Registry 2004) and the 
ATSDR Toxicological Profile for Nickel (Agency for Toxic Substances and Disease Registry 2005) for 
health effects information on cobalt and nickel, respectively.
Information in animals is restricted to reports of no deaths during 14 days following single 4-hour 
exposure of rats to atmospheres of sodium tungstate dihydrate powder at a concentration of 5.01 mg/L 
(Huntingdon Life Sciences Ltd 1999a) or tungsten metal powder at a concentration of 5.4 mg/L 
(Huntingdon Life Sciences Ltd 1999b). However, the particulate concentrations available for inhalation 
were likely much lower than those reported, due to rapid settling of the particles.  Lasfargues et al. (1992) 
found intratracheally-instilled hard metal (tungsten carbide and cobalt alloy) to be more acutely lethal to 
rats than either tungsten carbide or cobalt alone.  It has been suggested that tungsten carbide could 
increase the solubility of cobalt, effectively increasing cobalt-induced toxicity (Lasfargues et al. 1995; 
Lison et al. 1995, 1996), although such a mechanism has not been experimentally demonstrated. 
3.2.1.2 Systemic Effects  
Available information in humans is limited to occupational exposure to dusts containing tungsten and 
other substances such as cobalt in the hard metal industry, and reported systemic effects have been 
associated with cobalt rather than tungsten.  Therefore, human data are not included in Table 3-1 and 
Figure 3-1. Reliable LOAELs for respiratory and ocular effects in animals exposed to selected tungsten 
compounds are recorded in Table 3-1 and plotted in Figure 3-1. 
No reports were located in which cardiovascular, gastrointestinal, hematological, musculoskeletal, 
hepatic, renal, endocrine, or dermal effects were associated with inhalation exposure of humans or 
animals to tungsten or tungsten compounds. 
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Figure 3-1 Levels of Significant Exposure to Tungsten - Inhalation 
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Respiratory Effects. Respiratory effects were reported in workers who were occupationally exposed 
to airborne dusts containing tungsten trioxide, tungsten dioxide, metallic tungsten, and tungsten carbide in 
areas where high tensile strength tungsten was prepared (Mezentseva 1967).  Of 54 workers examined, 
5 exhibited early radiographic signs of pulmonary fibrosis after having been employed for 2–3 years 
(3 workers) or 19 or 24 years.  The study of Mezentseva (1967) lacks critical information regarding 
smoking, medical, and work histories of the examined workers.  Furthermore, other potentially hazardous 
substances may have also been present in the workplace air.  It is generally believed that the health effects 
observed in hard metal workers are the result of exposure to cobalt (see Davison et al. 1983; Harding 
1950) or other metals (e.g., nickel), not tungsten.  Refer to the ATSDR Toxicological Profile for Cobalt 
(Agency for Toxic Substances and Disease Registry 2004) and the ATSDR Toxicological Profile for 
Nickel (Agency for Toxic Substances and Disease Registry 2005) for health effects information on cobalt 
and nickel, respectively.  See Kerley et al. (1996) and NIOSH (1977) for discussions of respiratory effects 
associated with the hard metal industry.
Few reports were located regarding respiratory effects in animals.  Signs of mild pulmonary fibrosis were 
noted in rats exposed to atmospheres containing tungsten carbide at a concentration of 600 mg/m3, 
1 hour/day for 5 months (Mezentseva 1967).  Other rats exhibited similar signs of pulmonary fibrosis 
following intratracheal instillation of metallic tungsten, tungsten trioxide, or tungsten carbide and 
subsequent observations for up to 8 months postinstillation (Mezentseva 1967).  Guinea pigs that received 
3 weekly doses of tungsten metal dust or tungsten carbide and carbon dust via intratracheal instillation 
were examined for up to 12 months post treatment (Delahant 1955; Schepers 1955a, 1955b).  Gross 
histological examinations of the lungs revealed pigmented lung lesions that did not appear to involve 
lymphoid tissue; the results were not suggestive of pulmonary fibrosis.  The lungs of mice exhibited no
signs of a fibrotic response following intratracheal instillation of tungsten carbide (Lardot et al. 1998).
Lasfargues et al. (1992) reported severe acute pulmonary edema in rats that had received hard metal 
(tungsten carbide and cobalt alloy) via intratracheal instillation, but not in rats similarly exposed to 
tungsten carbide or cobalt alone.  In a subsequent study of repeated intratracheal instillation (Lasfargues 
et al. 1995), it was demonstrated that intratracheally-instilled tungsten carbide and cobalt in combination, 
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Ocular Effects.    Signs of slight conjunctival irritation were noted in rabbits following single ocular 
instillation of 100 mg of sodium tungstate dihydrate powder or tungsten metal powder (Huntingdon Life 
Sciences Ltd 1999c, 2000). 
3.2.1.3 Immunological and Lymphoreticular Effects  
No reports were located regarding immunological or lymphoreticular effects in humans or animals 
following inhalation exposure to tungsten or tungsten compounds. 
Intratracheal instillation of 250 µg of water-insoluble calcium tungstate crystals (in saline) in mice 
resulted in a marked inflammatory response characterized by infiltration of leukocytes with cellular peaks 
at days 1 and 14 postinstillation (Peão et al. 1993).  The inflammatory response was likely the result of 
local irritation rather than an adverse immunological effect. 
3.2.1.4 Neurological Effects 
Signs of memory and sensory deficits have been reported among workers in the hard metal industry who 
were exposed to atmospheres of hard metal dusts (Jordan et al. 1990; Kaplun and Mezentseva 1959; 
Vengerskaya and Salikhodzhaev 1962).  Cobalt was the likely causative agent, not tungsten.  Potential 
contributions of dust from other metals that may have been present in the workplace air were not 
assessed.  It is generally believed that the health effects observed in hard metal workers are the result of 
exposure to cobalt (see Davison et al. 1983; Harding 1950) or other metals (e.g., nickel), not tungsten.  
Refer to the ATSDR Toxicological Profile for Cobalt (Agency for Toxic Substances and Disease Registry
2004) and the ATSDR Toxicological Profile for Nickel (Agency for Toxic Substances and Disease 
Registry 2005) for health effects information on cobalt and nickel, respectively. 
Information in animals is limited to a single report of a series of inhalation exposures to airborne sodium
tungstate powder (Idiyatullina 1981).  Muzzle scratching and increased activity (interpreted by the author 
as anxiety manifestations) were noted in male rats continuously exposed to atmospheres containing 
sodium tungstate powder at concentrations of 100 and 600 mg/m3 for up to 30 days.  Statistically 
significantly depressed blood cholinesterase activity (magnitude not specified in the available account of 
the original study) was noted following 18 hours of exposure at a concentration of 600 mg/m3 and 
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0.5 and 1.0 mg/m3 for 4 months, blood cholinesterase levels were depressed by 22 and 25%, respectively,
relative to controls, and diffuse sclerosis was noted in brain tissue.  These effects were not seen at a lower 
concentration (0.1 mg/m3). The low magnitude blood cholinesterase depression renders the results of 
questionable toxicological significance. 
3.2.1.5 Reproductive Effects  
No reports were located regarding reproductive effects in humans following inhalation exposure to 
tungsten or tungsten compounds. 
Decreased sperm motility (10–12% lower than controls) was reported in male rats continuously exposed 
to atmospheres containing sodium tungstate powder for 17 weeks at concentrations of 1.0 and 0.5 mg/m3, 
but not at 0.1 mg/m3 (Idiyatullina 1981). 
3.2.1.6 Developmental Effects 
No reports were located regarding developmental effects in humans or animals following inhalation 
exposure to tungsten or tungsten compounds. 
3.2.1.7 Cancer 
No reports were located in which cancer in humans or animals could be associated with inhalation 
exposure to tungsten or tungsten compounds. 
3.2.2 Oral Exposure  
The toxicity of ingested tungsten in humans is not known.  In an early report, Kruger (1912) reported no 
adverse effects on patients administered 25–80 g of tungsten powder as a substitute for barium in 
radiological exams.  Nausea, followed by seizure, 24-hour coma, temporary renal failure, and subsequent 
tubular necrosis and anuria were reported in a male subject who had accidentally consumed metallic 
tungsten in a mixture of beer and wine (Marquet et al. 1997).  However, these effects could not be 
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been widely studied in animals.  Available reports implicate reproductive, developmental, and 
neurological effects as end points of concern following oral exposure to tungsten (Karantassis 1924;
Nadeenko 1966; Nadeenko and Lenchenko 1977; Nadeenko et al. 1977, 1978).  However, these reports 
are lacking in some study details, thus limiting their value for purposes of quantitative risk assessment. 
3.2.2.1 Death 
No reports were located in which death in humans was associated with oral exposure to tungsten or 
tungsten compounds. 
Acute oral exposure to tungsten does not appear to be a particular toxicity concern, based on acute oral 
LD50 values ranging from 240 to 11,300 mg/kg/day for several soluble tungsten compounds (Table 3-2).  
Death was reported in guinea pigs following single oral (gavage) administration of sodium tungstate at 
doses ≥780 mg/kg (Karantassis 1924). Concentrations of 2.0% tungsten (as sodium tungstate), 4% 
tungsten (as tungstic oxide), or 5.0% tungsten (as ammonium paratungstate), in the daily diet of rats 
resulted in 100% mortality within 10 days following the initiation of test diet (Kinard and Van de Erve 
1941).  Diets containing the equivalent of 0.5% tungsten (as sodium tungstate, tungstic oxide, or 
ammonium paratungstate) resulted in mortality of 3/6 males and 4/6 females, 4/5 males and 5/5 females, 
and 0/5 males and 0/5 females, respectively.  No deaths occurred in rats receiving 0.1% tungsten (as 
sodium tungstate or tungstic oxide) in the diet for 70 days.  In another study, no deaths were reported in 
rats administered diets containing as much as 10% tungsten metal powder for 70 days (Kinard and Van de 
Erve 1943).  Approximately 15% decreases in longevity were observed in male, but not female, rats 
administered tungsten (as sodium tungstate) in the drinking water at a concentration of 5 mg/L for life (up 
to 3 years) (Schroeder and Mitchener 1975a, 1975b). 
Available information regarding mortality and LD50 values in animals orally exposed to selected tungsten 
compounds is recorded in Table 3-3 and plotted in Figure 3-2. 
3.2.2.2 Systemic Effects  
No human data were located in which systemic toxicity could be associated with oral exposure to 
tungsten or tungsten compounds.  Reliable NOAELs and LOAELs for body weight changes in animals 
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Rat 840a 1,190±129.5a 11,300b 1,600±201a 
Rabbit NA 875a NA NA
Guinea pig NA 1,152a NA NA
aNadeenko 1966 
bSmyth et al. 1969 






























































11300 M (LD50) Smyth et al. 1969 
ammonium paratungstate 
5 Mouse Once 240 (LD50) Nadeenko 1966 
sodium tungstate 
6 Mouse Once 700 (LD50) Nadeenko 1966 
sodium phosphotungstate 
7 Gn Pig Once 1152 (LD50) Nadeenko 1966 
sodium tungstate 
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Kinard and Van de Erve 1941 
sodium tungstate 
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metallic tungsten 





TSa The number corresponds to entries in Figure 3-2 
b Differences in levels of health effects and cancer effects between male and females are not indicated in Figure 3-2. Where such differences exist, only the levels of effect for the 
most sensitive gender are presented. 
Bd Wt = body weight; F = female; (F) = feed; LD50 = dose producing 50% death; LOAEL = lowest-observed-adverse-effect level; M = male; NOAEL = no-observed-adverse-effect 

















Figure 3-2. Levels of Significant Exposure to Tungsten - Oral
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No reports were located in which respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, endocrine, dermal, or ocular effects were associated with oral exposure of 
humans or animals to tungsten or tungsten compounds. 
Renal Effects. Available information in humans is restricted to an account of temporary renal failure 
and subsequent tubular necrosis and anuria in a male subject 1 day following the accidental consumption 
of metallic tungsten in a mixture of beer and wine that had been poured into the hot barrel of a 155-mm
gun (Marquet et al. 1997).  The author estimated the absorbed dose of tungsten to be in the range of 5– 
12 mg/kg.  The subject fully recovered.  The renal effects could not be attributed to tungsten per se, and 
Lison et al. (1997) suggested that nitroaromatics used as propellants for large caliber ammunition may
have contributed to the renal toxicity. 
No information was located regarding renal effects in animals following oral exposure to tungsten or 
tungsten compounds. 
Body Weight Effects.    No information was located regarding body weight effects in humans 
following oral exposure to tungsten or tungsten compounds. 
Available information regarding tungsten-induced body weight effects in animals is limited to reports by
a single group of investigators (Kinard and Van de Erve 1941, 1943).  Reduced body weight gains were 
noted in rats exposed to sublethal concentrations of tungsten (0.5%, as ammonium paratungstate; 0.1%, as 
sodium tungstate or tungstic oxide) in the diet for 70 days (Kinard and Van de Erve 1941).  Body weight 
gain in these treated groups ranged from 3.9 to 10.6% lower than respective controls.  Weight gain in 
female rats, administered a diet that included 10% tungsten (as insoluble tungsten metal) for 70 days, was 
approximately 15.5% less than that of controls; weight gain in similarly dosed male rats was described as 
“normal” (Kinard and Van de Erve 1941).  The authors stated that diets containing 2 or 5% tungsten (as 
tungsten metal) were “without marked effect” on growth.  Statistically significantly increased body
weights were noted at some time points in male and female rats administered tungsten (as sodium
tungstate) in the drinking water at a concentration of 5 mg/L for a lifetime (Schroeder and Mitchener 
1975a). Since the body weights were less than 10% higher than controls and were only seen in males at 
180–540 days of treatment and in females at the 360-day examination period, the increased body weight 
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3.2.2.3 Immunological and Lymphoreticular Effects  
No reports were located regarding immunological or lymphoreticular effects in humans or animals 
following oral exposure to tungsten or tungsten compounds. 
3.2.2.4 Neurological Effects 
Information in humans is restricted to a single account of nausea, followed by seizure and 24-hour coma
in a male subject who had accidentally consumed metallic tungsten in a mixture of beer and wine that had 
been poured into the hot barrel of a 155-mm gun (Marquet et al. 1997).  The author estimated the 
absorbed dose of tungsten to be in the range of 5–12 mg/kg.  The subject fully recovered. 
Available early animal data indicate that orally administered tungsten may induce neurological effects.  
Guinea pigs exhibited clinical signs that included trembling and abnormal locomotor behavior following 
single oral (gavage) administration of sodium tungstate at ultimately lethal doses (≥780 mg/kg) 
(Karantassis 1924).  Decreased blood cholinesterase activity and impaired conditioned reflexes were 
reported in rats orally exposed to sodium tungstate at doses in the range of 0.05–5.0 mg/kg/day for 
7 months (Nadeenko 1966).  Deficiencies in study details render the results of this Russian study of 
limited value for purposes of quantitative risk assessment. 
3.2.2.5 Reproductive Effects  
No information was located regarding reproductive effects in humans following oral exposure to tungsten 
or tungsten compounds. 
Information in animals is limited to reports of embryotoxicity in rats following oral administration of an 
unspecified tungsten compound at dose levels as low as 0.005 mg/kg for up to 8 months before and 
during pregnancy (Nadeenko and Lenchenko 1977; Nadeenko et al. 1977, 1978). However, these reports 
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3.2.2.6 Developmental Effects 
No information was located regarding developmental effects in humans following oral exposure to 
tungsten or tungsten compounds. 
Information in animals is limited to reports of delayed fetal skeletal ossification following oral exposure 
to tungsten at reported dose levels as low as 0.005 mg/kg to pregnant rat dams (Nadeenko and Lenchenko 
1977; Nadeenko et al. 1977, 1978).  However, these reports are lacking in some study details, thus 
limiting their value for purposes of quantitative risk assessment. 
3.2.2.7 Cancer 
Information regarding the carcinogenicity of ingested tungsten in humans is restricted to a single report of 
the Center for Disease Control (CDC 2003b) in which no statistically significant association (odds ratio 
0.78, p-value 0.57) was found between exposure to tungsten in the drinking water and leukemia observed 
in a population of Churchill County, Nevada. 
Gross tumor incidences in rats administered tungsten (as sodium tungstate) in the drinking water at a 
concentration of 5 mg/L for life were similar to those of controls (Schroeder and Mitchener 1975a).  Male
rats administered sodium tungstate (100 ppm) in the drinking water for 19 or 30 weeks did not exhibit 
treatment-related evidence of carcinoma in the esophagus or forestomach; nor did sodium tungstate 
treatment enhance the carcinogenic effect of N-nitrososarcosine ethyl ester, a chemical known to induce 
esophageal cancer in rats (Luo et al. 1983). In a study designed to assess the effect of systemic sulfite on 
benzo[a]pyrene-induced lung carcinoma in rats, Gunnison et al. (1988) administered sodium tungstate to 
induce sulfite oxidase deficiency, thus increasing systemic sulfite.  In this study, sodium tungstate did not 
statistically significantly affect the initiation of squamous cell carcinoma of the respiratory tract of 
benzo[a]pyrene-treated rats or incidences of mammary gland tumors.  Results of Wei et al. (1987) 
indicated that tungsten may act as a tumor promoter in rats administered 150 ppm of tungsten in the 
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3.2.3 Dermal Exposure  
3.2.3.1 Death 
No reports were located in which death in humans was associated with dermal exposure to tungsten or 
tungsten compounds. 
Available information in animals was limited to a single report of death in 0/2, 2/2, and 2/2 rabbits 
following dermal application of a 5% tungsten chloride solution in single doses of 100, 200, and 
1,000 mg/kg, respectively (Dow Chemical Company 1982).  The results of this study are recorded in 
Table 3-4. 
3.2.3.2 Systemic Effects  
No reports were located in which respiratory, cardiovascular, gastrointestinal, hematological,
musculoskeletal, hepatic, renal, endocrine, or body weight effects were associated with dermal exposure 
of humans or animals to tungsten or tungsten compounds. 
Dermal Effects.    No reports were located in which dermal exposure to tungsten compounds in humans 
could be associated with dermal effects.  Although dermatitis has been reported among employees of the 
hard metal industry, results of patch testing implicated cobalt, not tungsten (Schwartz et al. 1945; Skog 
1963). 
In the only available report of dermal effects in animals following dermal exposure to tungsten, single or 
repeated dermal application of a 5% tungsten chloride solution in rabbits resulted in contact dermatitis 
(Dow Chemical Company 1982).  The results of this study are recorded in Table 3-4. 
Ocular Effects.    No reports were located in which dermal exposure to tungsten compounds in humans 
could be associated with ocular effects.
Instillation of a 5% tungsten chloride solution into the rabbit eye resulted in conjunctivitis, iritis, and 
corneal haziness that resolved within 14 days postinstillation (Dow Chemical 1982).  The results of this 
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No reports were located regarding the following health effects in humans or animals following dermal 
exposure to tungsten or tungsten compounds: 
3.2.3.3 Immunological and Lymphoreticular Effects  
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
3.2.4 Other Routes of Exposure 
No reports were located in which systemic (other than possible hematological effects), neurological, or 
reproductive effects were associated with exposure of humans or animals to tungsten or tungsten 
compounds by routes other than inhalation, oral, or dermal exposure. 
Death. Parenteral injection studies that have been performed using laboratory animals were designed 
to establish lethal doses of tungsten compounds and to assess the efficacy of methods to reduce toxicity
(see also Section 3.11). An LD50 value of 500 mg/kg was reported for intraperitoneally injected tungsten 
metal in rats; tungsten carbide was considered to be essentially inert, although dose levels were not 
included in the report (Fredrick and Bradley 1946).  An LD50 was between 140 and 160 mg/kg for 
tungsten (as sodium tungstate) subcutaneously injected into 66-day-old rats; younger rats appeared to be 
less sensitive (Kinard and Van de Erve 1940).  Intramuscular injection of a 10% aqueous solution of 
sodium tungstate in rats (Sivjakov and Braun 1959) and rabbits (Lusky et al. 1949) resulted in LD50 
values of 220.6 and 105 mg/kg, respectively. 
Hematological Effects. The results of Kalinich et al. (2005) indicate the potential for tungsten alloy-
induced hematotoxicity (expressed by increases in leukocyte and erythrocyte counts, hemoglobin, and 
hematocrit).  However, since the tungsten alloy pellets consisted of nickel and cobalt in addition to 
tungsten, the role of tungsten in the observed effects is not known. Results of in vitro testing by one 
group of investigators (Miller et al. 2001, 2002) indicate the potential for synergistic effects following 
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Immunological and Lymphoreticular Effects.    The results of Kalinich et al. (2005) indicate the 
potential for tungsten alloy-induced immunotoxicity (expressed by increased spleen weight and decreased 
thymus weight).  However, since the tungsten alloy pellets consisted of nickel and cobalt in addition to
tungsten, the role of tungsten in the observed effects is not known. Results of in vitro testing by one 
group of investigators (Miller et al. 2001, 2002) indicate the potential for synergistic effects following 
exposure to tungsten alloys such as tungsten-cobalt-nickel and tungsten-nickel-iron. 
Developmental Effects. Wide (1984) assessed the potential for tungsten to induce developmental 
toxicity in mice.  Pregnant dams were administered a single intravenous injection (0.1 mL) of a 25 mM
sodium tungstate solution on gestation day 8.  Although there was no indication of tungsten-induced fetal 
malformations at examination on gestation day 17, a significantly increased incidence of resorptions was 
noted. 
Cancer. Kalinich et al. (2005) recently assessed the potential health consequences of intramuscularly
implanted weapons-grade tungsten alloy pellets in male F344 rats.  Within 4–5 months, all of the tungsten 
alloy-implanted (n=92) rats developed extremely aggressive localized tumors (high-grade pleomorphic 
rhabdomyosarcomas) that rapidly metastasized to the lungs, necessitating euthanasia.  No tumors were 
found in a group of 46 rats implanted with an inert control metal (tantalum), even up to 12 months 
postimplantation.  The tungsten alloy pellets consisted of 91.1% tungsten, 6% nickel, and 2.9% cobalt.  
Kalinich et al. (2005) also embedded 36 rats with nickel pellets to serve as positive controls for the 
tungsten-alloy embedded rats since intramuscularly-injected nickel has previously been demonstrated to 
cause injection-site tumors (Heath and Daniel 1964). All of the nickel-embedded rats developed tumors 
similar to those observed in the tungsten alloy-embedded rats (Kalinich et al. 2005).  Previous 
experiments with intramuscularly-injected cobalt have also demonstrated a carcinogenic effect (Heath 
1954, 1956).  Since both nickel and cobalt, components of the tungsten-alloy pellets used by Kalinich et 
al. (2005), are known to be carcinogenic when injected intramuscularly, the potential role of tungsten in
the carcinogenic effect of the tungsten alloy pellets used by Kalinich et al. (2005) could not be
determined. 
3.3 GENOTOXICITY  
The genotoxic potential of tungsten and tungsten compounds has not been extensively assessed.  Sodium
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(Pf-13) (Ulitzur and Barak 1988).  Sodium tungstate induced lambda prophage in Escherichia coli
WP2s (λ) (Rossman et al. 1984, 1991) and gene conversion at trp 5 and reverse mutation at ilv 1 in 
Saccharomyces cerevisiae strain D7 (Singh 1983), and increased recombinant frequency in strain DIS13 
(Sora et al. 1986). Positive results were obtained for tungstate anion in Chinese hamster lung V79 cells 
using the HGPRT forward mutation assay (Zelikoff et al. 1986).  Tungsten (form not specified) enhanced 
mutagenic activity in Salmonella typhimurium strain TA98 and Ames mixed strains (TA7001-7006) 
(Miller and Page 1999). 
Sodium tungstate did not increase sister chromatid exchanges in human whole blood cultures or cause 
chromosome aberrations in human lymphocytes or Syrian hamster embryo cells (Larramendy et al. 1981).
The chemical did not induce morphological transformation in Syrian hamster cells (DiPaolo and Casto 
1979). 
Dose- and time-dependent increases in DNA single strand breaks (comet and alkaline elution tests) and 
micronucleus induction were observed in human peripheral lymphocytes incubated in either tungsten 
carbide cobalt alloy or cobalt alone, but not in tungsten carbide alone (Anard et al. 1997; Van Goethem
1997). In each of these tests, the genotoxic effect of the tungsten carbide cobalt alloy was greater than 
that of cobalt alone, which is consistent with a suggestion that physicochemical properties of the alloy
may result in increased production of hydroxyl radicals (see also Section 3.5.2).  Using human osteoblast 
cells, Miller et al. (2001) found that heavy metal-tungsten alloys composed of tungsten (92%), nickel 
(5%), and either cobalt (3%) or iron (3%) are capable of inducing neoplastic transformation 
(characterized by anchorage-dependent growth, tumor formation in nude mice, and expression of high 
levels of the K-ras oncogene), as well as increased DNA strand breakage and micronuclei at rates 
exceeding that of nickel sulfide (a well-known transforming agent and carcinogen).  More recently, Miller 
et al. (2004) demonstrated that pure tungsten is capable of inducing a similar effect, but at a significantly
reduced magnitude relative to the heavy metal-tungsten alloys.   
3.4 TOXICOKINETICS 
3.4.1 Absorption
3.4.1.1 Inhalation Exposure 
No quantitative data were located concerning absorption of tungsten in humans following inhalation 
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a report that tungsten levels in urine, toenails, and hair of workers occupationally exposed to airborne 
tungsten were higher than those of controls without known inhalation exposure (Nicolaou et al. 1987). 
Available animal data, derived primarily from studies that employed radioactive tungsten isotopes that are 
identical to their respective nonradioactive isotopes with respect to toxicokinetics, demonstrate absorption 
following exposure to airborne tungsten.  Beagle dogs were exposed (nose only) once (duration 
unspecified) to particulate aerosols of tungstic oxide (181WO3) (Aamodt 1975).  Inhaled radioactivity was 
determined to range from 1.9 to 8 µCi and the inhaled radioactivity exhibited an activity median 
aerodynamic diameter (AMAD) of 0.7 µm and a geometric standard deviation of 1.5 µm.  An estimated 
60% of the inhaled radioactivity was deposited in the respiratory tract, approximately half of which was 
contained in the tracheobronchial and pulmonary regions.  These estimates were based on periodic 
measurements of radioactivity in inspired versus expired air, in the lung region versus the lower body, and 
in the urine and feces.  An estimated 33% of the radioactivity deposited in the lung was absorbed directly
into the blood, most of which had entered the blood within the first 10 days following exposure.  Based 
on measurements of radioactivity in the urine and feces, an estimated 66% of the initial lung burden was 
cleared to the gastrointestinal tract via the ciliary escalator system.  Comparison with results of the 
investigator’s ingestion experiment using a single beagle dog indicated that one-fourth of the radioactivity
entering the gastrointestinal tract may have been absorbed to the blood.  Therefore, about half of the 
amount that was initially deposited in the lungs, corresponding to about one-third of the inhaled amount, 
may have eventually been absorbed to blood. 
3.4.1.2 Oral Exposure  
No quantitative data were located concerning absorption of tungsten in humans following oral exposure to 
tungsten or tungsten compounds.  However, total intake and urinary and fecal excretion of tungsten and 
other nonessential elements were recorded for four healthy human volunteers given controlled diets for 
5 days (Wester 1974).  Assuming that the subjects were in tungsten balance, that the intake was primarily
via the diet, and that daily urinary excretion of tungsten (approximately 6 µg/day) was proportional to the 
daily intake (approximately 10 µg/day), approximately 60% of the ingested tungsten appeared to have 
been absorbed from the gastrointestinal tract.  Additional indication of the absorption of ingested tungsten 
derives from the findings of high concentrations of tungsten in blood, urine, hair, and nail samples of a 
19-year-old male who had consumed a mixture of beer and wine that contained a high concentration of 
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coupled plasma (ICP) emission-spectrometry, a procedure that did not detect tungsten in samples taken 
from individuals without known exposure to tungsten at levels above normal background. 
Results of animal studies suggest that tungsten is readily absorbed following oral administration of 
soluble tungsten compounds.  In rats, approximately 40% of an orally administered dose of 185W sodium
tungstate (Na2WO4) was collected in the 24-hour urine (Ballou 1960; Kaye 1968).  Approximately 25%
of the activity in a single gavage dose of tungstic oxide was excreted in the urine of a single dog (Aamodt 
1975), which indicates that tungsten is readily absorbed from the gastrointestinal tract of the dog as well.  
Poucheret et al. (2000) and LeLamer et al. (2000) assessed the absorption of tungsten (as sodium
tungstate) following single oral administration in rats (36 mg sodium tungstate/kg) and dogs (25 mg
sodium tungstate/kg) by plotting plasma tungsten concentrations at a number of time points (up to 
24 hours) postadministration and comparing the area under the curve (AUC) in each plot to that obtained 
from species-specific animals that had received single intravenously-administered doses of 8.97 mg
sodium tungstate/kg.  Using this approach, absorption of tungsten was calculated to approximate 92% in 
the rat and 65% in the dog.  Absorption of tungsten was calculated to approximate 55% during repeated 
oral dosing of dogs at 5–20 mg sodium tungstate/kg, 3 times/day for 13 weeks (LeLamer et al. 2001).   
3.4.1.3 Dermal Exposure  
No studies were located regarding absorption of tungsten in humans or animals following dermal 
exposure to tungsten or tungsten compounds.  However, the report of death in rabbits following dermal 
application of a 5% tungsten chloride solution in single doses of 100–1,000 mg/kg (Dow Chemical 
Company 1982) indicates that dermal absorption of tungsten occurs to some extent. 
3.4.2 Distribution  
3.4.2.1 Inhalation Exposure 
No reports were located regarding quantifiable distribution of tungsten in humans following inhalation 
exposure to tungsten or tungsten compounds.  However, when compared to controls without known 
occupational exposure to tungsten, higher levels of tungsten in hair and nails of workers occupationally
exposed to airborne tungsten serves as indication that inhaled tungsten may be distributed to these sites 
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Beagle dogs were exposed (nose only) once (duration unspecified) to particulate aerosols of tungstic 
oxide (181WO3) (Aamodt 1975).  Inhaled radioactivity was determined to range from 1.9 to 8 µCi, and the 
inhaled radioactivity exhibited a mean aerodynamic diameter (AMAD) of 0.7 µm and a geometric 
standard deviation of 1.5 µm.  Approximately 70% of the initial tungsten lung burden, which was 
estimated to have been approximately 60% of the inhaled radioactivity, was removed with a half-time of 
4 hours.  Another 20–25% was removed with a half-time of 20 hours, and approximately 5% with a half­
time of 6.3 days.  A small amount of tungsten may have been retained by the lung for months.  
Approximately 33% of the tungsten that was removed from the lung entered the blood directly.  An 
estimated 66% was transported upwards via mucociliary action and swallowed, most of which was 
subsequently excreted in the feces.  At sacrifice (approximately 165 days postexposure), the average body
burden calculated from organ and tissue samples was 0.017 (1.7%) of the inhaled activity.  The highest 
concentrations were in the lungs and kidneys.  Radioactivity measured in bone, gall bladder, liver, and 
spleen was approximately 10-fold lower than that of lungs and kidneys.  Measurable activity was also 
found in decreasing concentration in testes, pancreas, large intestine, small intestine, diaphragm, stomach, 
heart, and skeletal muscle, respectively. In terms of total activity in individual organs and tissues, activity
was highest in bone (37% of the body burden at sacrifice), followed by lung (31%), kidneys (15%), liver 
(9.7%), and skeletal muscle (5.7%). 
3.4.2.2 Oral Exposure  
No reports were located regarding quantifiable distribution of tungsten in humans following oral exposure 
to tungsten or tungsten compounds.  However, findings of measurable levels of tungsten in blood, urine, 
hair, and nail samples, taken from a 19-year-old male who had consumed a mixture of beer and wine that 
contained a high concentration of metallic tungsten (Marquet et al. 1997), indicated that ingested tungsten 
is absorbed by the blood and distributed systemically.  The presence of tungsten in the urine of subjects 
who voluntarily consumed diets that were supplemented with tungsten is further indication that ingested 
tungsten is distributed systemically (Wester 1974). 
Results of animal studies indicate that orally administered tungsten (in soluble form) rapidly enters the 
blood and is distributed via systemic circulation.  In rats, most of the radioactivity in an initial oral 
(gavage) dose of sodium tungstate (activity of 34.3 µCi) had been eliminated in the first 24 hours 
postadministration (Ballou 1960).  However, approximately 2% of the initial radioactivity was retained.  
On day 1 postadministration, the highest concentrations of radioactivity were measured in the 
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also noted in liver > ovaries > pancreas > lung > heart > blood > fat > muscle.  At 102 days
postadministration, the highest concentrations of retained radioactivity were in the spleen and skeleton.  
Total skeletal deposition was about 0.4% of the administered dose. 
Similar results were reported by Kaye (1968).  Rats were administered single gavage doses of solutions 
containing radiotungsten (187W or 185W) as tungstate. Distribution and elimination of radioactivity was 
examined for 72 hours (187W) or 254 days (185W) postadministration.  During the first 24 hours following 
dosing, virtually all of the radioactivity measured in the blood was associated with the plasma portion.  
During the next 2 days of measurements, radioactivity appeared in the cellular portion and accounted for 
approximately two-thirds of the radioactivity in the blood 72 hours following dosing, at which time, 
approximately 97% of the initially administered dose of radiotungsten had been eliminated from the body. 
During the first week after dosing, highest concentrations of radiotungsten in soft tissues were observed in 
spleen, hair, kidney, uterus, liver, prostate, and ovary.  After 100 days, >99% of the remaining total body 
burden (approximately 0.4% of the administered dose) was retained in bone. 
Results of an earlier rat study (Kinard and Aull 1945) also indicated that bone and spleen retained the 
highest concentrations of tungsten following dietary administration of tungsten (as tungstic oxide, sodium
tungstate, ammonium paratungstate, or tungsten metal) for 100 days. 
3.4.2.3 Dermal Exposure  
No studies were located regarding distribution of tungsten in humans or animals following dermal 
exposure to tungsten or tungsten compounds.  However, a report of death in rabbits following a single 
dermal application of a 5% tungsten chloride solution (Dow Chemical Company 1982) is evidence of 
systemic distribution of dermally-applied tungsten. 
3.4.2.4 Other Routes of Exposure 
Intravenous injection studies of radiotungsten (Na2181WO4) support the results of inhalation and oral 
studies (Ando et al. 1989; Wase 1955; Wide et al. 1986).  Three hours postadministration, levels of 
radiotungsten in rats were as follows: kidney > bone > liver >lung > adrenal > spleen > pancreas > blood 
> thymus > cardiac muscle > skeletal muscle > brain (Ando et al. 1989).  At 48 hours postadministration, 
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amounts were noted in the other examined tissues and organs.  Eight hours following intraperitoneal 
injection of 185W (as K2185WO4) in mice, relative concentrations of radioactivity were:  bone > 
gastrointestinal tract > spleen > kidney > red blood cells > heart > lung > liver > plasma > brain (Wase 
1955). After 48 hours postadministration, nearly all of the measurable radioactivity was in the bone. 
Wide et al. (1986) demonstrated that intravenously injected tungstate (185W) readily crossed the placenta 
of pregnant rats and was distributed to the fetus.  Embryonic uptake was greater in dams injected at later 
stages of gestation (day 17) as opposed to earlier stages (day 8 or 12).  Radiotungsten accumulated in yolk
sac epithelium at all examined gestational stages.  The highest level of fetal retention was noted in the 
skeleton. 
3.4.3 Metabolism 
Tungsten ion in the body is not known to be metabolized.  It has been postulated that tungsten may
preferentially occupy enzyme sites normally reserved for the essential element, molybdenum, because 
sodium tungstate has been shown to antagonize the normal metabolic action of molybdate in its role as 
cofactor for the enzymes xanthanine dehydrogenase (Higgins et al. 1956a, 1956b), sulfite oxidase, and 
aldehyde oxidase (Johnson and Rajagopalan 1974), and xanthine oxidase secretion to milk (Owen and 
Proudfoot 1968) in animal systems.  See Section 3.5.2 for detailed information regarding mechanisms of 
tungsten-induced toxicity. 
3.4.4 Elimination and Excretion 
Elimination and excretion of tungsten is discussed without subdividing data according to route of 
exposure. Once tungsten has been systemically distributed following inhalation, oral, or dermal exposure 
or parenteral injection, the pattern of elimination is similar across exposure routes. 
Information concerning elimination and excretion of tungsten in humans is limited to findings of 
measurable amounts of tungsten in urine of individuals exposed to tungsten either in the workplace air 
(see Barborik 1972; Nicolaou et al. 1987) or by controlled (Wester 1974) or accidental (Marquet et al. 
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Inhalation, oral, and parenteral injection studies in laboratory animals all indicate that absorbed tungsten 
is rapidly eliminated from the blood and quickly excreted in large quantities in the urine.  Combined 
urinary and fecal excretion of radiotungsten from dogs following inhalation exposure to particulate 
aerosols of 181WO3 was described by three exponential components (Aamodt 1975).  Approximately 90%
of the inhaled radioactivity was removed with a biological half-time of about 14 hours; 6% with a half­
time of 5.8 days, and 4% with a half-time of 63 days. The average urine to fecal ratio was 1.14 for the 
100 days of postexposure measurements, including the portion of tungsten that entered the blood directly
from the lungs (approximately 33% of the deposited dose) as well as that which was deposited in the 
gastrointestinal tract via mucociliary clearance (approximately 66% of the initial lung burden).
Radiotungsten was rapidly excreted from rats following oral dosing (Kaye 1968).  In a study of rats 
administered single gavage doses of 185W and followed for 72 hours, approximately 40% of the 
administered dose of radiotungsten had been eliminated in the urine in the first 12 hours 
postadministration; an additional 3% was eliminated during the subsequent 60 hours.  The initial rate of 
fecal excretion was lower than that of urinary excretion; however, by 72 hours, fecal excretion had 
accounted for approximately 53% of the administered dose.  Thus, 72-hour urinary and fecal excretion 
accounted for 97% of the administered dose.  Other rats were similarly administered 185W and followed 
for up to 254 days.  During the first 3 days following dosing, approximately 36 and 39% of the 
administered dose had been recovered in the urine and feces, respectively.  By day 33 postadministration, 
radiotungsten could no longer be detected in the feces.  Trace amounts of radiotungsten were still detected 
in urine analyses conducted until day 191 and correlated with slow elimination of 185W from bone.  In 
dairy cows that were orally administered radiotungsten, approximately 0.4% of the administered dose was 
recovered in the milk during the first 84 hours postadministration (Mullen et al. 1976). 
Following intravenous injection of dogs with 181W (as sodium tungstate), elimination from the blood was 
rapid (Aamodt 1973).  By 24 hours, 91% of the injected radioactivity had been excreted in the urine.  An 
initial urinary to fecal ratio of 49 on day 1 was reduced to a constant value of 38 by day 7. 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
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potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.   
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps:  (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 





















43 TUNGSTEN  
3. HEALTH EFFECTS 
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in 
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.  
Figure 3-3 shows a conceptualized representation of a PBPK model. 
If PBPK models for tungsten exist, the overall results and individual models are discussed in this section 
in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations. 
International Commission for Radiological Protection (ICRP 1981) Biokinetic Model for 
Tungsten 
The ICRP’s modular approach to biokinetic modeling. 
In ICRP documents addressing occupational or environmental exposures to radionuclides, the biokinetic 
model for an element consists of three submodels:  a respiratory tract model, a gastrointestinal tract 
model, and an element-specific systemic biokinetic model.  For a given element, the generic respiratory 
tract model is used to describe the deposition and retention of inhaled material in the respiratory tract and 
subsequent clearance to blood or the gastrointestinal tract via mucociliary transport and swallowing.  The 
generic gastrointestinal tract model is used to describe the movement of swallowed or endogenously
secreted material through the stomach and intestines, and, together with an element-specific 
gastrointestinal absorption fraction (f1 value), to describe the rate and extent of absorption of the element 
to blood. An element-specific systemic biokinetic model is used to describe the time-dependent 
distribution and excretion of the element after its absorption into blood. 
The ICRP’s gastrointestinal model (ICRP 1979) as applied to tungsten (ICRP 1981). 
The ICRP’s generic gastrointestinal tract model divides the gastrointestinal contents into stomach (S), 
small intestine (SI), upper large intestine (ULI), and lower large intestine (LLI).  Material moves from S 
to SI at the rate of 24 day-1, from SI to ULI at 6 day-1, from ULI to LLI at 1.8 day-1, and from LLI to feces 
at 1 day-1. Absorption to blood is represented as transfer from SI to blood.  In the absence of radioactive 
decay, the fraction f1 of the ingested element moves from SI to blood and the fraction 1-f1 moves from SI
to ULI. The transfer coefficient from SI to blood is 6f1/(1-f1) day-1. An absorption fraction f1 of 0.3 is 
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Figure 3-3. Conceptual Representation of a Physiologically Based 

Pharmacokinetic (PBPK) Model for a  

Hypothetical Chemical Substance 

Source: adapted from Krishnan et al. 1994 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
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Differences in the values for f1 reflect measured differences in fractional absorption of various tungsten 
compounds in rats (Ballou 1960; Kaye 1968). 
The ICRP’s respiratory model (ICRP 1994a) as applied to tungsten (ICRP 1995).
The ICRP uses a generic respiratory model (ICRP 1994a) to describe deposition and retention of inhaled 
elements in the respiratory tract, absorption to blood, and transfer to the stomach via movement up the 
tracheobronchial tree in mucus and subsequent swallowing.  The kinetics of swallowed activity is 
described by the gastrointestinal tract model summarized above.  Elements or specific compounds of 
elements inhaled in particulate form are assigned to one of three “absorption types” representing the rate 
of transfer of material from the lungs to blood, which in turn is related to the rate of dissolution of the 
material in the respiratory tract.  The three absorption types are Type F, representing fast absorption; Type
M, representing moderately slow absorption; and Type S, representing slow absorption. There are 
numerous parameter values associated with each absorption type; these will not be listed here.  
Compounds of tungsten are assumed to be dissolved fairly rapidly in the respiratory tract and, thus, are 
assigned to Type F (ICRP 1994b). 
The ICRP’s systemic biokinetic model for tungsten (ICRP 1981). 
The ICRP uses an element-specific systemic biokinetic model to describe the kinetics of the element after 
its absorption to blood from the respiratory tract or gastrointestinal tract, or entry from wounds or direct 
injection into blood.  The ICRP’s current systemic biokinetic model for tungsten (ICRP 1981) was 
developed in the 1970s.  The model (Figure 3-4) consists of exponential curve fits to selected data on the 
relatively short-term behavior of tungsten in dogs, goats, and rats.  In the development of the model, no 
attempt was made to reflect the physiological processes that control the biokinetics of tungsten or to 
depict actual paths of movement of this element in the body.  Absorbed tungsten is assumed to enter the 
blood, from which 95% immediately transfers to excreta by unspecified routes, 2.5% transfers to bone 
mineral, 1% transfers to kidney, 1% transfers to liver, and 0.5% transfers to spleen.  Tungsten in bone is 
removed in excretion with half-times of 4 days (20%), 100 days (10%), and 1,000 days (70%).  Tungsten 
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Figure 3-4.  ICRP (1981, 2001) Biokinetics Model for Tungsten 
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Validation of the model. 
The extent to which the ICRP model has been validated is not described in ICRP (1981). 
Risk assessment. 
The model has been used to establish radiation dose equivalents (Sv/Bq) of ingested and inhaled 
radioactive tungsten isotopes for ages 1 day to 50 years (ICRP 2001). 
Target tissues. 
The model is designed to calculate intake limits for radioactive tungsten, based on radiation dose to all 
major organs, including the bone surfaces, bone marrow, and soft tissues. 
Species extrapolation. 
The model is designed for applications to human dosimetry and cannot be applied to other species without
modification. 
Interroute extrapolation. 
The ICRP’s systemic biokinetic model for tungsten can be applied to any route of exposure (e.g., from the 
respiratory or GI tract, wounds, through the skin, or via intravenous injection), provided information is 
available on the time-course of entry of tungsten into blood. 
Leggett (1997) Model of the Biokinetics of Absorbed Tungsten 
Description of the model. 
Leggett (1997) developed a compartmental model of the biokinetics of absorbed tungsten in adult humans 
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(ICRP 1994).  The model differs considerably from the ICRP’s systemic biokinetic model for tungsten 
with regard to structure, basis for parameter values, and predicted retention of tungsten in tissues.  The 
model structure (Figure 3-5) is intended to depict physiologically realistic directions of movement of 
tungsten in the human body, including the systemic redistribution of tungsten that enters blood after 
removal from tissues.  Model parameters are based on results of biokinetic studies of tungsten in dogs, 
swine, sheep, goats, cows, and rodents. Although tungsten biokinetics has been studied more frequently
in rats than other species, data for rats were given low weight in selection of most parameter values 
because of known qualitative differences between rats and humans in the handling of molybdenum, a 
chemical and physiological analogue of tungsten.  It is suspected that membrane transport may not 
distinguish between analogous compounds of tungsten and molybdenum, although biokinetic differences 
between tungsten and molybdenum arise, probably because molybdenum compounds are more easily
reduced in biological systems (Callis and Wentworth 1977).  The species differences recognized for 
molybdenum may apply to tungsten as well, as suggested by the much faster excretion of tungsten by rats 
than other studied species and apparent differences in the distribution of retained tungsten.  On the other 
hand, some aspects of the biokinetics of tungsten or molybdenum, including long-term skeletal retention 
due to substitution of tungstate or molybdate for phosphate in bone, are expected to be independent of 
species. 
The structure of the model for tungsten (Figure 3-5) is essentially the same as that applied in ICRP 
Publication 69 (1995) to a set of “bone-volume-seeking” elements, including calcium, strontium, barium, 
radium, lead, and uranium.  It is assumed that the kinetics of tungsten that deposits in bone can be related 
to the kinetics of the major components of bone mineral, calcium, and phosphorus.   
Transport of tungsten between compartments is assumed to follow first-order kinetics.  Three 
compartments are used to describe the kinetics of circulating tungsten:  (1) blood plasma, (2) red blood 
cells, and (3) a rapid-turnover soft-tissue compartment representing extracellular fluids.  The 
rapid-turnover soft-tissue compartment is used to depict an early build-up of tungsten in extravascular 
spaces followed by relatively rapid feedback to blood.  The total transfer rate from plasma to all 
destinations is set at 16.64 day-1, corresponding to a removal half-time of 1 hour.  The rapid-turnover soft-
tissue compartment receives 30% of tungsten leaving plasma and returns tungsten to plasma with a half- 
time of 2 hours.  The division of tungsten leaving the circulation, defined as atoms moving from plasma 
to compartments other than rapid-turnover soft-tissues, is as follows:  75% to the urinary bladder 
contents; 5% to kidney tissue; 5% to the contents of the upper large intestine (representing all secretions 
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Figure 3-5. Leggett (1997) Biokinetics Model for Tungsten 
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red blood cells. The assigned removal half-times from the various compartments within these tissues vary
from 1 day (from bone surfaces) to about 23 years (from cortical bone volume).  Tungsten removed from
the skeleton, certain kidney tissue, liver tissue, remaining soft tissues, and red blood cells is assigned to 
plasma and redistributed to excretion pathways and tissues in the same ratio as the initial input into 
plasma.  Most of the tungsten removed from kidney tissue is assigned to the urinary bladder contents. 
Bone is divided into cortical and trabecular portions and each of these is further divided into a bone 
surface compartment and exchangeable and nonexchangeable bone volume compartments.  
Approximately 55% of tungsten entering the skeleton is assigned to trabecular surfaces and 45% to 
cortical surfaces. Tungsten is removed from bone surface with a half-time of 1 day, with 5/6 returning to
plasma and 1/6 entering the corresponding exchangeable bone volume compartment.  It is removed from
exchangeable bone volume with a half-time of 100 days, with 60% assigned to the corresponding 
nonexchangeable bone volume compartment and 40% to the corresponding bone surface compartment.  
Removal from nonexchangeable bone to plasma occurs at the rate of bone turnover, estimated as 
0.03 year-1 for cortical bone (half-time of ~23 years) and 0.18 years-1 for trabecular bone (half-time 
approximately 4 year). 
The model predicts a rapid decline in body burden of tungsten after cessation of exposure; approximately
15% of the burden remains after 1 day, 5% after 1 week, 3% after 1 month, 1.6% after 1 year, and 0.4%
after 10 years.  The slowest component of the decline represents stores in bone volume; therefore, over 
time, the fraction of the body burden associated with bone increases to 60% after 1 year and 90% after 
4 years.  Steady state in soft tissue is predicted after approximately 300–500 days of continuous exposure, 
whereas, bone continues to accumulate tungsten with chronic exposure. 
Validation of the model. 
An evaluation of the extent to which the model has been validated was not located.  Predictions from the 
model were compared to those from the ICRP (1981) model (Leggett 1997).  Over the first few years 
after intake, the two models yield reasonably consistent predictions of total-body retention, but noticeably
different predictions of retention in specific tissues.  For example, the ratio of predicted retention values, 
ICRP model:Leggett model, at 1 day after acute uptake of tungsten to blood is 0.75 for the total body, but
0.44 for bone or kidney, 0.28 for liver, and 8.5 for spleen.  For times greater than a few years after intake, 
the ICRP model predicts considerably faster decline of activity in all tissues, with the ratio ICRP 
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<0.001 for retention in all other tissues.  Differences in predictions of the two models result in part from
differences in the databases considered, in that the ICRP restricted attention to specific data sets and 
relied heavily on data for rats, which were generally given low weight in the model of Leggett.  Predictive 
differences also arise from differences in the method of extrapolation to times beyond the periods of 
observation of tungsten retention in laboratory animals.  For example, in the ICRP model, a removal half­
time from bone of 1,000 days is arbitrarily applied to represent “a very long-term component of retention 
in the skeleton” (ICRP 1981). In the Leggett model, long-term removal of tungsten from bone is assumed 
to occur at the rate at which human bone is remodeled. 
Risk assessment. 
The extent to which the model has been applied to risk assessment is not described in Leggett (1997).  
The model is configured to be applicable for estimation of time-integrated target tissue doses, blood 
tungsten levels, and tungsten excretion.  
Target tissues. 
The model output includes tungsten levels in bone, blood, kidney, liver, other soft tissues, and plasma.  
Species extrapolation. 
Parameter values of the model were derived for adult humans.  The model structure is applicable to other 
mammalian species, but application to other species would require the derivation of appropriate parameter 
values based on species-specific information. 
Interroute extrapolation. 
The Leggett systemic biokinetic model for tungsten can be applied to any route of exposure (e.g., from
the respiratory or gastrointestinal tract, wounds, through the skin, or via intravenous injection), provided 
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3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
Absorption. Absorption of inhaled tungsten has been demonstrated in dogs (Aamodt 1975).  
Approximately one-third of a dose of radiotungsten (181WO3) that was deposited in the respiratory tract 
was transferred to the blood.  Based on relatively rapid clearance of a portion of the deposited activity
from the lungs (70% was cleared with a half-time of 4 hours), diffusion may account for at least a portion 
of the dose entering the blood.  Experimental data also indicate that tungsten particles may be dissolved 
within alveolar macrophages (De Sousa Pereira et al. 1992; Grande et al. 1990; Peão et al. 1993) and 
transported to the lymphatic system (Águas et al. 1991; Grande et al. 1990).  The relative solubility of a 
given tungsten compound also likely dictates the degree and rate of absorption.  At least a portion of 
tungsten inhaled as hard metal dust may be retained in lung tissue for an extended period (Cugell et al. 
1990; Edel et al. 1990). 
Ingested tungsten appears to be largely absorbed from the lower ileum, based on results of an in vitro
study using the rat small intestine (Cardin and Mason 1976).  Results of both in vitro and in vivo studies 
in rats indicate that gastrointestinal absorption and transport of tungsten probably occurs via the same 
pathways employed by the essential element molybdenum (Cardin and Mason 1976; Johnson and 
Rajagopalan 1974; Johnson et al. 1974).  The results further indicate that a transport system common to 
molybdenum and tungsten is subject to competitive inhibition. 
No information was located regarding mechanisms involved in absorption of tungsten through the skin. 
However, a report of death in rabbits following a single dermal application of a 5% tungsten chloride 
solution (Dow Chemical Company 1982) is evidence of absorption and systemic distribution of dermally­
applied tungsten. 
Distribution.    Absorbed tungsten is rapidly distributed throughout the body and quickly eliminated 
predominantly via the urine.  Mechanisms involved in the distribution of absorbed tungsten are not 
currently understood.  However, rapid distribution via the blood and elimination via the kidney serve as 
indication that distribution does not likely include major binding to cellular components or proteins in 
blood.  Retention of tungstate by the liver may be related to the findings that tungsten inhibits the binding 
of the essential element molybdenum to selected liver proteins (Johnson and Rajagopalan 1974).  
Retention of tungsten in bone has led to the suggestion that tungstate anions interact with calcium, 
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cells and blood, molecules binding anionic forms of tungsten might release these anions to water in 
exchange for dissolved phosphate ion, for which they may have greater affinity, as suggested by Wide et 
al. (1986). 
Excretion. Inhalation, oral, and parenteral injection studies in laboratory animals all indicate that 
absorbed tungsten is rapidly eliminated from the blood and quickly excreted in large quantities in the 
urine (Aamodt 1973, 1975; Kaye 1968).  Specific mechanisms involved in the excretion of tungsten were 
not identified in available reports. 
3.5.2 Mechanisms of Toxicity
Specific mechanisms of tungsten-induced toxicity have not been elucidated.  Pulmonary fibrosis in hard 
metal workers exposed to dusts containing tungsten carbide and cobalt has been historically attributed to 
the presence of cobalt, not tungsten (see Davison et al. 1983; Harding 1950).  Based on results of studies 
in which pulmonary fibrosis was induced in rats following intratracheal instillation of tungsten carbide 
and cobalt in combination, but not in rats exposed to tungsten carbide or cobalt alone (Lasfargues et al. 
1995), it has been proposed that tungsten carbide, a relatively good conductor of electrons, may facilitate 
the oxidation of cobalt metal to ionic cobalt, which could increase both the solubility of cobalt and the 
generation of active oxygen species (Lasfargues et al. 1995; Lison et al. 1995).  In vitro evidence for this 
mechanism includes the ability of hard metal particles, but neither cobalt nor tungsten carbide alone, to 
generate oxidant species and cause lipid peroxidation (Lison et al. 1995; Zanetti and Fubini 1997).  Hard 
metal particles have also been shown to increase the levels of inducible nitric oxide synthase (iNOS); the 
gene for iNOS is responsive to oxidant stress (Rengasamy et al. 1999). 
Leanderson and Sahle (1995) demonstrated that respirable tungsten oxide fibers, which were measured in 
the air of hard metal industries (80% of the fibers were ≤0.3 µm in diameter) (Sahle 1992; Sahle et al. 
1994), are capable of generating hydroxyl radicals in human lung cells in vitro, and that these fibers were 
more cytotoxic than crocidolite asbestos.  It could be argued that generation of hydroxyl radicals might 
contribute toward the development of pulmonary fibrosis in individuals occupationally exposed to fibrous 
tungsten oxide in the hard metal industry.  However, any attempt to link tungsten with the development of 
pulmonary fibrosis via a mechanism that includes the generation of hydroxyl radicals is speculative 
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In animals administered high levels of tungsten in combination with low dietary levels of molybdenum, 
the competitive agonistic properties of the two metals can be manifested by reduced levels of 
molybdenum and decreased activity of enzymes such as xanthine oxidase, sulfite oxidase and aldehyde 
oxidase, which normally incorporate molybdenum as a metal carrier (De Renzo 1954; Higgins et al. 
1956a, 1956b; Johnson and Rajagopalan 1974; Johnson et al. 1974).  Although these effects can be 
observed following exposure to elevated levels of tungsten, only very small amounts of supplemental 
molybdenum are required to reverse these tungsten-induced effects.  The competitive agonistic properties 
of tungsten and molybdenum have not been associated with any observable signs of toxicity. 
3.5.3 Animal-to-Human Extrapolations 
No data were located concerning major interspecies differences in pharmacokinetics or health effects 
associated with exposure to tungsten or tungsten compounds.  However, the rat exhibits a remarkably low
requirement for molybdenum, relative to other animal species (Higgins et al. 1956b).  The apparently low 
dietary requirement of molybdenum in the rat, as well as the competitive agonistic properties of 
molybdenum and tungsten and their chemical similarities, is suggestive evidence of species-specific 
differences in the biokinetics of tungsten. 
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the EPA 
to develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”.  To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine 
disruptors. In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents. The terminology endocrine modulators has also been used to 
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
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the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist 
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens 
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are 
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial, 
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or 
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997c).  Stated differently, such compounds may cause toxicities that 
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought 
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994; 
Giwercman et al. 1993; Hoel et al. 1992). 
No information was located regarding the potential of tungsten or tungsten compounds to disrupt 
endocrine function. 
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
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particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and 
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
No information was located regarding age-related differences in pharmacokinetics or toxicity of tungsten 
or tungsten compounds in humans.  In one animal study, increased embryonic uptake of tungsten was 
observed via rat dams administered tungstate (185W) intravenously during late gestation (day 17) 
compared to earlier treatment (gestation days 8 or 12) (Wide et al. 1986).  Both pre- and post-
implantation losses and delayed fetal skeletal ossification were reported in rats following oral 
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1977, 1978).  However, deficiencies in study details render the reports of limited value for purposes of 
quantitative health risk assessment. Particular sensitivity to tungsten during fetal development and 
postnatal periods of nursing may be of concern since absorption of tungsten in pregnant animals can result 
in the accumulation of tungsten in fetal tissues (Wide et al. 1986), and tungsten can enter the milk of 
tungsten-exposed animals (Mullen et al. 1976).  However, no information was located regarding the 
ability of tungsten to cross the placenta or enter the breast milk of humans. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 
preferred biomarkers of exposure are generally the substance itself or substance-specific metabolites in 
readily obtainable body fluid(s) or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to tungsten and tungsten compounds are discussed 
in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
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capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by tungsten and tungsten compounds are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10 “Populations that are Unusually Susceptible.” 
3.8.1 	 Biomarkers Used to Identify or Quantify Exposure to Tungsten and Tungsten 
Compounds 
The presence of tungsten in the blood, urine, or feces serves as a biomarker of exposure to tungsten or 
tungsten compounds. Levels in these media may be used in conjunction with biokinetic models to 
estimate previous exposure levels. 
3.8.2 	 Biomarkers Used to Characterize Effects Caused by Tungsten and Tungsten 
Compounds 
Biomarkers of effect for tungsten or tungsten compounds were not identified in available literature. 
3.9 INTERACTIONS WITH OTHER CHEMICALS  
Hard metal, consisting of tungsten carbide and cobalt, has been shown to present a more significant health 
concern than either tungsten carbide or cobalt alone (Lasfargues et al. 1995).  Potential mechanisms for 
this phenomenon are discussed in Section 3.5.2. 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to tungsten and tungsten 
compounds than will most persons exposed to the same level of tungsten and tungsten compounds in the 
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other toxic substances (e.g., cigarette smoke).  These parameters result in reduced detoxification or 
excretion of tungsten or tungsten compounds, or compromised function of organs affected by tungsten or 
tungsten compounds.  Populations who are at greater risk due to their unusually high exposure to tungsten 
and tungsten compounds are discussed in Section 6.7, Populations with Potentially High Exposures. 
Individuals with compromised respiratory function may exhibit increased sensitivity to airborne tungsten 
due to irritant properties of tungsten particles that may be deposited in the lungs.  Individuals with 
compromised renal function may also experience particular sensitivity to tungsten since decreased urinary
excretion could result in increased tungsten retention.  Russian studies (Nadeenko and Lenchenko 1977; 
Nadeenko et al. 1977, 1978) indicate that developing fetuses may be particularly sensitive to tungsten.  
However, these studies are limited in reporting of study details, which renders them of limited value for 
purposes of risk assessment. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to tungsten or tungsten compounds.  However, because some of the treatments discussed may be 
experimental and unproven, this section should not be used as a guide for treatment of exposures to 
tungsten or tungsten compounds.  When specific exposures have occurred, poison control centers and 
medical toxicologists should be consulted for medical advice.   
No texts were located regarding treatment following exposures to tungsten or tungsten compounds. 
3.11.1 Reducing Peak Absorption Following Exposure  
No data were located regarding reduction of peak absorption of tungsten following exposure. Cathartics 
such as magnesium sulfate, as well as gastric lavage, might shorten the transit time of ingested tungsten in 
the gastrointestinal tract. Oral administration of activated charcoal shortly following oral exposure to 
tungsten might be effective in reducing peak absorption. 
3.11.2 Reducing Body Burden  
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3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
No data were located regarding reduction of the toxic effects of tungsten through interfering with 
mechanisms of action. 
3.12 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of tungsten and tungsten compounds is available.  Where 
adequate information is not available, ATSDR, in conjunction with the National Toxicology Program
(NTP), is required to assure the initiation of a program of research designed to determine the health 
effects (and techniques for developing methods to determine such health effects) of tungsten and tungsten 
compounds. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Tungsten and Tungsten Compounds 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
tungsten and tungsten compounds are summarized in Figure 3-6.  The purpose of this figure is to illustrate 
the existing information concerning the health effects of tungsten and tungsten compounds.  Each dot in 
the figure indicates that one or more studies provide information associated with that particular effect.  
The dot does not necessarily imply anything about the quality of the study or studies, nor should missing 
information in this figure be interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision 
Guide for Identifying Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic 
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comprehensive public health assessments.  Generally, ATSDR defines a data gap more broadly as any 
substance-specific information missing from the scientific literature.
Available data regarding health effects in humans exposed to tungsten predominantly involves 
occupational exposure to dusts that include particles of tungsten and other metals (particularly cobalt) at 
facilities in which hard metal is produced.  It is generally considered that cobalt is the source of adverse 
health effects such as pulmonary fibrosis and dermatitis in hard metal workers, not tungsten.  A single 
case report was located concerning acute oral exposure to tungsten in a male subject.  However, reported 
symptoms could not be specifically attributed to tungsten. 
Relatively few reports were located regarding health effects in animals following acute-, intermediate-, or 
chronic-duration exposure to tungsten or tungsten compounds.  Several early Russian reports were 
located, mainly originating from a single group of investigators.  The reports predominantly assessed 
acute lethality or reproductive or developmental effects following oral exposure to soluble tungsten 
compounds.  The carcinogenicity and genotoxicity of tungsten and tungsten compounds has not been 
adequately assessed in humans or animals.  However, tungsten has been recently nominated by the 
National Center for Environmental Health for toxicological characterization including carcinogenicity 
(NTP 2003). 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    No human studies were located regarding health effects associated with 
acute-duration inhalation exposure to tungsten.  Information in animals is restricted to exposure via 
intratracheal instillation of tungsten compounds.  Intratracheal instillation of water-insoluble calcium
tungstate crystals resulted in an inflammatory response in mice (Peão et al. 1993).  Acute pulmonary
edema was reported in rats that had received hard metal (tungsten carbide and cobalt alloy) via
intratracheal instillation, but not in rats exposed to tungsten carbide or cobalt alone (Lasfargues et al. 
(1992).  Due to the lack of information concerning adverse effects and targets of toxicity following acute-
duration inhalation exposure to tungsten or tungsten compounds, no acute-duration inhalation MRLs were 
derived. Results of acute-duration inhalation toxicity studies that adequately characterize dose-response 
characteristics and target organs could serve as a basis to derive acute-duration inhalation MRLs for 
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Information regarding health effects in humans following acute-duration oral exposure to tungsten is 
restricted to a single case report in which a male subject experienced neurological (nausea, seizure, and 
24-hour coma) and renal (temporary renal failure, tubular necrosis, and anuria) effects following the 
accidental consumption of metallic tungsten in a mixture of beer and wine (Marquet et al. 1997).  
However, the observed effects could not be specifically attributed to tungsten.  Reports of tungsten-
induced adverse health effects in animals following acute-duration oral exposure to tungsten consist 
primarily of reports in which lethality was assessed (Karantassis 1924; Kinard and Van de Erve 1941; 
Nadeenko 1966; Smyth et al. 1969).  Guinea pigs exhibited clinical signs that included trembling and 
abnormal locomotor behavior following single oral administration of sodium tungstate at ultimately lethal 
doses (≥780 mg/kg) (Karantassis 1924).  Due to the lack of information concerning adverse effects and 
targets of toxicity following acute-duration oral exposure to tungsten or tungsten compounds, no acute-
duration inhalation MRLs were derived.  Results of acute-duration oral toxicity studies that adequately
characterize dose-response characteristics and target organs could serve as a basis to derive acute-duration 
oral MRLs for tungsten and tungsten compounds. 
Information concerning dermal effects in humans exposed to tungsten is restricted to a report of
dermatitis in employees of the hard metal industry, but results of patch testing implicated cobalt, not 
tungsten, as the causative agent (Schwartz et al. 1945; Skog 1963).  Relatively little information is 
available concerning adverse effects in animals following acute-duration dermal exposure to tungsten.  
Contact dermatitis was reported in rabbits following dermal application of a 5% tungsten chloride 
solution in single doses ≥100 mg/kg; doses ≥200 mg/kg also resulted in death (Dow Chemical Company
1982).  Instillation of a 5% tungsten chloride solution into the rabbit eye resulted in initial ocular irritation 
that resolved within 14 days postinstillation (Dow Chemical Company 1982).  Additional animal studies 
could be designed to assess the sublethal systemic toxicity of tungsten and selected tungsten compounds 
following acute-duration dermal exposure. 
Intermediate-Duration Exposure.    No human studies were located regarding health effects 
associated with intermediate-duration inhalation exposure to tungsten.  Rats that were repeatedly exposed 
to atmospheres containing tungsten carbide at a concentration of 600 mg/m3 exhibited signs of pulmonary
fibrosis and clinical signs that were interpreted as anxiety manifestations (Mezentseva 1967).  Decreased 
sperm motility was noted in rats continuously repeatedly exposed to atmospheres containing sodium
tungstate at concentrations ≥0.5 mg/m3 (Idiyatullina 1981).  Mixed results were reported in laboratory
animals following intratracheal instillation of selected tungsten compounds and examinations that 
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observed for up to 8 months following intratracheal instillation of metallic tungsten, tungsten trioxide, or 
tungsten carbide (Mezentseva 1967).  Lung lesions in the absence of apparent pulmonary fibrosis were 
reported in guinea pigs that had received 3 weekly doses of intratracheally-instilled metallic tungsten or 
tungsten carbide and carbon dust, followed by up to 12 months of posttreatment examination (Delahant 
1955; Schepers 1955a, 1955b).  No signs of a fibrotic response were seen in the lungs of mice that had 
received tungsten carbide via intratracheal instillation (Lardot et al. 1998).  Due to the lack of information 
concerning adverse effects and targets of toxicity following intermediate-duration inhalation exposure to 
tungsten or tungsten compounds, no intermediate-duration inhalation MRLs were derived.  Results of 
intermediate-duration inhalation toxicity studies that adequately characterize dose-response characteristics 
and target organs could serve as a basis to derive intermediate-duration inhalation MRLs for tungsten and 
tungsten compounds. 
No human studies were located regarding health effects associated with intermediate-duration oral 
exposure to tungsten.  In rats, early reports have associated repeated oral exposure to tungsten with 
neurological (Karantassis 1924), reproductive (Nadeenko and Lenchenko 1977; Nadeenko et al. 1977, 
1978), and developmental (Nadeenko and Lenchenko 1977; Nadeenko et al. 1977, 1978) effects.  Body
weight changes, in the absence of other signs of toxicity, were reported in rats following repeated oral 
exposure to various tungsten compounds (Kinard and Van de Erve 1941, 1943). However, the available 
animal studies did not include critical dose-response information and other details (including methods 
used in statistical analysis of data), which precludes their usefulness for the purpose of MRL derivation.  
Therefore, no intermediate-duration oral MRLs were derived for tungsten.  Results of intermediate-
duration oral toxicity studies that adequately characterize dose-response characteristics could serve as a 
basis to derive intermediate-duration inhalation and oral MRLs for tungsten and tungsten compounds. 
No human or animal data were located regarding noncancer or cancer end points associated with 
intermediate-duration dermal exposure to tungsten or tungsten compounds.  Intramuscularly-implanted 
tungsten alloy (91.1% tungsten, 6.0% nickel, and 2.9% cobalt) was recently shown to rapidly cause 
aggressive tumors in rats (Kalinich et al. 2005).  However, since both nickel and cobalt are known to 
cause tumors following intramuscular injection in rats (Heath 1954, 1956; Heath and Daniel 1964), the 
carcinogenic role of tungsten itself was not determined. 
Chronic-Duration Exposure and Cancer.    Information regarding chronic exposure of humans to 
tungsten primarily involves respiratory effects such as pulmonary fibrosis, memory and sensory deficits, 
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tungsten and other metals (particularly cobalt) (see Bech 1974; Bech et al. 1962; Coates and Watson 
1971a, 1971b; Jordan et al. 1990; Kaplun and Mezentseva 1959; Lasfargues et al. 1994; Mezentseva 
1967; Miller et al. 1953; Moulin et al. 1998; Vengerskaya and Salikhodzhaev 1962; Wild et al. 2000).  It 
is generally considered that cobalt is the source of major toxicity concern, not tungsten (see Davison et al. 
1983; Harding 1950).  However, it has been suggested that tungsten oxide fibers may contribute to the 
development of pulmonary fibrosis in hard metal workers (Sahle 1992).  No studies were located 
regarding chronic-duration inhalation exposure of laboratory animals to tungsten or tungsten compounds.  
Based on the lack of human and animal data, no chronic-duration inhalation MRLs were derived for 
tungsten or tungsten compounds.  Results of well-designed chronic-duration inhalation studies in animals 
could serve as a basis to derive chronic-duration inhalation MRLs for tungsten and tungsten compounds. 
No human studies were located regarding noncancer or cancer end points associated with chronic-
duration oral exposure to tungsten.  Information concerning health effects in animals following chronic-
duration oral exposure to tungsten or tungsten compounds is restricted to reports by Schroeder and 
Mitchener (1975a, 1975b) in which tungsten-treated (5 ppm of tungsten as sodium tungstate in the 
drinking water for a lifetime) and control rats and mice exhibited similar growth patterns and incidences 
of gross tumors.  However, these studies were limited to assessment of growth, gross tumor incidence, 
and longevity.  Limited study design, including lack of both dose-response data and comprehensive 
histopathologic examinations preclude their usefulness for MRL derivation.  Results of well-designed 
chronic-duration oral studies in animals could serve as a basis to derive chronic-duration oral MRLs for 
tungsten and tungsten compounds. 
Recent findings of elevated tungsten body burdens in residents of Churchill County (City of Fallon), 
Nevada (CDC 2003b), and the discovery that a relatively limited amount of information is available 
concerning the potential for long-term adverse health effects following exposure to tungsten, have 
resulted in the nomination of tungsten by the National Center for Environmental Health (NCEH) for 
toxicological characterization, which includes carcinogenicity (NTP 2003). 
No human or animal data were located regarding noncancer or cancer end points associated with chronic-
duration dermal exposure to tungsten or tungsten compounds.  Intramuscularly-implanted tungsten alloy
(91.1% tungsten, 6.0% nickel, and 2.9% cobalt) was recently shown to rapidly cause aggressive tumors in 
rats (Kalinich et al. 2005).  However, since both nickel and cobalt are known to cause tumors following 
intramuscular injection in rats (Heath 1954, 1956; Heath and Daniel 1964), the carcinogenic role of 
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Genotoxicity.    No information was located regarding tungsten-induced genotoxicity following 
inhalation, oral, or dermal exposure to tungsten or tungsten compounds in humans or laboratory animals.  
Sodium tungstate was found to induce mutagenic activity in a bacterial bioluminescence test (Ulitzur and 
Barak 1988), lambda prophage in E. coli (Rossman et al. 1984, 1991), and gene conversion and reverse 
mutation in Saccharomyces cerevisiae (Singh 1983).  An unspecified form of tungsten enhanced 
mutagenic activity in Salmonella typhimurium (Miller and Page 1999). Tungstate anion induced forward 
mutation in Chinese hamster lung V79 cells in vitro (Zelikoff et al. 1986).  Sodium tungstate did not 
increase sister chromatid exchanges in human whole blood cultures or cause chromosome aberrations in 
human lymphocytes or Syrian hamster embryo cells (Larramendy et al. 1981).  Nor did sodium tungstate 
induce morphological transformation in Syrian hamster cells (DiPaolo and Casto 1979).  Heavy metal-
tungsten alloys are capable of inducing neoplastic transformation of human osteoblast cells (Miller et al. 
2001).  Pure tungsten is capable of inducing a similar effect (Miller et al. 2004), but at a significantly
reduced magnitude relative to the heavy metal-tungsten alloys.  Additional studies could be designed to 
further assess the potential for tungsten and tungsten compounds to induce genotoxicity. 
Reproductive Toxicity. No information was located regarding reproductive toxicity in humans 
following inhalation exposure to tungsten or tungsten compounds.  Information in animals is restricted to 
a single account of decreased sperm motility (10–12% lower than controls) in male rats continuously
exposed to atmospheres containing sodium tungstate powder for 17 weeks at concentrations of 1.0 and 
0.5 mg/m3, but not at 0.1 mg/m3 (Idiyatullina 1981). 
No information was located regarding reproductive toxicity in humans following oral exposure to 
tungsten or tungsten compounds.  Information in animals is restricted to reported embryotoxicity 
(expressed as increased percentages of pre- and post-implantation losses, relative to controls) following 
oral administration of an unspecified tungsten compound to adult female rats at a single dose level of 
0.005 mg/kg for up to 8 months before and during pregnancy (Nadeenko and Lenchenko 1977; Nadeenko 
et al. 1977, 1978).  However, deficiencies in study details regarding exposure and quantitative results 
render the results of these Russian studies of limited value for purposes of quantitative risk assessment.  
Additional well-designed animal studies would be useful to adequately assess the reproductive toxicity of
orally-administered tungsten and tungsten compounds.  Such studies could include standard reproductive 
toxicity studies as well as conventional intermediate-duration oral toxicity studies that would include an 
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No information was located regarding reproductive toxicity in humans or animals following dermal 
exposure to tungsten or tungsten compounds.  However, inhalation is the most likely significant route of
exposure to tungsten or tungsten in workers employed in industries that produce or use tungsten-
containing products.  Elevated levels of tungsten in groundwater, such as was detected in well water in 
Churchill County (City of Fallon), Nevada (CDC 2003b), indicate the potential for significant oral 
exposure to tungsten and tungsten compounds as well.  It does not appear that additional studies of health 
effects associated with dermal exposure to tungsten or tungsten compounds are necessary at this time. 
Developmental Toxicity.    No information was located regarding developmental toxicity in humans 
or animals following inhalation exposure to tungsten or tungsten compounds.  Animal studies could be 
performed to assess the potential for tungsten-induced developmental effects via the inhalation exposure 
route. 
No information was located regarding developmental toxicity in humans following oral exposure to 
tungsten or tungsten compounds.  Information in animals is restricted to reported delayed fetal skeletal 
ossification following oral administration of an identified tungsten compound to adult female rats at a 
single dose level of 0.005 mg/kg for up to 8 months before and during pregnancy (Nadeenko and 
Lenchenko 1977; Nadeenko et al. 1977, 1978).  However, deficiencies in study details regarding exposure 
and quantitative results render the results of these Russian studies of limited value for purposes of 
quantitative risk assessment.  Additional well-designed animal studies should be performed to adequately
assess both pre- and post-natal potential for tungsten-induced developmental effects via the oral exposure 
route. 
No information was located regarding developmental toxicity in humans or animals following dermal 
exposure to tungsten or tungsten compounds.  However, inhalation is the most likely significant route of
exposure to tungsten in workers employed in industries that produce or use tungsten-containing products.  
Elevated levels of tungsten in groundwater, such as was detected in well water in Churchill County (City 
of Fallon), Nevada (CDC 2003b), indicate the potential for significant oral exposure to tungsten and 
tungsten compounds as well. It does not appear that additional studies of health effects associated with 
dermal exposure to tungsten or tungsten compounds are necessary at this time. 
Immunotoxicity.    No information was located concerning tungsten-induced immunotoxicity in 
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single report was located in which a marked inflammatory response characterized by infiltration of 
leukocytes in the lungs of mice following intracheal instillation of water-insoluble calcium tungstate 
powder (Peão et al. 1993).  The inflammatory response was likely the result of local irritation rather than 
an adverse immunological effect.  Repeated exposure animal studies by the inhalation exposure route 
could be designed to assess the immunotoxicity potential of tungsten. 
Neurotoxicity.    No human data were located in which neurological signs could be associated with 
inhalation, oral, or dermal exposure to tungsten.  Signs of memory and sensory deficits have been 
reported among workers in the hard metal industry who were exposed to atmospheres of hard metal dusts 
(Jordan et al. 1990; Kaplun and Mezentseva 1959; Vengerskaya and Salikhodzhaev 1962); however, 
these effects likely reflect exposure to cobalt, not tungsten.  No studies were located regarding 
neurological effects in animals following inhalation exposure to tungsten or tungsten compounds.  Results 
of available animal studies indicated clinical signs of neurotoxicity following acute oral dosing at levels 
resulting in death (Karantassis 1924) and learning deficits and brain lesions following repeated oral 
dosing (Nadeenko 1966) at sublethal doses.  However, clinical signs at lethal doses are not a reliable 
indicator of primary neurotoxicity and the report of Nadeenko (1966) was not designed to adequately
assess neurotoxicity end points.  Additional well-designed neurotoxicity studies in animals exposed to 
tungsten or tungsten compounds via inhalation or oral exposure routes might serve to adequately assess 
the potential for tungsten to induce neurotoxicity. 
Epidemiological and Human Dosimetry Studies.    Pulmonary fibrosis, memory and sensory
deficits, and increased mortality due to lung cancer have been associated with occupational exposure to 
dusts generated in the hard metal industry (Bech 1974; Bech et al. 1962; Coates and Watson 1971a, 
1971b; Jordan et al. 1990; Kaplun and Mezentseva 1959; Lasfargues et al. 1994; Mezentseva 1967; Miller 
et al. 1953; Moulin et al. 1998; Vengerskaya and Salikhodzhaev 1962).  Hard metal is an alloy or 
encapsulated mixture that is composed of tungsten or tungsten carbide and cobalt (primarily, although the 
alloys may also contain yttrium, thorium, copper, nickel, iron, or molybdenum).  Historically, the 
respiratory and neurological effects observed in hard metal workers have been attributed to cobalt, not 
tungsten (see Davison et al. 1983; Harding 1950).  However, based on the presence of tungsten oxide 
fibers in air samples taken at some hard metal facilities (Sahle 1992; Sahle et al. 1994) and 
demonstrations that tungsten oxide fibers are capable of generating hydroxyl radicals in human lung cells 
in vitro (Leanderson and Sahle 1995), it has been suggested that tungsten oxide fibers may contribute to
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The most likely identifiable subpopulations exposed to tungsten are workers in the hard metal industry.
Available human and animal data do not appear to clearly identify targets of toxicity for tungsten. 
Additional epidemiological studies of tungsten should attempt to identify exposure scenarios that may not
be confounded by other known toxicants.  Such exposure scenarios might provide valuable information 
regarding potential tungsten-induced toxicity.  Studies of dosimetry would be useful in future 
epidemiological studies. 
Biomarkers of Exposure and Effect.     
Exposure. Tungsten can be detected in blood (Bowen 1966; Hartung 1991), urine (Paschal et al. 1998), 
feces , and tissue samples (Bowen 1966; Iyengar et al. 1978).  Since a large percentage of absorbed 
tungsten is rapidly eliminated from the body, detection would be most effective within a few days
following short-term exposure or termination of longer-term exposure.  Additional information regarding 
relationships between tungsten body burden and exposure levels could improve the ability to monitor 
workers’ exposure to tungsten.
Effect. Biomarkers of effect for tungsten and tungsten compounds have not been definitively identified.  
Additional animal studies designed to assess health effects associated with tungsten should elucidate 
biomarkers of effect. 
Absorption, Distribution, Metabolism, and Excretion.    Human reports demonstrate that inhaled 
and ingested tungsten may be absorbed, distributed systemically, and eliminated to a large extent in the 
urine (Marquet et al. 1997; Nicolaou et al. 1987; Wester 1974).  Animal studies support the human data 
and further demonstrate that distribution is rapid and widespread and that urinary excretion is also rapid 
(Aamodt 1975; Ballou 1960; Kaye 1968).  Tungsten that is deposited in bone (Kaye 1968; Kinard and 
Aull 1945) may be slowly released to the blood and also eliminated mainly in the urine (Kaye 1968). 
Insoluble forms of orally-administered tungsten are chiefly eliminated in the feces.  Tungsten has been 
detected in hair and nail samples of hard metal workers (Nicolaou et al. 1987).  Tungsten ion in the body
is not known to be metabolized as such.  Additional quantitative information regarding absorption and 
distribution of inhaled or ingested tungsten and tungsten compounds could be used to improve existing 
PBPK models of the biokinetics of tungsten (ICRP 1981, 2001; Leggett 1997).  Although the dermal 
exposure route does not appear to be a major human exposure route for tungsten, animal studies could be 
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Comparative Toxicokinetics.    Relatively little information is available regarding comparative 
toxicokinetics for tungsten and tungsten compounds. Available information concerning absorption, 
distribution, and elimination of tungsten in rats and dogs (Aamodt 1975; Ballou 1960; Kaye 1968) do not
indicate major species-specific differences in biokinetics,  Available toxicokinetic data in humans 
(Marquet et al. 1997; Nicolaou et al. 1987; Wester 1974), which have qualitatively demonstrated that 
airborne and ingested tungsten is absorbed and eliminated, do not indicate that the biokinetics of tungsten 
may differ greatly between humans and laboratory animals.  Apparent species-specific differences in the 
dietary requirement for molybdenum (Higgins et al. 1956b), coupled with similarities in the biokinetics of 
molybdenum and tungsten, suggest that significant species-specific differences in the biokinetics of 
tungsten may exist.  Additional animal toxicokinetic studies could be designed to identify species-specific 
differences that could serve to improve existing biokinetic models and elucidate specific mechanisms of 
action for tungsten. 
Methods for Reducing Toxic Effects.    Mechanisms concerning absorption, distribution, and toxic 
action of tungsten have not been studied to date; studies should be designed to identify such mechanisms.  
No established methods or treatments for reducing the body burden of tungsten were identified in 
literature searches. No information was located regarding treatments to repair damage or improve 
compromised function resulting from exposure to tungsten.  Well-designed mechanistic studies might 
provide valuable information that could aid in elucidating treatments to reduce tungsten body burden or
repair tungsten-induced damage. 
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and 
developmental effects expressed either prenatally or during childhood, are discussed in detail in the 
Developmental Toxicity subsection above. 
Results of studies published in Russian journals suggest that developing fetuses may be particularly 
sensitive to tungsten (Nadeenko and Lenchenko 1977; Nadeenko et al. 1977, 1978).  However, 
deficiencies in study details regarding exposure and quantitative results render the results of these Russian
studies of limited value for purposes of quantitative risk assessment.  Tungsten has been observed to cross 
the placenta of pregnant rats and to be distributed to the fetus (Wide et al. 1986).  Measurable amounts of 
tungsten have been observed in the milk of lactating cows (Mullen et al. 1976). However, no information 
was located regarding potentially significant age-related differences in the biokinetics of tungsten.  No 
information was located regarding the potential for tungsten to interact with other chemicals in such a 
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the toxic effects of tungsten and potential for age-related differences in susceptibility, animal studies 
should be designed to further assess health effects that may be related to tungsten.  Some of these studies 
could be designed to test for potential age-related differences in susceptibility and biokinetics as well. 
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:  
Exposures of Children. 
3.12.3 Ongoing Studies 
No ongoing research has been identified in the Federal Research in Progress database (FEDRIP 2004).  
However, tungsten has been nominated by the National Center for Environmental Health for toxicological 
characterization including carcinogenicity (NTP 2003).  Rationale for the nomination includes the use of 
tungsten in industrial materials and insufficient available data to assess human health implications of 
elevated urinary tungsten levels.  The NTP Interagency Committee for Chemical Evaluation and 
Coordination (ICCEC) has recommended that toxicological studies should focus on a representative 
soluble tungsten compound. 
The Armed Forces Radiological Research Institute (AFRRI) is currently receiving funding from the 
United States Army Medical Research and Material Command (USAMRMC) to assess the potential for 
embedded uranium and the heavy-metal tungsten alloy (tungsten/nickel/cobalt) to induce carcinogenicity
and immunotoxicity in rats (principal investigator:  Dr. J.F. Kalinich) and genetic damage in male mice 
and their offspring (principal investigator:  Dr. A.C. Miller). 
The following three AFFRI proposals have been submitted to the USAMRMC for review: 
•	 Carcinogenicity of embedded tungsten alloy in mice (principal investigator:  Dr. D.E. McClain).  
This project aims to support the findings of the earlier study in rats (Kalinich et al. 2005). 
•	 Carcinogenicity and immunotoxicity assessment of tungsten alloy components in the rat 
(principal investigator: Dr. J.F. Kalinich).  This project will assess the carcinogenic and 
immunotoxic potential of the heavy-metal tungsten alloy (tungsten/nickel/iron), as well as the 
individual metals of the alloy.
•	 Preconceptional paternal exposure to embedded tungsten alloy fragments:  Lifespan study of
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to investigate whether paternal preconceptional exposure to embedded tungsten alloy causes 




















73 TUNGSTEN  
4. CHEMICAL AND PHYSICAL INFORMATION 

4.1 CHEMICAL IDENTITY  

Tungsten is a naturally occurring element found in the earth=s surface rocks.  Tungsten metal typically 
does not occur as the free element in nature.  Of the more than 20 tungsten-bearing minerals, some of the 
commonly used commercial ones include feberite (iron tungstate), huebnerite (manganese tungstate), 
wolframite (iron-manganese tungstate), and scheelite (calcium tungstate).  Tungsten appears in Group 
VIB of the periodic table. Natural tungsten is composed of five stable isotopes: 180W (0.12%), 182W 
(26.5%), 183W (14.3%), 184W (30.6%), and 186W (28.4%).  Twenty-eight radioactive isotopes of tungsten 
are known; most of these isotopes have short half-lives.  Tungsten forms a variety of different 
compounds, such as tungsten trioxide, tungsten carbide, and ammonium paratungstate (Penrice 1997a).  
Information regarding the chemical identity of elemental tungsten and tungsten compounds is located in 
Table 4-1. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES  
Tungsten has several common oxidation states (e.g., W[0], W[2+], W[3+], W[4+], W[5+], and W[6+]).  
However, tungsten alone has not been observed as a cation.  Tungsten is stable, and therefore its most 
common valence state is +6.  The naturally occurring isotopes of tungsten are 180 (0.135%), 182 (26.4%), 
183 (14.4%), 184 (30.6%), and 186 (28.4%).  Artificial radioactive isotopes of tungsten are 173–179, 181, 
185, and 187–189 (O’Neil et al. 2001).  Elemental tungsten metal is stable in dry air at room temperature.  
Above 400 °C, tungsten is susceptible to oxidation. Tungsten is resistant to many chemicals and is also a 
good electrical conductor (Penrice 1997a).  Information regarding the physical and chemical properties of 
elemental tungsten is located in Table 4-2. 
Tungsten compounds differ widely in stereochemistry and oxidation states.  Tungsten forms binary halide 
compounds for all oxidation states between +2 and +6.  Oxyhalide compounds are only known for 
oxidation states +5 and +6.  In general, tungsten halogen compounds are reactive toward water and 
oxygen in air.  These compounds are all solid, colored compounds at room temperature, except the 
fluorides, and many decompose on heating before melting.  Tungsten oxides form a series of well-defined 









Table 4-1. Chemical Identity of Tungsten and Tungsten Compoundsa 
 







   CAS registry
   NIOSH RTECS
 EPA hazardous waste 
 OHM/TADS 





  Wolfram; VA (tungsten) Tungsten oxide; tungsten 
dioxide 




 7440-33-7  12036-22-5
 YO7175000  No data
No data No data 
No data No data 
No data No data 
 5036  No data
No data No data 
Tungsten blue; tungsten 
oxide (WO3); tungsten 
trioxide; tungsten(VI) 
oxide; tungstic acid; 
tungstic acid anhydride; 
tungstic anhydride; 
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Chemical structure WC W2C COCO 



















































Table 4-1. Chemical Identity of Tungsten and Tungsten Compoundsa 
Characteristic Tungsten Sodium tungstate, 





































tungstate (2-); disodium 
tungstate, dihydrate; sodium
tungsten oxide, dihydrate; 
sodium wolframate, dihydrate; 
tungstic acid, disodium salt, 
dihydrate 
No data 
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Table 4-1. Chemical Identity of Tungsten and Tungsten Compoundsa 












Chemical structure (NH4)6W7O24 F F 





12028-06-7 (anhydrous); 12208-54-7 
(hexahydrate)
No data; BS0480000 
7783-82-6 
YO7720000 











NCI No data No data 
aSources: Chemfinder 2004; ChemID 2004; HSDB 2004; NIOSH 1990; RTECS 2004 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMCO = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for 
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Materials/Technical Assistance Data System; 
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Table 4-2. Physical and Chemical Properties of Tungsten  
and Tungsten Compoundsa 
Property Tungsten Tungsten oxide Tungsten trioxide 
Molecular weight 183.85 215.84b 231.85 
Color Steel-gray to tin-white Blueb Canary yellow;  
dark orange when heatedc 
Physical state Solid metal Solidb Solid 
Melting point 3,410 °C 1,500–1,700 °C 1,472 °C
(decomposes) 
Boiling point 5,900 °C at 760 mm Hg Not applicable No data 
Density  (g/cm3) 18.7–19.3 at 20 °C/4 °C 10.82 (theoretical) 7.2
Odor No data No data No data 
Odor threshold: 
Water (mL/g) No data No data No data 
Air No data No data No data 
Solubility:
Water No data Insolubleb Insoluble 
Other solvent(s) Soluble in mixture of nitric 
acid and hydrofluoric acid 
Insoluble in organic 
solventsb 
Caustic alkalies; very slightly 
soluble in acids; slightly soluble 
in hydrofluoric acid
Partition coefficients: 
Kd (mL/g) Not applicable Not applicable Not applicable 
Kow Not applicable  Not applicable  Not applicable  
Koc Not applicable Not applicable Not applicable 
Vapor pressure 1.97x10-7 mm Hg at No data No data 
2,327 °C
Henry’s law constant No data No data No data 
Autoignition Not applicable Not applicable Not applicable 
temperature 
Flashpoint Not applicable Not applicable Not applicable 
Flammability limits Not applicable Not applicable Not applicable 
Conversion factor Not applicable Not applicable Not applicable 
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Table 4-2. Physical and Chemical Properties of Tungsten  
and Tungsten Compoundsa 
Property Tungsten carbide Ditungsten carbide Tungsten carbonyl 
Molecular weight 195.85 379.69b 351.90b 
Color Gray No data Whiteb 
Physical state Solid Solidb Solidb 
Melting point 2,785 °C ~2,800 °Cb 170 °C (decomposes)b 
Boiling point 6,000 °C No datab Sublimes in vacuob,d 
Density  (g/cm3) 15.6 14.8b 2.65b 
Odor No data No data No data 
Odor threshold: 
Water (mL/g) No data No data No data 
Air No data No data No data 
Solubility:
Water Insoluble Insolubleb Insolubleb 
Other solvent(s) Soluble in nitric acid/ No data Soluble in organic solventsb 
hydrogen fluoride; aqua 
regia 
Partition coefficients: 
Kd (mL/g) Not applicable Not applicable No data 
Kow Not applicable Not applicable No data 
Koc Not applicable Not applicable No data 
Vapor pressure 7.5x10-3 mm Hg at 
3,204 °Cb 
No data 0.1 mm Hg at 20 °Cc 
1.20 mm Hg at 67 °Cc 
Henry’s law constant No data No data No data 
Autoignition Not applicable Not applicable No data 
temperature 
Flashpoint Not applicable Not applicable No data 
Flammability limits Not applicable Not applicable No data 
Conversion factor  Not applicable Not applicable No data 
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Table 4-2. Physical and Chemical Properties of Tungsten  
and Tungsten Compoundsa 
Property Tungsten chloride Sodium tungstate, dihydrate Sodium phosphotungstate 
Molecular weight 	 396.56b 329.85b No data 
Color	 Purpleb Whiteb; colorlesse Whitec 
Physical state Solidb Solidb Solidd 
Melting point 275 °C Decomposes at 100 °C with No data 
loss of waterd and then melts 
at 692 °Cf 
Boiling point 346.75 °C Not applicable No data 
Density  (g/cm3) 3.52 3.25b No data 
Odor No data Odorless Odorless
Odor threshold: 
Water (mL/g) No data No data No data 
Air No data No data No data 
Solubility:
Water Decomposesd Very solubleb; about 1.1 parts Very solublee 
water (ca. 1x106 mg/L)c 




Kd (mL/g) No data No data No data 
Kow No data No data No data 
Koc No data No data No data 
Vapor pressure 	 43 mm Hg at No data No data 
215 °Ce 
Henry’s law constant No data No data 	 No data 
Autoignition No data Not applicable No data 
temperature 
Flashpoint No data Not applicable No data 
Flammability limits No data Not applicable No data 
Conversion factor  No data Not applicable No data 
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Table 4-2. Physical and Chemical Properties of Tungsten  
and Tungsten Compoundsa 
Property Ammonium paratungstate Tungstate hexafluoride
Molecular weight 1779.16f 297.83b 
Color Whitee Colorlessb; 
Pale yellow (liquid)c 
Physical state Solide Gas at room temperatureb 
Melting point No data 2.3 °Cb 
Boiling point No data 17 °Cb 
Density (g/cm3) No data 12.173b 
Odor No data No data 
Odor threshold: 
Water  No data No data 

Air No data No data 

Solubility:
Water Solublee Reacts with waterb 
Other solvent(s) Insoluble in alcohole Dissolves in benzene, cyclohexane, or dioxane; 
soluble in anhydrous hydrogen fluoridee 
Partition coefficients: 
Kd (mL/g) No data No data 
Kow No data No data 
Koc No data No data 
Vapor pressure (mm Hg) No data Gas at room temperatureb 
Henry’s law constant No data No data 
Autoignition temperature  No data No data 
Flashpoint No data No data 
Flammability limits No data No data 
Conversion factor  No data No data 
Explosive limits No data No data 
aInformation obtained from HSDB 2004, except where noted.
bLide 2000
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tungsten oxide may also vary over a fixed range without change in crystalline structure (Penrice 1997b).  
A unique characteristic of tungsten is its ability to form condensed complex ions of polytungstates in acid 
solution (e.g., ammonium paratungstate, [NH4]10[H2W12O42]·4H2O). The tungstate anion (WO42-) exists 
in monomeric form only in strongly alkaline solutions.  In mildly alkaline solution, the tungstate anions 
begin to polymerize, and this progresses with decreasing pH (Lassner et al. 1996).  Tungstate complexes 
(WO42-) of the alkali metals and magnesium are soluble in water.  Tungsten forms hard, refractory, and 
chemically stable interstitial compounds with nonmetals, particularly carbon, nitrogen, boron, and silicon 
(Penrice 1997b).  Information regarding the physical and chemical properties of tungsten compounds is 
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5.1 PRODUCTION 
No information is available in the TRI database on facilities that manufacture or process tungsten because 
this chemical is not required to be reported under Section 313 of the Emergency Planning and Community
Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986) (EPA 
1997a). 
Mining of tungsten is almost exclusively by underground methods.  Since the tungsten content of typical 
deposits is only 0.3–1.5% WO3, all mines have beneficiation facilities that produce a concentrate 
containing 60–75% WO3. During the beneficiation process, the ores are crushed and ground in stages 
with the fine fractions being removed after each stage and the coarse fraction being recirculated.  Because 
tungsten minerals have a high specific gravity, they can be beneficiated by gravity separation, usually by
tabling. The ore concentrate may first be pretreated by acid leaching with hydrochloric acid or roasting 
with soda ash in an autoclave with a solution of aqueous sodium carbonate at ca. 200 °C and a pressure of 
>11.9 atm.  This is followed by digestion to extract the tungsten as sodium tungstate.  This compound is 
subsequently converted to ammonium tungstate by means of a liquid ion-exchange process.  The solvent 
is then evaporated and tungsten is converted to crystalline ammonium paratungstate (APT, 
[NH4]10[H2W12O42]·4H2O). Tungsten metal powder is obtained from ammonium paratungstate by
stepwise reduction with carbon or hydrogen.  The reduction is carried out in either tube or rotary furnaces.  
Tungsten carbide is produced by heating tungsten metal powder and carbon black at high temperatures.  
The presence of hydrogen or a hydrocarbon gas catalyzes the reaction.  Tungsten carbide may also be 
prepared from oxygen containing tungsten compounds.  Tungsten hexachloride is prepared by the direct 
chlorination of pure tungsten metal in a flow system at 1 atmosphere and 600 °C.  Tungsten hexafluoride 
may be prepared by treating hydrogen fluoride, arsenic trifluoride, or antimony pentafluoride or by direct 
fluorination of tungsten metal powder.  Tungsten hexacarbonyl may be prepared by the aluminum
reduction of tungsten hexachloride in anhydrous ether under a pressure of ca. 1 atm of carbon monoxide 
at 70 °C. Tungsten trioxide is usually prepared from tungstic acid or tungstates (Penrice 1997a, 1997b).  
Ferrotungsten is produced by carbothermic reduction in an electric arc furnace or by metallothermic 
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No tungsten was reported to have been mined in the United States in 2003.  World production of tungsten 
concentrates was 62,100 metric tons in 2003.  The primary world producer of tungsten concentrates is 
China, which produced 52,000 metric tons in 2003.  The U.S. supply of raw tungsten is comprised of 
imports, tungsten-bearing scrap, releases from industrial stocks, and sales of excess materials from the 
National Defense Stockpile.  Major processors of tungsten materials operating in 2003 included (USGS 
2003a): Allegheny Technologies Inc.’s Metalworking Products business (Huntsville, Alabama); Buffalo 
Tungsten, Inc. (Depew, New York); General Electric Co. (Euclid, Ohio); Kennametal, Inc. (Latrobe, 
Pennsylvania; Fallon, Nevada); and Osram Sylvania, Inc. (Towanda, Pennsylvania).  
Producers of tungsten compounds in the United States in 2003 are as follows (SRI 2003):  Tungsten 
carbide: Alldyne Powder Technologies (Huntsville, Alabama); Dow Chemical U.S.A. (Midland, 
Michigan; Traverse City, Michigan); Geoliquids, Inc. (Prospect Heights, Illinois); OMG Apex (St. 
George, Utah); and Osram Sylvania, Inc. (Towanda, Pennsylvania).  Tungsten trioxide:  Johnson 
Matthey, Inc. (Ward Hill, Massachusetts); and Osram Sylvania, Inc. (Towanda, Pennsylvania).  Tungsten 
hexafluoride:  Air Products and Chemicals (Hometown, Pennsylvania) and Ozark Fluorine Specialties 
(Tulsa, Oklahoma). Tungsten carbonyl: Strem Chemicals, Inc. (Newburyport, Massachusetts).  Tungsten 
hexachloride: Osram Sylvania, Inc. (Towanda, Pennsylvania).  
Since tungsten and tungsten compounds are not covered under Superfund Amendments and 
Reauthorization Act (SARA), Title III, manufacturers and users are not required to report releases to the 
EPA’s Toxics Release Inventory.
5.2 IMPORT/EXPORT 
In 2003 approximately 12,300 metric tons of tungsten concentrates and other forms were imported into 
the United States amounting to approximately 21% of world production.  The largest amounts of 
tungsten-bearing materials imported for consumption into the United States were from China (e.g., 
4,790 metric tons in 2003).  Tungsten concentrates and other forms imported for consumption were 
11,100, 10,200, 10,800, and 10,600 metric tons for the years 1999, 2000, 2001, and 2002, respectively
(USGS 2003a, 2004a, 2004b).  
In 2003, approximately 5,090 metric tons of tungsten concentrates and other forms were exported from
the United States.  Exports of tungsten concentrates and other forms were 2,880, 2,870, 5,080, and 
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5.3 USE 
Tungsten is consumed in the form of tungsten carbide (65%), alloy additives (16%), metallic tungsten 
(16%), and tungsten chemicals (3%).  Tungsten carbide, because of its high hardness at high temperature, 
is used as a component of cutting tools, abrasion-resistant surfaces, and forming tools.  It is used
primarily in the form of cemented carbides, which are used for cutting tools, mining and drilling tools, 
forming and drawing dies, bearings, valve seats, and several other wear-resistant applications.  As an 
alloy additive, tungsten metal imparts high-temperature strength and wear resistance in steel, nickel, and 
cobalt-based super-alloys.  Metallic tungsten is used as welding electrodes (e.g., thoriated tungsten); in 
the manufacture of lamp filaments; as an electron emitter; in x-ray and electron tubes, turbine blades, 
counterbalance weights, golf club components, darts, and fishing weights; as furnace elements; as heat 
shields; as vacuum metalizing coils and boats; in glass melting equipment; and as arc-lamp electrodes; in 
contact points (for vehicle, telegraph, radio, and television equipment), in rocket nozzles and other 
aerospace applications, and in high-speed rotors (e.g., gyroscopes) (Dermatas et al. 2004; Lassner and 
Schubert 1999; USGS 1999, 2001). It is also used in high-speed impact printers, in glass-to-metal seals, 
and as a base for silicon semiconductors (O’Neil et al. 2001; Penrice 1997a, 1997b).  An increasing use is 
in military weaponry, in which tungsten alloys are used as an alternate to depleted uranium for armor 
penetration and tungsten is replacing lead in “green” bullets.  Currently, 200 million tungsten bullets are 
produced annually, using an ounce of tungsten each (>5,500 tons) (ITIA 2001).  Tungsten chemicals, 
especially the oxides, sulfides, and heterpoly complexes, form stable catalysts for a variety of commercial 
chemical processes.  Tungsten hexachloride is used for preparing tungsten metathesis catalysts and 
metallic tungsten films.  Sodium tungstate is used in the manufacture of heteropolyacid color lakes used 
in printing inks, plants, waxes, glasses, and textiles and as a fuel-cell electrode material, and in cigarette 
filters. Other uses of sodium tungstate include the manufacture of tungsten-based catalysts and for 
fireproofing textiles.  Ammonium paratungstate is commercially significant because it is the precursor of 
high purity tungsten oxides, tungsten, and tungsten carbide powders.  Tungsten trioxide is a principal 
source of tungsten metal and tungsten carbide powders.  It is also used as a pigment in oil and water 
colors, in a wide variety of catalysts, and in the control of air pollution and industrial hygiene (O’Neil et 
al. 2001; Penrice 1997a, 1997b).  Tungsten hexafluoride is used by the electronics industry as a source of 
tungsten metal that connects the aluminum layers within semiconductor devices (USGS 2001).  
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5.4 DISPOSAL 
A significant percentage of tungsten is recycled.  During the year 2002, the tungsten content of scrap 
consumed by processors and end-users was estimated at 4,380 metric tons.  This represented 
approximately 37% of apparent U.S. consumption of tungsten in all forms (USGS 2002).  
Most tungsten minerals, tungsten compounds, and tungsten-containing materials do not require special 
disposal and handling requirements.  However, some chemical forms may be classified as hazardous 
materials if the compound is chemically reactive, flammable, or toxic.  Care should be taken to read and 
understand all of the hazards, precautions, and safety procedures for each specific chemical form.  In 
addition, all federal, state, and local laws and regulations should be investigated and subsequently
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Tungsten has been identified in at least 6 of the 1,662 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (HazDat 2005).  However, the number of sites 
evaluated for tungsten is not known.  The frequency of these sites can be seen in Figure 6-1. Of these 
sites, all are located within the United States. 
The concentration of tungsten in surface soil and streambed sediment varies by location across the 
continental United States. Figure 6-2 is a composite United States Geological Survey (USGS) dataset 
obtained using various analytical methods over many years, and shows a concentration range from <1 to 
>17 ppm.  Though not depicted in Figure 6-2, some measured levels in Alaska exceed 24 ppm.  The 
analysis of archived and supplemental samples using newer and more accurate techniques is enabling the 
USGS to produce improved maps, which currently include portions of the east coast, Alaska, Nevada, and 
California (USGS 2005). 
Tungsten is naturally released to the atmosphere as windblown dusts.  Processes of human origin, such as 
ore processing, hard-metal fabrication, tungsten carbide production and use, and municipal waste 
combustion, release tungsten to the atmosphere.  Tungsten naturally enters waterways through the 
weathering of rocks and soils.  The sources of anthropogenic releases of tungsten to surface waters 
include water effluents from tungsten mining and manufacturing processes.  Deposition of atmospheric 
tungsten particulate aerosols from both natural and sources of human origin is also a source of tungsten in
surface waters.  Some tungsten compounds are naturally present in soil, but the concentration of tungsten 
in localized soils can be increased by land application of sewage sludge, fertilizers, municipal solid waste 
ash, and industrial wastes that contain tungsten, or deposition of atmospheric aerosols. 
Atmospheric tungsten particulates will eventually settle to the earth's surface by dry deposition or may be 
removed from the atmosphere by wet deposition (i.e., precipitation).  Upon reaching water and soil, 
tungsten will be in either soluble (e.g., tungstate ion, WO42-) or insoluble forms (e.g., tungsten trioxide) in 
sediment and soil.  The mobility of tungsten will depend on environmental conditions such as pH.  Under 
normal environmental conditions, tungsten is expected to have moderate to low mobility.  Although 
chemical reactions may transform one tungsten compound into another, tungsten cannot be degraded by
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Figure 6-2. Tungsten Soil and Streambed Concentration Maps (USGS 2005) 
Data from the National Uranium Resource Evaluation (NURE) using a variety of analytical methods.  The background
coloration indicates the tungsten detection limit for analytical methods employed in a particular region.  For example, 
violet in the west-central United States indicates that detection limits were in the range of 1.914–7.455 ppm. 
Data from instrumental neutron activation analysis (INAA) showing tungsten concentrations in excess of 2 ppm along 
the Appalachian ridge.  According to USGS (2005), the INAA method provides more accurate and uniform results 
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environmental reactions.  Data regarding transformation reactions of tungsten in water and soil are 
limited.  No information was available in the literature on the bioavailability of tungsten to plants and 
animals.  
The concentration of tungsten in ambient air is <10 ng/m3 (Dames et al. 1970; Haddad and Zikobsky
1985; Jagielak and Mamont-Cieśla 1979). Tungsten has not been reported in surface water or 
groundwater of the United States, except in areas of mineral formations containing tungsten.  Tungsten is 
the 18th most abundant metal, having an estimated concentration in the earth’s surface rocks of 1– 
1.3 mg/kg (Penrice 1997a).  Tungsten concentrations in soils and surface soils are 0.5–83 and 0.68– 
2.7 mg/kg dry weight, respectively (Senesi et al. 1988).  No monitoring data were located for food in the 
United States. Since tungsten is in soil, the absence of monitoring data for water and food indicates that 
analytical laboratories may not have been analyzing for this substance.  Analyzing such samples using 
adequately low detection limits could find tungsten at measurable levels.  For example, onions collected 
from 11 Danish sites uncontaminated by human activities other than routine agricultural practices 
contained tungsten at a mean level of 16.7 µg/kg fresh weight (n=64; range, 6.3–39 µg/kg) (Bibak et al. 
1998). 
The general population may be exposed to tungsten through inhalation of air and consumption of food.  
Exposure to tungsten above background levels may occur to the general population living near industries 
that process or use tungsten or its compounds, and to those living near hazardous sites that contain high 
concentrations of tungsten.  However, the total tungsten intake by the general U.S. population cannot be 
accurately estimated due to the lack of data regarding tungsten content in food and drinking water.  
People who work in tungsten manufacturing, fabricating, and reclaiming industries are exposed to higher 
levels of tungsten and its compounds than the general population. Tungsten poses a relatively new 
exposure concern due to its increasing use in armor-piercing munitions and as a replacement for lead in 
other ammunition. 
6.2 RELEASES TO THE ENVIRONMENT 
The TRI data should be used with caution because only certain types of facilities are required to report 
(EPA 1997a). This is not an exhaustive list.  Manufacturing and processing facilities are required to 
report information to the Toxics Release Inventory only if they employ 10 or more full-time employees; if 
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produces, imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds 
of a TRI chemical in a calendar year (EPA 1997a). 
There is no information on releases of tungsten to the atmosphere from manufacturing and processing 
facilities because these releases are not required to be reported (EPA 1997a). 
6.2.1 Air 
Tungsten naturally occurs in the earth’s crust and is released into the atmosphere as a result of natural 
processes such as entrainment of dust particles and resuspension of soil by wind.  Entrainment of soil and 
dust particles with significant concentrations of tungsten would be most significant in areas with higher 
soil tungsten concentrations.  Human activities, including milling and processing of tungsten and its 
compounds, burning of coal and municipal solid waste, and land application of fertilizers, release 
tungsten into the atmosphere.  
Tungsten and its compounds may be emitted into the atmosphere during milling and processing 
operations. In the production of tungsten carbide materials for the hard-metal industry, tungsten oxide 
fibers were released as a by-product during the reduction stage of the raw material (Sahle et al. 1994).  In 
1978, Germani et al. (1981) measured an average tungsten concentration of 15±2 ng/m3 
(0.015±0.002 µg/m3) in particulate emissions from five copper smelters in southeast Arizona.  The 
concentrations of tungsten in the ore, ore concentrate, and electrostatic precipitator dust from these 
smelters were 4.0±0.4, 4±1, and 44±8 µg/g, respectively. 
Tungsten may be discharged into the atmosphere from the operation of urban municipal waste 
incineration (MWI) plants.  The concentration of tungsten in fly ash from the MWI plants in Barcelona, 
Spain ranged from 13 to 17 µg/g in two samples (Fernandez et al. 1992).  Particle-borne tungsten 
concentration in stack air emissions of two coal-burning units in a Western U.S. power plant ranged from
2.0 to 23.2 µg/m3. Atmospheric concentrations of particle-borne tungsten in a power plant plume were 
0.019±0.003 µg/m3, not detected (i.e., 0.0050±0.011 µg/m3) and not detected at a distance of 0–8, 8–16, 
and 32–64 km, respectively, from the power plant (Ondov et al. 1989).  Air emissions from three different 
municipal waste deposits in British Columbia, Canada were sampled and analyzed for airborne tungsten 
compounds (e.g., tungsten carbonyl, W[CO]6). At these locations, tungsten compounds were found at 
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Tungsten has been identified in outdoor air at one site (i.e., Eastern Michaud Flats Contamination, Idaho) 
of the six NPL hazardous waste sites where it was detected in some environmental media (HazDat 2004). 
6.2.2 Water 
Anthropogenic and natural emissions of tungsten to water may result from mining operations and mineral 
weathering, respectively. Releases to surface water and groundwater typically occur in regions where 
natural formations of tungsten minerals are prevalent.  Tungsten was found in surface water and 
groundwater in Northern Iceland in areas that had natural formations of tungsten minerals.  
Concentrations of tungsten in these glacial and thermal waters (2–90 °C) were lower in surface water than 
in groundwater.  Levels of tungsten were 0.03–11.5, 0.015–0.49, 0.005–0.09, 0.005–0.34, and 0.005– 
0.33 ppb (µg/L) for groundwaters in lowland areas, groundwaters in highland areas, lakes, rivers and 
streams, and peat soil waters, respectively (Arnórsson and Lindvall 2001).  In Japan, the concentration of 
tungsten was 0.67 mg/L (0.00067 µg/L) in river water (location not specified) polluted with liquid wastes 
from a tungsten mine (Mamuro et al. 1971).   
Tungsten has been identified in groundwater at one site (i.e., Stringfellow, California) of the six NPL 
hazardous waste sites where it was detected in some environmental media (HazDat 2004). 
6.2.3 Soil 
Tungsten is naturally present in soils and sediments.  Land application of sewage sludge and fertilizers 
containing higher than background concentrations of tungsten can be an anthropogenic source of tungsten 
emission to soil.  Typical concentrations of tungsten in the lithosphere, parent rocks, and soil amendments 
such as fertilizers are listed in Table 6-1. 
Military installations and areas involved in military combat operations and training may have higher 
concentrations of tungsten as a result of the use of military hardware containing tungsten.  For example, 
the concentration of tungsten in surface soils samples was measured in areas of atmospheric fallout of 
particulates from the use of explosives in the Gulf War (1990–1991).  In areas nearest to the Saudi 
Arabian-Kuwait border where the heaviest fall-out occurred, the maximum concentration of tungsten in 
soil was 126.50 mg/kg (sampling depth of 0–5 cm).  In areas 300 km from the border, the concentration 
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Table 6-1. Range and Average Amounts of Tungsten in the Lithosphere, 





Material Concentration (mg/kg) 
Lithosphere (0.1–2.4)
Rock phosphates and phosphorites (30–270) 
Rock carbonates 0.6 
Limestones (0.2–0.8)
Sewage sludges (1–100) 
Manure (8–2,800)
Calcium cyanamide 0.5 
Phosphate fertilizers 100 
Ammonium sulfate (ND–0.03) 
Ammonium nitrate (ND–0.20) 
Calcium nitrate 0.23 
Urea (ND–0.11)
Superphosphate 3.84 (1.47–7.04)
Triple superphosphate 3.29 (1.59–4.99) 
Potassium sulfate (ND–0.75) 
NP compound 1.28 (ND–3.99) 
NPK compound 0.89 (0.02–2.03) 
aSource: Senesi et al. (1988); detection limit = 0.002 mg/kg  
bThe values presented correspond also to the contribution, in g/ha, of tungsten from 1 mg of fertilizer applied 
to 1 ha of soil. 
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Tungsten has been identified in soil at one site (i.e., Anaconda Co. Smelter, Montana) of the six NPL 
hazardous waste sites where it was detected in some environmental media (HazDat 2004). 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Tungsten and most tungsten compounds have low vapor pressures at 25 °C and are expected to exist in 
the particulate phase in air (HSDB 2004; Penrice 1997b).  Some exceptions are tungsten carbonyl and 
tungsten hexafluoride.  According to a model of gas/particle partitioning of semivolatile organic 
compounds in the atmosphere, tungsten carbonyl, which has a vapor pressure of 0.1 mm Hg at 20 °C, is 
expected to exist in both vapor and particulate phases in the atmosphere (Bidleman 1988; O’Neil et al. 
2001). Tungsten hexafluoride is a gas at room temperature (Lide 2000).  Vapor- and particulate-phase 
tungsten compounds may be removed from the air by wet and dry deposition.  In Norway, between the 
years 1993 and 1995, the mean annual wet deposition flux of tungsten ranged from 2 to 10 µg/m2 per year 
(n=13) (Berg and Steinnes 1997).  Tungsten-containing soil can be re-suspended into the atmosphere by 
wind. 
In water, tungsten metal and metal alloys will exist as insoluble solids, while tungsten compounds will 
exist as ions or insoluble solids (Cotton and Wilkinson 1980).  Tungsten compounds are expected to 
adsorb to suspended soils and sediment in the water column.  Tungsten may be present in water as soluble 
tungstate ions, and also as species with inorganic colloids (Tanizaki et al. 1992). Soluble tungsten 
compounds (e.g., tungstates) may leach into groundwater.  Volatilization from moist soil and water 
surfaces is not expected to be important for tungsten metal, alloys, and compounds due to their low vapor 
pressures (HSDB 2004; Penrice 1997b). 
Tungsten is carried to rivers, lakes, and oceans by land erosion.  The estimated residence time of tungsten 
in ocean water, as the tungstate ion (WO42-), before it is removed from the aquatic phase by sedimentation 
or other removal processes, is approximately 1,000 years (Bowen 1966). 
Sorption coefficients for tungsten suggest that it is expected to have moderate to low mobility in soil 
under normal environmental conditions (Meijer et al. 1998).  The sorption coefficient (Kd) for tungsten 
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pH 5; 10–6,000 at about pH 6.5; and 5–90 at pH 8–9 (Meijer et al. 1998).  The sorption behavior of 
tungsten is due to changes in the surface charge of the soil as the contact solution becomes more acidic or 
alkaline. Tungsten combines with a large number of organic ligands (Lassner et al. 1996).  However, no 
information on stability of tungsten organic matter complexes was located in the literature.  Also, no 
information on the sorption of tungsten in saline environments was located in the literature.  
The concentration of tungsten in plants is low (Bowen 1960).  Beans were found to incorporate tungsten 
when grown in soil amended with 1, 5, and 10% by weight tungsten metal or tungsten trioxide powder.  
The uptake was higher for tungsten metal than its oxide (1,100 mg/kg for metal versus 820 mg/kg for 
oxide at 10% weight percent) and increased with soil concentration in an apparently asymptotic manner.  
Rye grass was also found to take up tungsten from soil into the plant stem (U.S. Army 2000). 
No information on the bioavailability of tungsten to animals was available in the literature.  Soluble forms 
of tungsten, such as tungstate ions, will be more bioavailable to fish and animals than insoluble forms.  
No evidence of the bioaccumulation of tungsten in the food chain of humans was located in the literature. 
6.3.2 Transformation and Degradation  
Degradation of an element, such as tungsten, is a nuclear process, by definition.  Stable elements, such as 
tungsten, typically undergo such processes only at insignificant rates in the environment.  As an element, 
tungsten cannot degrade chemically.  It can change, however, from one chemical form to another, 
sometimes reversibly, in numerous chemical reactions that can proceed under a wide range of common 
environmental conditions. 
6.3.2.1 Air 
Insoluble particulate-phase tungsten metal, alloys, and compounds are not expected to react in air.  
Soluble particulate-phase compounds, such as ammonium paratungstate and tungsten hexachloride, may
react with moisture in air to form tungstate ions (e.g., WO42-). There is no evidence in the literature for 
interaction of soluble or insoluble particulate-phase tungsten with CO2 (gas) or other compounds in the 
atmosphere.  No information was found in the literature on photooxidation or photolysis of tungsten 
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6.3.2.2 Water 
The reaction of tungsten in water is controlled by chemical speciation by which one species is converted 
to another. Tungsten exists in several oxidation states, 0, 2+, 3+, 4+, 5+, and 6+ (Bingham et al. 2001).  
The most stable is 6+ with the lower states being relatively unstable.  Tungsten can exist as ions in water 
with one or more elements such as oxygen.  In natural waters, tungsten is primarily in the form of the 
soluble tungstate ion (i.e., WO42-) under alkaline conditions or other tungsten polyanions under acidic 
conditions (Bowen 1966; Lassner et al. 1996; Tanizaki et al. 1992).  Dissolution of tungsten metal in 
aqueous solution likely occurs through a stepwise anodic oxidation of the metal to the W+6 oxidation state 
through the intermediate formation of the W+3, W+4, and W+5 oxidation states, as shown in the reaction 
scheme below (Dermatas et al. 2004; Lassner and Schubert 1999).  
W + 2OH– → WO+ + 3e– 
–WO+ + 2OH– → WO2 + e  + H2O 
WO2 + OH– → WO3H + e– 
WO3H + OH– → WO3 + e– + H2O 
WO3 + OH– → HWO4– 
HWO4– → WO4–2 + H2O 
The accompanying cathodic reaction involves the reduction of dissolved molecular oxygen: 
O2 + 2H2O + 4e– → 4OH– 
The dissolution of tungsten metal typically results in the decrease of the pH of the local media (Dermatas 
et al. 2004). The extent and rate of tungsten dissolution changes when alloyed with other metals.  Iron 
has been shown to enhance the dissolution of tungsten, but cobalt reduces the rate and extent of tungsten 
dissolution (Dermatas et al. 2004).   
Tungsten has a strong tendency to form complexes; this is exemplified by the large series of heteropoly
acids formed with oxides of phosphorous (e.g., phosphotungstic acid), arsenic, vanadium, silicon, and 
others (Bigham et al. 2001).  Tungsten combines with a large number of organic ligands (Lassner et al. 
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In surface water, elevated tungsten levels may inhibit ammonification and nitrification of organic 
compounds and growth of saprophytic microflors (Nadeenko 1966).  Experimental analysis using three 
different tungsten compounds (sodium tungstate, sodium phosphotungstate, or tungstic acid) revealed 
marked reduction in oxygen consumption at a tungsten concentration of 1 µg/L, a marginal reduction (10– 
20%) at 0.1 µg/L, and no significant effect at 0.01 µg/L. 
6.3.2.3 Sediment and Soil 
Typical transformation processes for tungsten in soil include precipitation, complexation, and anion 
exchange. Important factors affecting the transformation of tungsten in soils and sediments include pH, 
ionic strength (i.e., salinity), redox potential, concentration and distribution of species, composition of the 
mineral matrix, organic matter, and temperature.  It is likely that dissolution of tungsten in soil will occur 
through a similar reaction process to those described for tungsten in water, resulting in a similar decrease 
of soil pH. Dermatas et al. (2004) have demonstrated that this lowering of soil pH can result in the death 
of soil organisms.  Tungsten binds with soils with the extent of tungsten uptake into soils appearing to 
follow the order:  Pahokee peat > montmorillonite >> illite > sand (Dermatas et al. 2004).  High uptake of 
tungsten in high organic soils, such as Pahokee peat, is thought to occur through the formation of tungsten 
complexes with humic substances in these soils.  Binding of tungsten to some soils (e.g., montmorillonite 
and illite) occurs through cooperative adsorption, likely through the polymerization of tungstates to form
isopolytungstates (Dermatas et al. 2004).  The uptake of tungsten into montmorillonite and illite soils is 
usually accompanied by an increase in the pH of the local media.  These binding processes have the effect
of limiting the mobility of tungsten in soils.  Leachability and mobility tests were conducted on bullets 
made of tungsten or tungsten-tin powder that were pressed and crushed to simulate degradation when 
fired into several media (sand, soil, and mixtures containing gravel, steel plates, and concrete).  The 
powders were mixed with soil (sand or topsoil), exposed to a leachant (deionized water, acid rain, or salt 
water), and leached by up-flow and hold methods.  Little or no tungsten leached from the topsoil, but 
tungsten did penetrate the sand column and filter, indicating that small-sized particles of tungsten can be 
mobile in sandy soil (U.S. Army 2000).  No other biotransformation studies of tungsten or its compounds 
were located in the literature. 
6.3.2.4 Other Media  
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6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
Reliable evaluation of the potential for human exposure to tungsten depends in part on the reliability of 
supporting analytical data from environmental samples and biological specimens.  Concentrations of 
tungsten in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits 
of current analytical methods.  In reviewing data on tungsten levels monitored or estimated in the 
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
equivalent to the amount that is bioavailable.  The analytical methods available for monitoring tungsten in 
a variety of environmental media are detailed in Chapter 7. 
6.4.1 Air 
Ambient concentrations of tungsten in air have been measured at levels <10 ng/m3  (Dames et al. 1970; 
Haddad and Zikobsky 1985; Jagielak and Mamont-Cieśla 1979). Between 1972 and 1976, mean values 
of tungsten determined for atmospheric air in Siersza (a small industrial town) and the Warsaw district of 
Zerań, Poland were 5.8 and 4.5 ng/m3, respectively, while concentrations in dust were 44 and 19 ppm,
respectively, for the same locations (Jagielak and Mamont-Cieśla 1979).  The ambient average air 
concentration of tungsten in the urban air of Montréal, Quebec, Canada was 5.2 ng/m3 (Haddad and 
Zikobsky 1985).  Dames et al. (1970) measured the concentration of tungsten in urban air at East 
Chicago, Indiana, an industrial area of northwest Indiana, and Niles, Michigan, which is about 50 miles to 
the northeast of this industrial area.  The concentration of tungsten in suspended particulates from East 
Chicago, Indiana was 5.8 ng/m3 while the concentration in samples taken from Niles, Michigan was 
0.4 ng/m3. 
Tungsten has been detected at sub-nanogram concentrations at remote locations around the world, 
possibly the result of natural processes such as entrainment of dust particles and resuspension of soil by 
wind. The average concentrations of tungsten in particles collected from the Arctic haze of the free 
troposphere, in the stratosphere, and in the marine boundary over various Arctic regions were as follows 
(Sheridan and Zoller 1989):  North American Arctic, 0.14±0.09 ng/m3 (n=10); Norwegian Arctic, 
0.073±0.031 ng/m3 (n=9); stratosphere filters, 0.033±0.011 ng/m3 (n=10); and marine boundary layer 
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geographic South Pole was 0.0015±0.0008 ng/m3 during the Austral summer of 1974–1975 (Maenhaut et 
al. 1979).  
Tungsten levels in indoor air have been determined as part of a 1998 study of metal exposures for 
residents of a retirement home in Towson, Maryland (Graney et al. 2004).  The study participants had a 
mean age of 84, were all non-smokers, and did not typically cook their own meals.  Median tungsten 
concentrations of 0.010 and 0.007 ng/m3 in air were reported in particulate matter (PM2.5) samples 
collected from indoor air and personal exposure samplers, respectively. 
6.4.2 Water 
Limited data have been reported on the concentrations of tungsten in surface water and groundwater from
the United States.  Taylor et al. (1990) reported semi-quantitative concentrations of tungsten in river 
waters of the Mississippi River and its tributaries at concentrations ≤0.2 µg/L (i.e., semi-quantitative 
detection limit of 0.2 µg/L) with 4 of 15 samples showing positive analytical results for tungsten.  These 
results indicate that tungsten may be present in ambient surface waters.  However, semi-quantitative 
results should be interpreted with caution since they may not reflect actual concentration levels.  In 1992, 
water samples were analyzed for three river systems (Truckee, Walker, and Carson, Nevada), which are 
in regions of natural tungsten mineral formations (Johannesson et al. 2000).  The purpose of the study was 
to assess the interrelationships among metal and other ionic concentrations as the three rivers lost water 
through evaporation.  In the Truckee river system, tungsten varied from a low value of 1.73 nmol/kg 
(0.319 µg/L) to a high value of 391 nmol/kg (72.1 µg/L).  In the Walker and Carson systems, tungsten 
varied from 0.82 to 22.1 nmol/kg (0.15–4.07 µg/L), and from 8.21 to 1,029 nmol/kg (1.51–189.7 µg/L),
respectively. The high concentration of tungsten in these rivers reflects the relative stability of the 
tungstate ion (WO42-) in the alkaline and well-oxygenated waters; contributions from hydrothermal 
waters; and weathering of rocks/regoliths with high concentrations of tungsten.  Samples from these 
rivers may potentially be potable drinking water sources.   
Limited monitoring data were located for urban environments in the United States.  However, in the City
of Fallon in Churchill County, Nevada, several studies have been conducted.  In 2002, a mean 
concentration of 19.9 µg/L was determined for tungsten in tap water sampled from 76 private and 
municipal residential water supplies (Agency for Toxic Substances and Disease Registry 2003).  Upon 
further analysis of the concentration data, it was found that tungsten levels were highest in water taken 
















6. POTENTIAL FOR HUMAN EXPOSURE 
In comparison, the tungsten concentrations were found to be lower in tap water sampled from residences 
using municipal water supplies, with values ranging from 0.25 to 27.2 µg/L and a mean value of 
19.1 µg/L.  In a study conducted by the Centers for Disease Control and Prevention (CDC) of household 
water supplies in the Churchill County community the concentrations of tungsten were found to range 
from 0 to 217.3 µg/L (CDC 2003b).  However, in a follow-up study of three nearby communities, 
Yerington, Lovelock and Pahrump, tungsten concentrations in tap water were found to be lower, with 
values ranging from 0.01 to 40 µg/L, 0.02–2.0 µg/L, and 0.01–1.0 µg/L and mean (geometric) values of 
3.32, 0.11 and 0.04 µg/L, respectively (CDC 2003c).  No further data were located on the concentrations 
of tungsten in drinking water from the United States.  However, according to EPA sampling and 
analytical methods, tungsten is not a substance that is typically measured in drinking water.   
For non-U.S. locations, tungsten has been detected in surface water from urban areas.  The levels of 
tungsten were measured in river water from the Tamagawa and Sagamigawa Rivers located near Tokyo, 
Japan (Tanizaki et al. 1992a).  The range of tungsten concentrations in the dissolved and suspended 
fractions of these samples were as follows:  dissolved fraction (particulates <0.45 µm), 0.0265– 
0.107 µg/L; dissolved fraction (molecular weight <500), 0.0105–0.0341 µg/L; dissolved fraction 
(molecular weight=500–104), 0.0141–0.0701 µg/L; dissolved fraction (molecular weight >104), 0– 
8.7 ng/L; and suspended solids (particulates >0.45 µm), 0–0.104 µg/L.  In river water from the Asakawa, 
Nogawa, and Hisasegawa Rivers and effluent from a sewage treatment plant (all located near Tokyo, 
Japan), the levels of tungsten were determined to range as follows:  dissolved fraction (particulates 
<0.45 µm), 0.014–0.785 µg/L ; dissolved fraction (molecular weight <500), 0.0206–0.247 µg/L; dissolved 
fraction (molecular weight=500–104), 0.0270–0.537 µg/L; dissolved fraction (molecular weight >104), 0– 
0.0023 µg/L; and suspended solids (particulates >0.45 µm), 0.002–0.060 µg/L (Tanizaki et al. 1992b).  
Tungsten was measured in highly solute-rich river systems in a heavily industrialized region of India.  
Mean concentrations of tungsten in the Mahanadi, Brahmani, and Baitarani Rivers were 0.05 µg/L (range, 
0.02–0.9 µg/L), 0.15 µg/L (range, 0.04–0.89 µg/L), and 0.08 µg/L (range, 0.04–0.18 µg/L), respectively
(Konhauser et al. 1997).   
Locations with natural formations of tungsten have elevated levels of tungsten in surface water and 
groundwater. The Nahanni River, a spring-fed river system in an area of scheelite/wolframite baring 
minerals located in Northwest Territories of Canada, was found to contain tungsten at concentrations 
ranging from <0.1 to 224.5 µg/L (Hall et al. 1988).  Tungsten was found in surface water and 
groundwater in Northern Iceland in areas that had natural formations of tungsten minerals.  
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in groundwater.  Levels of tungsten were 0.03–11.5, 0.015–0.49, 0.005–0.09, 0.005–0.34, and 0.005– 
0.33 ppb (µg/L) for groundwater in lowland areas, groundwater in highland areas, lakes, rivers and 
streams, and peat soil waters, respectively (Arnórsson and Lindvall 2001).  Tungsten that is found in the 
surface water and groundwater of the Ethiopian Rift Valley is associated with thermal activity in the 
region. Tungsten concentrations ranged from <0.002 to 3.81 µg/L in water samples taken from deep 
(>60 meters depth) and shallow (<60 meters depth) wells, hot springs, and rivers, with a median value of 
0.011 µg/L (Reimann et al. 2003).  The concentrations were lowest in water samples taken from rivers 
and shallow wells and highest in samples obtained from hot springs and deep wells.  In a separate study
of the rivers and soda lakes within the Rift Valley, tungsten concentrations ranged from <0.1 to 
545.9 µg/L with the highest concentrations found in Lakes Abijata and Mechaferra (Zinabu and Pearce 
2003). The high levels of tungsten and other heavy metals (e.g., As, Hg, Mo, Rb, Ti) in these lakes were
attributed to a high degree of wildlife habitation in these lakes. 
The concentration of tungsten in seawater is typically about 0.1 µg/L (Bowen 1966). 
Tungsten has been detected at low concentrations in rainwater near locations with tungsten emissions.  
Rainwater analysis performed in the United Kingdom illustrated that ambient tungsten concentrations in 
rainwater typically are <1 µg/L (Hartung 1991).  Kist (1994) determined the levels of tungsten in 
rainwater sampled 8 km from a hard-metal factory in Russia.  The concentrations of tungsten in the solid 
and soluble phases of rainwater were 0.00014 and 0.00076 µg/L, respectively. The authors suggest that 
the enrichment of tungsten in the liquid phase may be explained for this area by a high concentration of 
tungsten as liquid aerosols and vapor-phase compounds rather than particulates. 
6.4.3 Sediment and Soil 
Tungsten is the 18th most abundant metal, having an estimated concentration in the earth’s surface rocks 
of 1–1.3 mg/kg (Penrice 1997a).  Tungsten concentrations in soils and surface soils are 0.5–83 and 0.68– 
2.7 mg/kg dry weight, respectively (Senesi et al. 1988).  Agricultural soils from New Zealand had mean 
concentrations of tungsten ranging from 1.9 to 21.4 mg/kg (n=2), while mineralized areas had tungsten 
concentrations ranging from 65 to 125 mg/kg (n=3) (Quin and Brooks 1972a, 1972b).  Fu and Tabatabai 
(1988) measured a mean concentration of 0.89 mg/kg (range, 0–2 mg/kg) for agricultural soils from Iowa 
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6.4.4 Other Environmental Media 
Tungsten was detected in ambient air and gas wells within three municipal waste disposal sites near 
Vancouver, British Columbia (Feldman and Cullen 1997).  The concentration of tungsten compounds in 
the landfill gas collected from gas wells ranged between 5 and 10 ng W/m3. Concentrations of tungsten 
compounds in the ambient air over the landfills were under 1 ng W/m3. Based on mass spectrometric 
analysis of the gas components, the tungsten measured in the landfill gas and ambient air samples was in 
the form of hexacarbonyl tungsten (W[CO]6). 
At Cayuga Lake, New York, tungsten was not detected in lake trout (Salvelinus namaycush) ranging in 
age from 1 to 12 years at a detection limit of 0.2 ppb fresh weight (Tong et al. 1974).  Sea animals have 
been reported to contain tungsten in dry tissues at concentrations ranging from 5x10-4 to 5x10-2 mg/kg 
(Bowen 1966). 
No monitoring data were located for food in the United States.  Onions collected from 11 Danish sites 
uncontaminated by human activities other than routine agricultural practices contained tungsten at a mean 
level of 16.7 µg/kg fresh weight (n=64; range, 6.3–39 µg/kg) (Bibak et al. 1998).  Blueberries and 
lingonberries collected from 35 urban and mining area sites in Northern Sweden from September to 
October 1998 contained tungsten at concentrations of 0.23–3.7 ng/g and 0.22–7.2 ng/g, respectively
(Rodushkin et al. 1999). Perez-Jordan et al. (1998) semi-quantitatively determined the concentrations of 
tungsten in Spanish wines as follows: red-Valencia, 0.25±0.06 ng/mL; red-Utiel-Req, 0.09±0.03 ng/mL; 
red-Rioja, 0.55±0.05 ng/mL; white-Valencia, 0.25±0.01 ng/mL; white-Utiel-Req, 0.11±0.01 ng/mL; and 
white-Rioja, 0.6±0.4 ng/mL. 
The concentration of tungsten in land plants ranges from 0.0005 to 0.150 mg/kg dry weight (Bowen 
1960).  Mean concentrations of tungsten in plants were reported as follows: source unknown from New 
Zealand, 0.27–39.5 mg/kg; tree leaves from New Zealand, 2.2–3.5 mg/kg; and agricultural plants from
Iowa, 0.18 mg/kg (Fu and Tabatabai 1988; Quin and Brooks 1972a, 1972b).  Quin and Brooks (1972b) 
determined the tungsten content of some native trees and ferns growing in an area of tungsten 
mineralization in Westland, New Zealand.  The highest value reported was 1,500 mg/kg of ash weight in 
the leaves of black hard fern (Blechnum nigrum). The concentration of tungsten in tree ferns showed a 
significant correlation with the concentration in the soil; the tungsten content of trees did not. The mean 
concentration of tungsten in tree bark (oak) sampled from the western part of the Czech Republic was 
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the concentration of heavy metals in aquatic macrophytes from the Fractal Dam (Tejo River, Portugal) in 
March 1987.  Tungsten was found in whorled-water milfoil (Myriophyllum verticilatum), water buttercup 
(Ranunculus sp.), and pondweed (Potamogetam sp.) at average levels of 3.1±0.4, 5.6±0.2, and 
2.5±0.1 ppm, respectively. Lichen (Hypogymnia physodes L.) sampled in Slovenia in 1992 was found to 
contain tungsten at a mean concentration of 0.17±0.13 µg/g dry weight (n=82, range, 0.04–0.80 µg/g dry 
weight) (Jeran et al. 1996).  Two species of moss (i.e., Hylocomium splendens and Pleurozium schreberi) 
collected around Norway between the years 1993 and 1995 were found to contain tungsten at 
concentrations of 0.027–0.15 µg/g (n=13) and 0.012–0.093 µg/g (n=13), respectively (Berg and Steinnes 
1997). In areas around Norway and Russian Kola Peninsula and Tver region, the concentrations of 
tungsten in moss (H. splendens), lichen (Usnea sp.), and pine needles (Pinus sylvestris L.) were 0.73, 
<0.2, and 0.34 ppm, respectively (Nazarov et al. 1995).  
Tungsten concentrations in the lithosphere, some parent rocks, some soil-added materials, and  
various fertilizers are illustrated in Table 6–1.  Sewage sludge samples from 16 major U.S. cities and 
Iowa contained tungsten at mean concentrations of 19.4 mg/kg (n=16; range, 0.9–99.6 mg/kg) and 
4.3 mg/kg (range, 0.5–62 mg/kg), respectively (Furr et al. 1976; Senesi et al. 1988).  The mean 
concentration of tungsten in sewage sludge samples from 23 U.S. cities was 14.4 ppm dry weight (n=30; 
range, 0.65–140 ppm dry weight) for samples collected in 1980 (Mumma et al. 1984).  Municipal waste 
ash samples from Japan contained tungsten at median levels as follows: food scrap ash, 0.9 mg/kg (range, 
0.24–1.25 mg/kg); animal waste ash, 0.8 mg/kg (range, 0.20–1.56 mg/kg); horticulture waste ash, 
1.6 mg/kg (range, 0.86–3.99 mg/kg); sewage sludge ash, 11.8 (range, 5.13–21.5 mg/kg); and incinerator 
bottom ash, 4.4 mg/kg (range, 2.46–11.4 mg/kg) (Zhang et al. 2002).   
Some types of coal may contain tungsten at significant levels.  In the United States, tungsten was found in 
Pocahontas coal at concentrations of 0.5 and 49 ppm dry weight in the organic and sulfide fractions, 
respectively (Pires et al. 1997).  However, it was not detected in any fraction of Davis, Colchester, Herrin, 
or Pittsburgh coals.  
Tungsten content has been measured in slags collected from smelters located on abandoned copper and 
silver mines.  Tungsten concentrations were found to range from 0.4 to 2.6 mg/kg in slags taken from the 
Ely and Elizabeth mines in Vermont and the mining district of Ducktown, Tennessee (Piatak et al. 2004).  
In one measurement for a slag from the Clayton silver mine in the Bayhorse mining district of Idaho, a 
tungsten concentration of 175 mg/kg was obtained.  In the same study, it was found that tungsten was not 
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simulated precipitation in the eastern United States.  This is demonstrated in the finding that the 
concentration of tungsten in the extractants was at or near the limit of detection of the assay (<0.3– 
0.6 µg/L) for all of the slags tested.  
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
Although data are limited, the general population may be exposed to trace amounts of tungsten by
inhalation of air.  Bowen (1966) reported a provisional dietary intake of 49 µg/day for tungsten for a 
70-kg man with a diet of 750 g dry weight per day.  Since no drinking water data are available for 
tungsten, an estimated daily intake from drinking water could not be estimated.  However, based on 
limited surface water data for tungsten, the estimated daily intake from drinking water is predicted to be 
negligible. No information on the concentrations of tungsten in food was located in the available 
literature. 
A National Occupational Exposure Survey conducted by NIOSH during 1981–1983 estimated the number 
of individuals who were potentially exposed to tungsten and its compounds in the workplace (NIOSH 
1983).  The total number of individuals occupationally exposed to tungsten was 47,052 (i.e., the sum of 
three hazard classifications).  The number of individuals occupationally exposed to tungsten compounds 
was as follows (number in parenthesis):  sodium tungstate, dihydrate (2,254); sodium tungstate, 
anhydrous (15,470); sodium phosphotungstate (73); and tungsten carbide (3,395).  
Most exposures to tungsten and its compounds in occupational environments occur during production of 
tungsten metal from the ore, and preparation of tungsten carbide powders.  Exposures to cemented 
tungsten carbide occur in manufacturing and grinding cemented tungsten carbide hard-metal parts.  Dusts 
and mists of tungsten and its compounds or cemented tungsten carbide are produced during crushing, 
mixing, ball milling, loading and unloading, sintering, cutting, sandblasting, and grinding operations.  
Because of the high melting points of tungsten compounds, exposures to their vapors are negligible 
(NIOSH 1977). Table 6-2 lists occupations with potential exposure to tungsten and its compounds. 
Tungsten exposure levels for individuals working in the hard-metal industry are illustrated in Table 6-3.  
In the United States, the breathing zone air concentration of tungsten ranged from 0.2 to 12.8 mg/m3 for 
workers involved in the wet grinding of sintered pieces without ventilation (NIOSH 1977).  Schwartz et 
al. (1998) reported that tungsten was found in lung tissues of five individuals occupationally exposed 
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Table 6-2. Occupations with Potential Tungsten Exposure 
Alloy makers Melting, pouring, casting workers 
Carbonyl workers Metal sprayers 
Ceramic workers Ore-refining and foundry workers 
Cemented tungsten carbide workers Paint and pigment makers 
Cement makers Papermakers 
Dyemakers Penpoint makers
Dyers Petroleum refinery workers
Flameproofers Photographic developers
High-speed tool steelworkers Spark-plug makers
Incandescent-lamp makers Textile dryers 
Industrial chemical synthesizers Tool grinders 
Inkmakers Tungsten and molybdenum miners 
Lamp-filament makers Waterproofing makers 
Lubricant makers Welders 













      
   
     
     
     
     
     
   
     
     
     
     
     
     
   
     
     
     
     
     
     
  






6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-3. Worker Exposure to Tungsten in the Hard-Metal Industry
Type of operation Total dust (mg/m3) Tungsten (mg/m3) Sample type Location
Powder processing 
14.9 7.7 G Austria
0.3–9.8 1.8–8.24 B Switzerland
1.1–32 0.88–25.6 B Sweden
3.1–130.3 2.2–3.5 G USSR
Tool and operations: casting 
0.22–7.5 0.52–4.56 B Switzerland
15 12 B Sweden
0.7–3.0 0.6–2.6 G Sweden
5.5–47.7 1.4–2.1 G USSR
21.5 17.6 G	 Austria
Tool and operations: forming 
0.5–24.6 0.97–26.7 B Switzerland
0.1–7.5 0.08–5.9 B Sweden
0.2–0.7 0.17–0.58 G Sweden
– 3.3–32.5 G	 USSR
11.1 8.8 B	 Austria
Grinding of sintered pieces: wet grinding without exhaust 
–	 0.2–12.8 B United
States 
Source: NIOSH (1977) and references within



























6. POTENTIAL FOR HUMAN EXPOSURE 
individuals occupationally exposed were studied in a hard metals plant (NIOSH 1977).  Of the 178 hard-
metal individuals occupationally exposed (52 men and 126 women), 81% were about 30 years old and
about 84% of the individuals occupationally exposed had been engaged in hard-metal operations for 
3 years.  The concentrations of tungsten in the work atmosphere during various operations varied from
0.75 to 6.1 mg/m3. The ranges of mean tungsten concentrations were 0.8–1.1 mg/L in the blood of 
45 individuals occupationally exposed and 0.6–1.1 mg/L in the urine of 40 individuals occupationally
exposed, while tungsten was not detectable in the blood of 11 individuals occupationally exposed or in 
the urine of 7.  Individuals occupationally exposed in this factory may have been exposed to both soluble 
and insoluble tungsten compounds.  At a factory in Syracuse, New York, which manufactured hard metal 
parts from tungsten carbide and cobalt, 1 out of 83 cases of individuals occupationally exposed showed 
appreciable amounts of tungsten carbide concentrations in the lungs (Auchincloss et al. 1992). 
Occupational exposure to tungsten and its compounds have also been observed around the world, 
especially in hard metal industries.  In Milan, Italy, individuals occupationally exposed with an average 
exposure period of 13 years at job functions such as grinding and cutting hard metal materials, had 
concentrations of tungsten in tissues as follows: lung, 107 ng/g; blood, 1.35 ng/g; and urine, 12 ng/g 
(Rizzato et al. 1986).  A control group of 17 unexposed individuals in this study had concentrations of 
tungsten in lung tissue, blood, and urine of 1.5, 0.4, and 0.7 ng/g, respectively.  In Germany,
87 individuals occupationally exposed in the hard metal manufacturing industry were assessed for 
exposure to tungsten (Kraus et al. 2001).  The median duration of exposure for these individuals 
occupationally exposed was approximately 13 years. Ambient monitoring yielded a range of tungsten 
concentrations from 3.3 to 417.0 µg/m3 in the production of heavy alloys.  The highest tungsten 
concentrations excreted in urine of individuals occupationally exposed were found in grinders (mean, 
94.4 µg/g creatinine; maximum, 169 µg/g creatinine).  Thus, despite its low solubility, tungsten carbide 
was bioavailable. Bioavailability of tungsten and its compounds increases in the order of tungsten metal, 
tungsten carbide, and tungstate ion (Kraus et al. 2001).  At two hard metal manufacturing facilities in 
Sweden, Sahle et al. (1996) reported total dust personal measurements of 1.2±0.7, 1.6±0.8, and 
0.8±0.6 mg/m3 for ammonium paratungstate (APT), blue oxide (WO2.9), and tungsten trioxide (WO3), 
respectively. Airborne blue oxide fibers were detected in both static and personal samples when APT was 
calcined to blue oxide rather than tungsten trioxide.  
Occupational exposures have been observed in other industries such as welding shops, smelter/refineries, 
and shops using tools with cemented tungsten carbide.  Brune et al. (1980) determined levels of tungsten 























6. POTENTIAL FOR HUMAN EXPOSURE 
smelter and refinery had levels of tungsten which ranged as follows (n=21): kidney, <0.003–0.018 µg/g 
wet weight; liver, <0.003–0.014 µg/g wet weight; and lung, <0.003–0.15 µg/g wet weight.  The range of 
concentrations of tungsten in tissues from a control group were as follows (n=8): kidney, <0.003– 
0.005 µg/g wet weight; liver, <0.003–0.036 µg/g wet weight; and lung, and <0.003–0.011 µg/g wet 
weight. The concentration of tungsten in the workplace air from welding shops in Montréal, Quebec, 
Canada averaged 0.67 µg/m3 (n=13; range, <0.15–1.50 µg/m3) while the average concentration of 
tungsten in urban air was 0.0052 µg/m3 (Haddad and Zikovsky 1985).  Lichtenstein et al. (1975) reported 
the airborne tungsten concentrations in operations involving wet-grinding of tool bits and inserts made of 
two commercial grades of cemented carbides.  The air was sampled with filters in the workers’ breathing 
zones and the filters were analyzed for tungsten.  The mean concentration of tungsten was 5.16 mg/m3 
(range, 0.2–12.8 mg/m3). Of the 25 samples taken, 40% exceeded 5 mg/m3. 
Recent toxicological interest in tungsten is based on its increased use as a component of armor-piercing 
munitions and a replacement for lead in other ammunition.  Embedded tungsten shrapnel represents a 
unique source of internal exposure to tungsten. 
Tungsten may be found in human tissues and body fluids.  Serum concentrations of tungsten in healthy
human subjects are approximately 1–6 µg/L (Bowen 1966; Hartung 1991).  The mean tungsten 
concentrations in the serum of Swedish 15-year-old adolescents from Uppsala and Trollhättan were 
0.14±0.2 µg/L (n=355; range, <0.04–1.8 µg/L) for the period between 1993 and 1994 (Bránáy et al. 
2002a), while whole blood concentrations for this same population group were <0.2 µg/L (n=326; range, 
<0.2–0.94 µg/L).  
Tungsten occurs in human urine at low concentrations.  As part of the National Health and Nutrition 
Examination Survey (NHANES III) study from 1988 to 1994, 500 urine specimens were analyzed from a 
nationally representative sample of some 30,000 persons across the contiguous United States and Alaska 
(Paschal et al. 1998).  The mean concentration of tungsten in urine from this study was 1.92 µg/L (n=496; 
limit of detection=0.3 ng/mL) for all ages and sexes, while the creatinine adjusted mean concentration 
was 1.92 µg/g creatinine.  Between the years of 1999 and 2000, the geometric mean concentration of 
tungsten in urine for the U.S. population aged 6 years and older was 0.085 µg/L, while the creatinine 
adjusted mean concentration was 0.079 µg/L (CDC 2003a).  Schramel et al. (1997) reported that the mean 























6. POTENTIAL FOR HUMAN EXPOSURE 
Tungsten occurs in other body tissues at low concentrations.  For example, the concentrations of tungsten 
in human teeth and mammalian heart tissue were 0.25 and 5 ppb dry weight, respectively (Bowen 1966). 
For adults, tungsten levels have been determined in human tissues and body fluids: 0.25 ppb in bone; 
16 ppb in hair; 2 ppb in heart tissue; <0.7 mg/L in plasma; <0.07 mg/L in serum; 26–160 ppb in skin; 
240 ppb in tooth enamel; 2,600 ppb in tooth dentine; and up to 32 µg in urine (Iyengar et al. 1978).  
Concentrations of tungsten in human teeth, tooth enamel, and tooth dentine vary over a range of 3– 
6 orders of magnitude. These studies, considered together, provide no basis for explanation of these 
divergent values.   
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993). 
Specific information on the exposure of children to tungsten is limited.  As for adults in the general 
population, small exposures occur from normal ingestion of food and inhaling air.  These exposures may
be higher in areas near industrial facilities that manufacture, processes, recycle, or use tungsten and its 
compounds.  
At waste sites, tungsten that is found in excess of natural background levels is most likely to be in soil, 
and presents a special hazard for young children.  Hand-to-mouth activity and eating contaminated dirt 
will result in oral exposure to tungsten. The hazard in this case depends on the form of tungsten present 
at the waste site.  Tungsten in soil at waste sites is in both soluble and insoluble forms; tungsten in 

























6. POTENTIAL FOR HUMAN EXPOSURE 
Tungsten exposure to children from parents’ work clothes, skin, hair, tools, or other objects from the 
workplace is possible if the parent uses tungsten or its compounds at work.  However, no cases of home 
exposure have been reported for tungsten in the literature. 
Other home exposures are unlikely since no household products or products used in crafts, hobbies, or 
cottage industries contain significant amounts of tungsten.  One exception is tungsten filaments, which are 
used in and around the home in light bulbs or other electrical devices.  
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
Several populations are at high risk for exposure to tungsten and its compounds.  Individuals with the 
highest risk include people who are occupationally exposed to tungsten and its compounds from
manufacturing, fabricating, or reclaiming industries (see Section 6.5).  In particular, occupational 
exposures have been reported in industries using hard metals, welding shops, smelters/refineries, and 
shops using tools with cemented tungsten carbide.  Occupationally exposed workers who carry tungsten 
dust on their clothes from the workplace to their home may increase the risk of tungsten exposure to their 
family members.  People living near tungsten-emitting industries may be at a slightly increased risk of 
tungsten exposure due to contact with tungsten-contaminated dust within the household, as opposed to 
ambient air levels.   
Populations living in areas with above-average levels of natural tungsten may be at higher risk to 
exposure. For example, tungsten was found in the municipal water supply of the City of Fallon in 
Churchill County, Nevada, at a mean concentration of 19.1 µg/L (ppb).  In household water derived from
private wells in this community a mean tungsten concentration of 37.5 µg/L was obtained (Agency for
Toxic Substances and Disease Registry 2003).  This was the first finding of excess community-wide 
exposure to tungsten.  At these mean concentrations, the intake of tungsten through drinking water would 
amount to 38.2 and 75.0 µg per day for residents using water obtained from municipal and private water 
supplies, respectively, assuming the consumption of 2 liters of water per day.  The CDC reported that 
urine samples of leukemia cases and control subjects from residents in this community had elevated levels 
of tungsten (CDC 2003b).  The mean (geometric) tungsten concentrations in this study was 1.17 µg/L 
compared with 0.09 µg/L in the U.S. population.  However, no correlation was found in this study























6. POTENTIAL FOR HUMAN EXPOSURE 
In a follow-up CDC study of Churchill County and three surrounding communities, it was found that the 
tungsten concentrations in urine followed the concentrations of tungsten in drinking water.  The mean 
(geometric) concentrations of tungsten in the urine of adults in the Churchill County, Yerington, Lovelock 
and Pahrump communities were determined to be 0.81, 1.04, 0.38 and 0.4 µg/L, respectively, as 
compared to tungsten concentrations in tap water of 4.66, 3.32, 0.11, and 0.04 µg/L, respectively (CDC 
2003c). In children, the mean (geometric) concentrations of tungsten in urine of 2.31, 1.18, 0.62, and 
0.56 µg/L were higher than in adults.  In addition, the mean tungsten concentrations in urine collected 
from residents in the Churchill County and three surrounding communities were above the 95% percentile 
level for tungsten concentrations measured in the general U.S. population.   
Patients who have undergone percutaneous coil embolism, which is a medical procedure that is used to 
occlude unwanted vascular connections such as intracranial aneurysms, aorto-pulmonary, and venous 
collaterals and coronary artery fistulae, have been found with elevated levels of tungsten in blood and
urine (Peuster et al. 2003a). These elevated levels of tungsten are due to the corrosion of tungsten coils 
that are implanted in blood vessels during the procedure.  Tungsten concentrations of <0.7–7.2 and 1.98– 
837.7 µg/L in blood and urine, respectively, and <10–300 µg/g hair have been reported (Bachthaler et al. 
2004). Because of the degradation of the tungsten coils and the elevated tungsten levels found in these 
patients, coils made from tungsten are no longer used in the percutaneous coil embolism procedure.  
However, no adverse health effect has been associated with the elevated levels of tungsten within these 
patients. Military personnel wounded in combat may experience elevated tungsten levels from embedded 
tungsten-containing ammunition or shrapnel; the toxicological significance of such an exposure scenario 
has not been determined. 
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of tungsten is available.  Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of tungsten.
The following categories of possible data needs have been identified by a joint team of scientists from




















6. POTENTIAL FOR HUMAN EXPOSURE 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The relevant physical and chemical properties of tungsten and 
its compounds are available in the literature, but are limited for many tungsten compounds (Ashford 
1994; HSDB 2004; Lewis 1997; Lide 2000; O’Neil et al. 2001; Penrice 1997a, 1997b).  Additional data 
on the physical and chemical properties of tungsten compounds would permit estimation of the 
environmental fate of tungsten and its compounds 
Production, Import/Export, Use, Release, and Disposal.    According to the Emergency 
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this 
information for 2001, became available in May of 2004.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions. 
Data regarding the past and present production and import/export volumes for tungsten and its
compounds are available (SRI 2003; USGS 2001, 2004a, 2004b).  Information about the future 
production of tungsten and its compounds would be useful.  The uses of tungsten and tungsten 
compounds are well known (ITIA 2001; Lassner and Schubert 1999; Lassner et al. 1996; O’Neil et al. 
2001; Penrice 1997a, 1997b; USGS 2002).  Tungsten and its compounds are widely used in the home and 
workplace (O’Neil et al. 2001; Penrice 1997a, 1997b).  Limited information on the concentrations of 
tungsten in food was located in the available literature (Bibak et al. 1998; Perez-Jordan et al. 1998; 
Rodushkin et al. 1999).  Additional information would help to determine whether tungsten may be a 
contaminant in food.  Typical releases of the substance in the home, environment, and workplace indicate 
that water (Arnórsson and Lindvall 2001; HazDat 2004) and air (Feldmann and Cullen 1997; Fernandez 
et al. 1992; HazDat 2004; Ondov et al. 1989) are likely to be contaminated with tungsten in areas where 
natural formations occur or where tungsten is used in industry.  Most tungsten minerals, tungsten 
compounds, and tungsten-containing materials do not require special disposal and handling requirements 
(see Section 5.4). A significant portion of tungsten is routinely recycled (USGS 2002).  Since tungsten 
and tungsten compounds are not covered under Superfund Amendments and Reauthorization Act 






















6. POTENTIAL FOR HUMAN EXPOSURE 
Environmental Fate. Information about how tungsten and its compounds partition in the 
environment is available (Bidleman 1988; Dermatas et al. 2004; HSDB 2004; Lassner et al. 1996; Meijer 
et al. 1998; O’Neil et al. 2001; Penrice 1997b; Tanizaki et al. 1992), although it is limited in scope.  
Additional information about the partitioning of tungsten and its compounds would be useful for 
determining which environmental media tungsten and its compounds are likely to partition to.  The 
mobility of tungsten has been briefly characterized in soil (Meijer et al. 1998).  Additional and 
comprehensive information about the mobility of tungsten and its compounds would be useful in 
determining the potential of tungsten and its compounds to migrate into groundwater.  Tungsten can 
change from one chemical form to another, sometimes reversibly, in numerous chemical reactions that 
can proceed under a wide range of common environmental conditions (Bigham et al. 2001; Bowen 1966;
Dermatas et al. 2004; Lassner and Schubert 1999; Lassner et al. 1996; Tanizaki et al. 1992).  However, 
data on the transformation of tungsten and its compounds are limited.  Additional information would help 
to describe the chemical forms of tungsten and its compounds in different environmental media. 
Bioavailability from Environmental Media.    The absorption and distribution of tungsten and 
tungsten compounds as a result of inhalation or dermal exposures, or oral dosing have been discussed.  
Limited information on the bioavailability (i.e., adsorption from contaminated air, water, or soil) of 
tungsten and its compounds is available.  Updated and more comprehensive data on the bioavailability of 
tungsten and its compounds from environmental media are needed. 
Food Chain Bioaccumulation. Information on the bioconcentration of tungsten and its compounds 
in plants, aquatic organisms, or animals is not available.  Bioconcentration data would be useful in 
determining the level of storage of tungsten in the organisms as a result of exposure to contaminated 
media. Information on whether tungsten and its compounds are biomagnified is not available.  
Biomagnification data would be helpful in determining whether increased levels of tungsten in predators 
result from consumption of contaminated prey organisms.  
Exposure Levels in Environmental Media.    Reliable monitoring data for the levels of tungsten in
contaminated media at hazardous waste sites are needed so that the information obtained on levels of 
tungsten in the environment can be used in combination with the known body burden of tungsten to 



















6. POTENTIAL FOR HUMAN EXPOSURE 
Information about concentrations of tungsten and tungsten compounds in air (Dames et al. 1970; Haddad 
and Zikobsky 1985; Jagielak and Mamont-Cieśla 1979; Maenhaut et al. 1979; Sheridan and Zoller 1989), 
water (Arnórsson and Lindvall 2001; Bowen 1966; CDC 2003b, 2003c; Agency for Toxic Substances and 
Disease Registry 2003; Hall et al. 1988; Hartung 1991; Johannesson et al. 2000; Kist 1994; Konhauser et 
al. 1997; Tanizaki et al. 1992a, 1992b; Taylor et al. 1990), soil (Fu and Tabatabai 1988; Penrice 1997a; 
Quin and Brooks 1972a, 1972b; Senesi et al. 1988), and food (Bibak et al. 1998; Perez-Jordan et al. 1998; 
Rodushkin et al. 1999) are available, but limited.  Updated and more comprehensive data on the 
concentration levels of tungsten in air, water, soil, and food would be useful to provide a more 
comprehensive characterization of human exposure.  Additional data would also be useful in describing 
historical trends in tungsten concentrations in various environmental media.  Reliable monitoring data for 
the levels of tungsten in contaminated media at hazardous waste sites are needed so that the information 
obtained on levels of tungsten in the environment can be used in combination with the known body 
burden of tungsten to assess the potential risk of adverse health effects in populations living in the vicinity
of hazardous waste sites.  Estimates have not been made for human intake of tungsten and its compounds 
from various environmental media.  These data would help to determine the potential for human exposure 
to tungsten and its compounds.  
Exposure Levels in Humans. Tungsten has been detected in the following human tissues and 
fluids: blood, plasma, and serum (Bowen 1966; Bránáy et al. 2002a; Hartung 1991; Iyengar et al. 1978); 
urine (CDC 2003a; Iyengar et al. 1978; Paschal et al. 1998; Schramel et al. 1997); teeth (Bowen 1966; 
Iyengar et al. 1978); heart tissue (Bowen 1966); bone (Iyengar et al. 1978); and hair (Iyengar et al. 1978).  
Data are also included for tungsten levels in urine from individuals exposed to high (1.82–7.30 µg/L) 
concentrations of tungsten in drinking water (CDC 2003c). 
Although there are data from the CDC study of Churchill County (City of Fallon) and surrounding 
communities describing the levels of tungsten as in urine of residents exposed to high levels of tungsten 
in drinking water suggesting that there is no correlation between the high tungsten intake and a cluster of 
childhood acute lymphocytic and myelocytic leukemias in the Churchill County area (CDC 2003c), 
leukemias were the only health effect end point examined in the study.  It would be useful to know if the 
tungsten intake measured in CDC study participants is correlated with other health effect end points and 
populations (e.g., elderly residents) both within this study and in other populations where high tungsten 
intake has been identified.  This information would be useful in assessing the need to conduct health 
























6. POTENTIAL FOR HUMAN EXPOSURE 
Exposures of Children. Children may be exposed to tungsten and tungsten compounds in the same 
manner as adults in the general population (e.g., air, food, and water).  Exposure and body burden studies 
on children would be useful.  No information was available on unique exposure pathways for children 
(e.g., pica children, dermal exposure, and parental transport from the workplace).  Studies may be needed 
to determine if unique exposure pathways exist for children, and if they do, to determine the significance 
they might have on child health.  No childhood-specific means to decrease exposure were identified.  
Child health data needs relating to susceptibility are discussed in 3.12.2 Identification of Data Needs: 
Children’s Susceptibility.  
Exposure Registries. No exposure registries for tungsten were located.  This substance is not 
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established.  The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance. 
The population of Churchill County (City of Fallon), Nevada is known to have unusually high exposures 
to tungsten (CDC 2003b, 2003c; Agency for Toxic Substances and Disease Registry 2003).  However, no 
exposure registry has been established for this population.  
6.8.2 Ongoing Studies 
No ongoing studies investigating potential for human exposure of tungsten or its compounds were 


























7. ANALYTICAL METHODS 
The purpose of this chapter is to describe the analytical methods that are available for detecting, 
measuring, and/or monitoring tungsten, its metabolites, and other biomarkers of exposure and effect to 
tungsten. The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to 
identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
A variety of analytical methods can be used to determine trace concentrations (sub-ppb to ppb) of 
tungsten in biological tissues.  These include inductively coupled plasma-atomic emission spectroscopy
(ICP-AES), inductively coupled plasma-mass spectrometry (ICP-MS), and neutron activation analysis 
(NAA), as well as other techniques, such as atomic absorption spectroscopy (AAS) and UV/Visible 
spectroscopy (UV/VIS).  Table 7-1 lists analytical methods used for determining tungsten and tungsten 
compounds in biological fluids and tissues. 
ICP-AES and ICP-MS have been used to determine tungsten concentrations in biological samples 
(Bárány et al. 2002a, 2002b; Le Lamer-Déchamps et al. 2003; Marquet et al. 1997; Paschal et al. 1998; 
Schramel et al. 1997).  Samples are typically wet ashed with nitric acid at elevated temperatures and then 
diluted for analysis.  Tungsten is quantified by ICP-AES using the emission line at 207.91 nm and by
ICP-MS using isotope masses of 182W and 186W. The instrument detection limits have been determined to 
be 50 µg/L and 0.02–0.3 µg/L for ICP-AES and ICP-MS, respectively.  Huang et al. (2002) recently
developed a method using chelation ion chromatography (CIC) coupled with on-line detected by ICP-MS. 
The advantage of this method is the ability to analyze trace amounts of tungsten (and other metals) in 
complex matrices such as biological samples.  Using a bis-(2-aminoethylthio) methylate (BAETM) resin 







































7. ANALYTICAL METHODS 
Table 7-1. Analytical Methods for Determining Tungsten in Biological Materials 








Human blood Not specified ICP-MS 0.2 µg/L No data Bárány et al. 
2002a, 
2002b 
Human serum Not specified ICP-MS 0.04 µg/L No data Bárány et al. 
2002a, 
2002b 
Human plasma Dilute ICP-MS 0.01 µg/L 97–102% Le Lamar-
Déchamps et
al. 2003 




Hydrolysis in nitric 
acid; dilute 








Deep freeze (or 
freeze dry); grind to 
powder 
NAA No data No data Brune et al. 
1980 
Human urine Dilute (and acidify) ICP-MS 0.3 ng/mL No data Paschal et 
al. 1998 







Wet digestion using 
HNO3/HClO4; 
evaporate to dryness; 
dissolve in ionic buffer 
(LiNO3/HNO3) 
DCP-AES ~0.037 µg/L No data Frank and 
Petersson 
1983 
Rat and dog 
plasma
None ICP-AES 100 ng/mL 89–105% Poucheret et 
al. 2000 
AES = atomic emission spectroscopy; DCP = DC plasma; HClO4 = perchloric acid; HNO3 = nitric acid; 






















7. ANALYTICAL METHODS 
NAA techniques provide low detection limits for tungsten (0.005 µg tungsten per gram of sample), but 
there are few reactors at which NAA facilities and expertise are available (Dams et al. 1970).  A common 
NAA procedure for tungsten determination is to produce the short-lived 187W radionuclide (half-life of 
24 hours; gamma-lines of 479.3 and 685.7 keV).  Counting can be initiated after an irradiation period of 
2–5 hours and a cooling period of 20–30 hours (Dams et al. 1970).  Biological samples that have been 
analyzed for tungsten using the NAA technique include human blood and tissues (e.g., kidney, liver, and 
lung) (Bowen 1960; Brune et al. 1980).  Because facilities at which NAA can be performed are extremely
limited, NAA's most useful application is as a reference method against which other less expensive and 
more common methods can be compared for accuracy.  
7.2 ENVIRONMENTAL SAMPLES 
Many of the basic analytical methods used for determining tungsten in biological media are also used for 
determining tungsten levels in environmental samples (e.g., soil, water, and air).  ICP-AES, ICP-MS, 
Flame AAS, UV/VIS spectrophotometry, and NAA are the most common techniques utilized for analysis 
of tungsten in environmental samples.  Table 7-2 lists the methods used for determining tungsten in 
environmental samples. 
The NIOSH-recommended technique (Method 7074) for determining tungsten in air uses Flame AAS.  
Detection limits for tungsten are 50 µg of soluble tungsten per sample and 125 µg of insoluble tungsten 
per sample using an absorption line at 255.1 nm (NIOSH 1994). 
Inductively coupled plasma techniques have been used to measure tungsten concentrations in water 
samples.  Samples are typically filtered and acidified before analysis.  Johannesson et al. (2000) used 
ICP-MS to measure the levels of total tungsten in river water samples.  Detection limits for tungsten were 
0.8 nmol/kg (0.15 µg/kg). For spring water, Hall et al. (1988) reported detection limits of 0.06 and 
1.2 µg/L for ICP-MS and ICP-AES, respectively.  In order analyze waters with high concentrations of 
dissolved solids (e.g., seawater), Huang et al. (2002) employed CIC coupled with ICP-MS and achieved 
detection limits of <0.05 ng/mL.  
UV/VIS spectroscopy has been used to measure tungsten in environmental samples.  Parker and Boltz 
(1968) used UV/VIS spectroscopy at 262 nm to determine total tungsten levels in water samples as a 



























   








7. ANALYTICAL METHODS 




Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Air Digest with  HNO3/HF; Flame 50 µg soluble W No data NIOSH 1994 
evaporate to dryness; AAS per sample; (Method 7074) 
add NaOH/NaSO4; 125 µg insoluble 
dilute W per sample
Workspace Filter air; leach soluble Flame 10 µg soluble 90.8– Hull and 
air W using DI water; AAS W/L; 8 mg 103% Haartz 1980 
dissolve residual W insoluble W per soluble; 
HNO3/HF after HCl sample 90.8– 
extraction 105% 
insoluble 
Workspace/ Filter air for NAA 0.20±0.09 µg/m3 No data Haddad and 
urban air particulates Zikovsky 1985 
Water Dilute tungstate UV/VIS of No data No data Parker and 
solution; add H2SO4 peroxy- Boltz 1968 
and HOOH; dilute tungstic 
acid at 
262 nm 
Water Add sodium acetate Flame 0.1 mg/L No data Korrey and 
buffer; add benzoin AAS Goulden 1975
anti-oxime then extract 








~2 µg/L No data Tomiyasu and 
Yonehara 
and (NH4)2Fe(SO4)2; y (λ=525 1996 
mix; add HOOH to nm) 
initiate reaction 
River water Filter; acidify with ICP-MS No data No data Konhauser et
HNO3 al. 1997 
River water ICP-MS 0.8 nmol/kg No data Johannesson
Filter; acidify with (0.15 µg/kg) et al. 2000 
HNO3 
River water Filter; acidify with NAA No data No data Tanizaki et al. 
HNO3 1992a, 1992b
Spring Acidify with HCl; add ICP-AES 1.2 µg/L No data Hall et al. 1988 
water oxime dissolved in 
EtOH and activated ICP-MS 0.06 µg/L 
charcoal; filter; ash; 









    




   
 
 
   













7. ANALYTICAL METHODS 




Sample Analytical Sample Percent 
matrix Preparation method method detection limit recovery Reference 
Polluted Microwave digestion ICP-AES 30 mg/L No data Ferri et al. 
waters using HF/HCl/HNO3; 1999 
column
chromatography using 
Chelex-100 in Na 
resin; dilute 
Seawater Acidify, dilute CIC-ICP­ <0.05 ng/mL No data Huang et al. 
MS 2002 
Seawater Acidify; add NAA 0.05 µg/L No data van der Sloot
ammonium pyrrolidine et al. 1977 
dithiocarbamate; add 
activated charcoal; stir 
Soil Dry; digest in aqua ICP-AES No data No data Sadiq et al. 
regia/perchloric acid; 1992 
filter; dilute 
Soil, stream Fuse sample with UV/VIS of ~1 ppm 95–105% Quin and 
sediment, KHSO4; leach with tungsten- Brooks 1972a 
and rocks HCl; mix with SnCl2; dithiol 
add dithiol; dissolve complex at
with petroleum spirits λ=630 nm 
Fertilizers Digest in HNO3, HCl, ICP-AES 0.002 mg/kg No data Senesi et al. 
and/or HClO4 acid(s); 1988 
dilute 
Onion Digest and redistill in ICP-MS 0.0180 µg/kg No data Bibak et al. 
HNO3; dilute fresh weight 1998 
Vegetation Ash; add SnCl2 UV/VIS of 0.01 ppm dry 95–105% Quin and
solution; add dithiol; tungsten- weight Brooks 1972a 
dissolve with dithiol 
petroleum spirits complex at
λ=630 nm 
Berries Microwave digestion; ICP-AES 0.0001 mg/g dry 108% Rodushkin et
dilute weight al. 1999 
Wine Dilute sample to ICP-MS 0.01 ng/mL No data Pérez-Jordán
volume. et al. 1998 
λ = wavelength; AAS = atomic absorption spectroscopy; AES = atomic emission spectrometry; CIC=chelation ion 

chromatography; DI = deionized; EtOH = ethanol; HCl = hydrochloric acid; HClO4 = perchloric acid; 

HF = hydrofluoric acid; HNO3 = nitric acid;  HOOH = hydrogen peroxide; H2SO4 = quinine sulfate; ICP = inductively
 
coupled plasma; KHSO4 = potassium hydrogen sulfate; MIBK = methyl isobutyl ketone; MS = mass spectroscopy; 

NAA = neutron activation analysis; NaOH = sodium hydroxide; NaSO4 = sodium sulfate; 

(NH4)2Fe(SO4)2 = ammonium iron(II) sulfate; SnCl2 = tin chloride; UV/VIS = ultraviolet-visible spectroscopy; 

































7. ANALYTICAL METHODS 
a tungsten-dithiol complex with an absorption wavelength at 630 nm.  The detection limit for this 
technique was approximately 1 ppm in soil and 0.01 ppm dry weight in vegetation.  
NAA has been used to determine tungsten levels in environmental samples.  Haddad and Zikovsky (1985) 
reported a detection limit of 0.20±0.09 µg/m3 tungsten using NAA for determining tungsten in 
workplace/urban air particulate matter.  Tungsten levels in seawater have been determined by NAA after 
first concentrating tungsten on activated charcoal by adsorption as the ammonium pyrrolidine
dithiocarbamate complex (van der Sloot et al. 1977). The detection limit is 0.05 µg tungsten/L after a 
simple chemical separation.  
Tomiyasu and Yonehara (1996) determined the concentration of trace amounts of tungstate ions (WO42-) 
using a catalytic spectrophotometric method.  In the presence of iron(II), chloropromazine is oxidized by
hydrogen peroxide in a hydrochloric acid solution to form a red free radical, which is further oxidized to 
form a colorless compound.  The reaction can be followed by measuring the increase in absorbance of the 
red free radical at 525 nm.  Tungsten(VI) inhibits the color formation, and the maximum absorbance 
value decreases with an increase in tungsten(VI) concentration.  Tungsten(VI) has been determined by
this method in the concentration range of 2–500 µg/L.
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of tungsten is available.  Where adequate information is not
available, ATSDR, in conjunction with the National Toxicological Program (NTP), is required to assure 
the initiation of a program of research designed to determine the health effects (and techniques for 
developing methods to determine such health effects) of tungsten.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 





















7. ANALYTICAL METHODS 
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.     
Exposure. Analytical methods with satisfactory sensitivity, precision, and reliability are available to 
determine the levels of tungsten in human tissues and body fluids (Bárány et al. 2002a, 2002b; Le Lamer-
Déchamps et al. 2003; Marquet et al. 1997; Paschal et al. 1998; Schramel et al. 1997).  Existing analytical 
methods are sensitive enough to measure background levels in the population and levels at which 
biological effects occur.  For example, detection limits of <0.05 ng/mL have been reported for tungsten in
biological samples (Huang et al. 2002).  Standard methods of analysis for determining the levels of 
tungsten in human tissues and body fluids are not available and are needed for inter-laboratory 
comparability of results.  Methods for determining levels of tungsten compounds (e.g., tungstate ions) in 
human tissues and body fluids are not available.  Additional methods for determining tungsten 
compounds in human tissues and body fluids may be useful for determining exposure from different 
tungsten species. 
Effect. There are no known sensitive and specific biomarkers of effect for tungsten.  Therefore, no 
analytical method recommendations can be made for biomarkers of effect for tungsten at the present time. 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Sensitive analytical methods are available to measure the levels of tungsten in environmental 
media (Hall et al. 1988; Johannesson et al. 2000; Konhauser et al. 1997; NIOSH 1994; Quin and Brooks 
1972a; Sadiq et al. 1992), although very limited information is available regarding the accuracy and 
precision of these methods.  Further studies would be useful to ascertain the accuracy and precision of 
methods used to determine tungsten in environmental media so that the reliability of tungsten levels may
be assessed. Most analytical methods are sensitive enough to determine levels of tungsten at which health 
effects may occur.  Some of the available methods can be used to detect tungsten at nanogram levels 
(Huang et al. 2002). Most of these techniques measure total tungsten and do not distinguish among 
various tungsten compounds.  Although limited, methods are available that determine levels of tungstate 
ions in environmental media (Tomiyasu and Yonehara 1996).  Additional methods would be useful in 
determining environmental levels of specific tungsten compounds such that human exposure to these 













7. ANALYTICAL METHODS 
7.3.2 Ongoing Studies 
No ongoing studies investigating new methods for detection and speciation of tungsten or tungsten 


















8. REGULATIONS AND ADVISORIES 

The international, national, and state regulations and guidelines regarding tungsten in air, water, and other 
media are summarized in Table 8-1. 
No MRLs were derived for inhalation or oral exposure to tungsten or tungsten compounds. 
EPA has not classified tungsten or tungsten compounds for carcinogenicity, nor has the EPA derived 
reference concentrations (RfCs) or reference doses (RfDs) for tungsten or tungsten compounds (IRIS 
2005).  EPA regulates the effluent discharge of tungsten at primary tungsten facilities (EPA 2005a) and 
tungsten or cobalt at secondary tungsten and cobalt facilities processing tungsten or tungsten carbide 
scrap raw materials (EPA 2005b). 
The American Conference of Governmental Industrial Hygienists (ACGIH), National Institute of 
Occupational Safety and Health (NIOSH), and Occupational Safety and Health Administration (OSHA) 
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Tungsten 
Agency Description	 Information Reference
INTERNATIONAL 
Guidelines: 
IARC Carcinogenicity classification 






ACGIH TLV (8-hour TWA) 
 Tungsten (as W) 





NIOSH REL (10-hour TWA) 
Tungsten (also applies to 
insoluble tungsten 
compounds [as W]) 
STEL (15-minute TWA)
OSHA PEL (8-hour TWA) for 
general industry 
PEL (8-hour TWA) for 
construction industry 
 Tungsten (as W) 
Insoluble compounds 
Soluble compounds 





USNRC 	 Occupational values








185W (LLI wall) 
185W 
187W 





























29 CFR 1926.55, 
Appendix A 
OSHA 2005a
29 CFR 1915.1000 
USNRC 2005
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Agency 
Table 8-1. Regulations and Guidelines Applicable to Tungsten 
Description Information Reference 
NATIONAL (cont.) 







185W (LLI wall) 
187W 
188W (LLI wall) 
b. Water No data 
c. Food No data 
d. Other 
ACGIH Carcinogenicity classification 
EPA Carcinogenicity classification 
RfC 
RfD 
Effluent guidelines and 
standards; nonferrous
metals manufacturing point 
source category applicable 
to discharges resulting from 
the production of tungsten at 
primary tungsten facilities 
Effluent guidelines and 
standards; nonferrous
metals manufacturing point 
source category applicable 
to discharges resulting from 
the production of tungsten or 
cobalt at secondary tungsten 
and cobalt facilities 
processing tungsten or 
tungsten carbide scrap raw 
materials 






185W (LLI wall) 
185W 
187W 
























































40 CFR 421.100 
EPA 2005b 
40 CFR 421.310 
USNRC 2005
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Tungsten 
Agency Description Information Reference 
NATIONAL (cont.) 




















10 CFR 20, 
Appendix B 
STATE
a. Air No data 
b. Water No data 
c. Food No data 
d. Other No data 
aThe ALIs in this table are the annual intakes of a given radionuclide by "Reference Man", which would result in 
either (1) a committed effective dose equivalent of 5 rems (stochastic ALI) or (2) a committed dose equivalent of 
50 rems to an organ or tissue (non-stochastic ALI).  The stochastic ALIs were derived to result in a risk, due to 
irradiation of organs and tissues, comparable to the risk associated with deep dose equivalent to the whole body of 
5 rems. The derivation includes multiplying the committed dose equivalent to an organ or tissue by a weighting 
factor, wT. This weighting factor is the proportion of the risk of stochastic effects resulting from irradiation of the 
organ or tissue, T, to the total risk of stochastic effects when the whole body is irradiated uniformly.  The non-
stochastic ALIs were derived to avoid non-stochastic effects, such as prompt damage to tissue or reduction in 
organ function. 
bThe ALIs and DACs for inhalation are given for an aerosol with an activity median aerodynamic diameter (AMAD) 
of 1 µm and for class D of radioactive material, which refers to their retention (clearance half-times of <10 days) in 
the pulmonary region of the lung. 
cThe DAC values are derived limits intended to control chronic occupational exposures.  The relationship between 
the DAC and the ALI is given by: DAC=ALI(in µCi)/(2,000 hours per working year x 60 minutes/hour x 2x104 mL 
per minute)=[ALI/2.4x109] µCi/mL, where 2x104 mL is the volume of air breathed per minute at work by "Reference 
Man" under working conditions of "light work."  The DAC values relate to one of two modes of exposure: either 
external submersion or the internal committed dose equivalents resulting from inhalation of radioactive materials.  
Derived air concentrations based upon submersion are for immersion in a semi-infinite cloud of uniform 
concentration and apply to each radionuclide separately. 
dApplicable to the assessment and control of dose to the public.  The concentration values given are equivalent to 
the radionuclide concentrations that, if inhaled or ingested continuously over the course of a year, would produce a 
total effective dose equivalent of 0.05 rem (50 millirem or 0.5 millisievert). 
eThe air concentration values were derived by one of two methods.  For those radionuclides for which the 
stochastic limit is governing, the occupational stochastic inhalation ALI was divided by 2.4x109mL, relating the 
inhalation ALI to the DAC, as explained above, and then divided by a factor of 300.  The factor of 300 includes the 
following components: a factor of 50 to relate the 5-rem annual occupational dose limit to the 0.1-rem limit for 
members of the public, a factor of 3 to adjust for the difference in exposure time and the inhalation rate for a 
worker and that for members of the public, and a factor of 2 to adjust the occupational values (derived for adults) 
so that they are applicable to other age groups.  For those radionuclides for which submersion (external dose) is 
limiting, the occupational DAC in Table 1, Column 3 of USNRC (2005), was divided by 219.  The factor of 219 is 
composed of a factor of 50, as described above, and a factor of 4.38 relating occupational exposure for 
2,000 hours per year to full-time exposure (8,760 hours/year).  Note that an additional factor of 2 for age 
considerations is not warranted in the submersion case.  
fThe water concentrations were derived by taking the most restrictive occupational stochastic oral ingestion ALI 
and dividing by 7.3x107. The factor of 7.3x107 (mL) includes the following components: the factors of 50 and 2 
described above and a factor of 7.3x105 (mL), which is the annual water intake of "Reference Man." 
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Agency 
Table 8-1. Regulations and Guidelines Applicable to Tungsten 
Description Information Reference 
The concentration values were derived by taking the most restrictive occupational stochastic oral ingestion ALI and 
dividing by 7.3x106(mL). The factor of 7.3x106(mL) is composed of a factor of 7.3x105(mL), the annual water 
intake by "Reference Man," and a factor of 10, such that the concentrations, if the sewage released by the licensee 
were the only source of water ingested by a reference man during a year, would result in a committed effective 
dose equivalent of 0.5 rem. 
ACGIH = American Conference of Governmental Industrial Hygienists; ALI = annual limits on intakes; CFR = Code 
of Federal Regulations; DAC = derived air concentrations; EPA = Environmental Protection Agency; 
IARC = International Agency for Research on Cancer; LLI = lower large intestine; NIOSH = National Institute for 
Occupational Safety and Health; OSHA = Occupational Safety and Health Administration; PEL = permissible 
exposure limit; REL = recommended exposure limit; RfC = inhalation reference concentration; RfD = oral reference 
dose; STEL = short-term exposure limit; TLV = threshold limit values; TWA = time-weighted average; 
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10.  GLOSSARY 

Absorption—The taking up of liquids by solids, or of gases by solids or liquids. 
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact. 
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase) 
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a 
fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per gram of soil or 
sediment. 
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a 
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the 
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be 
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.    
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological 
or epidemiological data to calculate a BMD. 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces 
significant increases in the incidence of cancer (or tumors) between the exposed population and its 
appropriate control. 
Carcinogen—A chemical capable of inducing cancer. 
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 




































Case Series—Describes the experience of a small number of individuals with the same disease or 
exposure. These may suggest potential topics for scientific research, but are not actual research studies. 
Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines 
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human
health assessment. 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point 
in the life span of the organism. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death. 
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
































Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time 
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube. 
In Vivo—Occurring within the living organism. 
Lethal Concentration(Lo) (LCLo)—The lowest concentration of a chemical in air that has been reported 
to have caused death in humans or animals. 
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population. 
Lethal Dose(Lo) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that 
has been reported to have caused death in humans or animals. 
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure. 
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk 
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty 
factors. The default value for a MF is 1. 
































Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time. 
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA. Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence 
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not 
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group. 
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase. 
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA) 
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control 
of agricultural and public health pests. 
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based 
and physiologically-based.  A data-based model divides the animal system into a series of compartments, 
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 


































Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments 
representing organs or tissue groups with realistic weights and blood flows.  These models require a 
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar 
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events 
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the 
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health 
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour 
workweek. 
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of 
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups) 
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.  
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the 
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious 
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level 
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect 
various types of data used to estimate RfDs and an additional modifying factor, which is based on a 
professional judgment of the entire database on the chemical.  The RfDs are not applicable to 
nonthreshold effects such as cancer. 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable 
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
































Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical. 
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or 
inherited characteristic that is associated with an increased occurrence of disease or other health-related 
event or condition. 
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among 
persons without risk factors. A risk ratio greater than 1 indicates greater risk of disease in the exposed 
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial 
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes 
continually. No more than four excursions are allowed per day, and there must be at least 60 minutes 
between exposure periods. The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded. 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen—A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit 
(STEL), or as a ceiling limit (CL). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 


















Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or 
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the 
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest­
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data. 
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used; 
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic 
average of 10 and 1. 






























TUNGSTEN  A-1 
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 
















MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as a hundredfold below levels 
that have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 
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APPENDIX B.  USER'S GUIDE 

Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions: 
1.	 What effects are known to occur in humans? 
2. 	 What effects observed in animals are likely to be of concern to humans?
3. 	 What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 



























meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 



































See Sample LSE Table 3-1 (page B-6)
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	 Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	 System. This column further defines the systemic effects.  These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 













































which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9) 	 LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15)	 Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 





















(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
(19)	 Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure. 
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2 → INTERMEDIATE EXPOSURE 

5 6 7 8 9 10 
3 → Systemic ↓ ↓ ↓ ↓ ↓ ↓
4 →
18 Rat 13 wk
5 d/wk 
6 hr/d 
Resp 3b 10 (hyperplasia) 





Wong et al. 1982 
L, lung tumors, 
al tumors) 
NTP 1982 
























































a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose ad
by an uncertainty factor of 100 (10 for extrapolation from animal to humans, 10 for human var






























































TUNGSTEN  C-1 
APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 

ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALT alanine aminotransferase
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DHEW Department of Health, Education, and Welfare 
DHHS Department of Health and Human Services 
DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy
DOL Department of Labor 







































DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 
LT50 lethal time, 50% kill 
m meter 
MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 





























MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA 
OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 

































OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit 
pg picogram
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States
USDA United States Department of Agriculture 
USGS United States Geological Survey
VOC volatile organic compound 
WBC white blood cell 




















> greater than 
≥ greater than or equal to 
= equal to 
< less than 








q1* cancer slope factor 
– negative 
+ positive 
(+) weakly positive result 
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ambient air .........................................................................................................................................2, 11, 87, 101, 109 
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disposal ........................................................................................................................................................86, 101, 111 
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endocrine .............................................................................................................................................17, 28, 31, 54, 55 





fetus .......................................................................................................................................................6, 12, 40, 55, 70 
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general population ...................................................................................................................12, 57, 89, 103, 108, 114 
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groundwater................................................................................................................. 3, 11, 67, 87, 91, 93, 98, 99, 112
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Kow .............................................................................................................................................................78, 79, 80, 81 

LD50 .................................................................................................................................................................23, 24, 33 
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milk........................................................................................................................................................6, 40, 41, 57, 70 











occupational exposure ........................................................................................... 12, 16, 17, 37, 62, 68, 109, 123, 126 

occupationally exposed.................................................................................................. 4, 20, 36, 37, 53, 103, 106, 109
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odds ratio .....................................................................................................................................................................30 











placenta............................................................................................................................................................40, 57, 70 

placental barrier ...........................................................................................................................................................12 

pulmonary edema ..................................................................................................................................................20, 62 

pulmonary fibrosis...................................................................................................................12, 20, 53, 62, 63, 64, 68 

renal effects .................................................................................................................................................................28 

retention.................................................................................................................................40, 43, 45, 48, 50, 59, 126 
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sodium tungstate .................................17, 21, 22, 23, 28, 29, 30, 33, 34, 37, 38, 39, 40, 41, 63, 65, 66, 83, 85, 96, 103 
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surface water................................................................................................................ 2, 11, 87, 91, 96, 97, 98, 99, 103
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tungsten carbide......2, 4, 7, 11, 12, 16, 17, 20, 33, 35, 53, 58, 62, 63, 68, 73, 85, 87, 90, 103, 104, 106, 109, 123, 125 

tungsten carbonyl.............................................................................................................................................75, 90, 93 

tungsten chloride..................................................................................................................................31, 37, 39, 52, 63 
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wet deposition........................................................................................................................................................87, 93 
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